Сокращения и труды авторов, использованные при подготовке статей по системным заболеваниям в эндокринологии на сайте Доммедика

В статьях использованы следующие сокращения:

• АД — артериальное давление
• АДГ — антидиуретический гормон
• АИТ — аутоиммунный тиреоидит
• АКТГ — адренокортикотропный гормон
• АПА — альдостерон-продуцирующая аденома
• АПС — аутоиммунные полигландулярные синдромы
• АПФ — ангиотензин-превращающий фермент
• иАПФ — ингибиторы ангиотензин-превращающего фермента
• АТ-ТГ — антитела к тиреоглобулину
• АТ-ТПО — антитела к тиреоидной пероксидазе
• АФА — антифосфолипидные антитела
• АЦЦП — антитела к циклическому цитруллиновому пептиду
• БДР — большое депрессивное расстройство
• БК — болезнь Кушинга
• БРА — блокаторы рецептора к ангиотензину II
• ВГ — вариабельность гликемии
• ВДКН — врожденная дисфункция коры надпочечников
• ГА — гиперандрогения
• ГГН — гипоталамус—гипофиз—надпочечники
• ГКС — глюкокортикоиды
• ГЛЖ — гипертрофия левого желудочка
• ГМ КС — гладкомышечные клетки сосудов
• ГПГА — глюкокортикоид-подавляемый гиперальдостеронизм
• ГСПГ — глобулин, связывающий половые гормоны
• ГЭРБ — гастроэзофагеальная рефлюксная болезнь
• ДА — дефицит андрогенов
• ДГЭА — дегидроэпиандростерон
• ДИ — доверительный интервал
• ДИСГ — диффузный идиопатический скелетный гиперостоз
• ДН — диабетическая нефропатия
• ДНК — дезоксирибонуклеиновая кислота
• ЖК — желчные кислоты
• ИБС — ишемическая болезнь сердца
• ИГК — интенсивный гликемический контроль
• ИЛ — интерлейкин
• ИМ — инфаркт миокарда
• ИМТ — индекс массы тела
• ИР — инсулинорезистентность
• ИФР — инсулиноподобный фактор роста
• КБС — карциноидная болезнь сердца
• КИМ — комплекс интима—медиа
• КМПТ — кардиомиопатия такоцубо
• КПГ — конечные продукты гликирования
• КРГ — кортикотропин-рилизинг-гормон
• КТ — компьютерная томография
• ЛГ — лютеинизирующий гормон
• ЛПВП — липопротеины высокой плотности
• ЛПНП — липопротеины низкой плотности
• ME — международная единица
• МК — минералокортикоиды
• МКР — минералокортикоидный рецептор
• МРТ — магнитно-резонансная томография
• МЭН — множественная эндокринная неоплазия
• НАЖБП — неалкогольная жировая болезнь печени
• НАСГ — неалкогольный стеатогепатит
• иНГЛТ-2 — ингибитор Na'/глюкозного котранспортера 2-го типа
• НД — несахарный диабет
• НЭО — нейроэндокринные опухоли
• ОКС — острый коронарный синдром
• ОР — относительный риск
• ОРИТ — отделения реанимации и интенсивной терапии
• ОШ — отношение шансов
• ПБДЭ — полибромированные дифениловые эфиры
• ПГА — первичный гиперальдостеронизм
• ПГП — первичный гиперпаратиреоз
• ППКМП — перипартальная кардиомиопатия
• ПРЛ — пролактин
• ПТГ — паратиреоидный гормон
• ПХБ — полихлорированные бифенилы
• ПХД — полихлорированные дифенилы
• РА — ревматоидный артрит
• РААС — ренин-ангиотензин-альдостероновая система
• ГнРГ — гонадотропин-рилизинг-гормон
• РКП — рандомизированные клинические исследования
• РНК — рибонуклеиновая кислота
• мРНК — матричная рибонуклеиновая кислота
• СГТ — субклинический гипотиреоз
• СД — сахарный диабет
• СДКА — спонтанная диссекция коронарной артерии
• СЗСТ — системные заболевания соединительной ткани
• СИР — субстрат инсулинового рецептора
• СК — синдром Кушинга
• СКВ — системная красная волчанка
• СКФ — скорость клубочковой фильтрации
• СНС — симпатическая нервная система
• СНСАДГ — синдром неадекватной секреции антидиуретического гормона
• СОЗ — стойкие органические загрязнители
• СПКЯ — синдром поликистозных яичников
• СС — сердечно-сосудистый
• ССЗ — сердечно-сосудистые заболевания
• СТГ — соматотропный гормон
• СШ — синдром Шегрена
• Т - тестостерон
• ТПН — терминальная стадия почечной недостаточности
• ТТГ — тиреотропный гормон
• ФНО — фактор некроза опухолей
• ФП — фибрилляция предсердий
• ФСГ — фолликулостимулирующий гормон
• ФХЦ — феохромоцитома
• ХБП — хроническая болезнь почек
• ХВРЭС — химические вещества, разрушающие эндокринную систему
• ЦНС — центральная нервная система
• ЭГ — эссенциальная гипертензия
• ЭК — эндотелиальные клетки
• ЭМГ — электромиография
• РЧ-ЭМП — радиочастотные электромагнитные поля
• ЭР — рецепторы эстрогена
• DIO — дейодиназа
• NO — оксид азота
• eNOS — эндотелиальная NO-синтаза
• THR — рецептор к тиреоидным гормонам
• TITR — время целевого диапазона гликемии
• VDR — рецептор витамина D

В ходе подготовки статей по системным заболеваниям в эндокринологии для пользователей сайта ДомМедика использованы труды признанных иностранных авторов представленных ниже.

Авторы трудов, которые использованы для подготовки статей:

1. Abraham A.D., Bug G. 3H-testosterone distribution and binding in rat thymus cells in vivo // Mol. Cell. Biochem. 1976. Vol. 13. P. 157—163.
2. Anaya J.M., Liu G.T., D’Souza E., Ogawa N., Luan X., Talal N. Primary Sjogren’s syndrome in the elderly: clinical and immunological characteristics // Lupus. 1999. Vol. 8. P. 20—23.
3. Arrenbrecht S. Specific binding of growth hormone to thymocytes // Nature. 1974. Vol. 252. P. 255-225.
4. Baerwald C.G., Wahle M., Ulrichs T., Jonas D., von Bierbrauer A., von Wichert P., Burmester G.R., Krause A. et al. Reduced catecholamine response of lymphocytes from patients with rheumatoid arthritis // Immunobiology. 1999. Vol. 200. P. 77—91.
5. Bailly S., Ferrua B., Fay M., Gougerot-Pocidalo M.A. Differential regulation of IL 6, IL 1a, IL 1 beta and TNF alpha production in LPS-stimulated human monocytes: role of cyclic AMP//Cytokine. 1990. Vol. 2. P. 205-210.
6. Besedovsky H.O., del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses // Endocr. Rev. 1996. Vol. 17. P. 64-102.
7. Agrawal L., Habib Z., Emanuele N.V. Neurologic disorders of mineral metabolism and parathyroid disease // Handb. Clin. Neurol. 2014. Vol. 120. P. 737-748.
8. Bertorini T.E., Perez A. Neurologic complications of disorders of the adrenal glands // Handb. Clin. Neurol. 2014. Vol. 120. P. 749-771.
9. Carvalho K.S., Grunwald T., De Luca F. Neurological complications of endocrine disease // Semin. Pediatr. Neurol. 2017. Vol. 24. P. 33—42.
10. Charnogursky G., Lee H., Lopez N. Diabetic neuropathy // Handb. Clin. Neurol. 2014. Vol. 120. P. 773-785.
11. De Leo S., Lee S.Y., Braverman L.E. Hyperthyroidism // Lancet. 2016. Vol. 388. P. 906—918.
12. Hoftberger R., Rosenfeld M.R., Dalmau J. Update on neurological paraneoplastic syndromes // Cur.r Opin. Oncol. 2015. Vol. 27. P. 489—495.
13. Ishii M. Neurologic complications of nondiabetic endocrine disorders // Continuum (Minneap Minn). 2014. Vol. 20. P. 560-579.
14. Kattah J.C., Kattah W.C. Neurologic disorders associated with disease of the ovaries and testis// Handb. Clin. Neurol. 2014. Vol. 120. P. 787-798.
15. Katzberg H.D., Kassardjian C.D. Toxic and endocrine myopathies // Continuum (Minneap Minn). 2016. Vol. 22. P. 1815-1828.
16. Acker C.G., Singh A.R., Flick R.P., Bernardini J., Greenberg A., Johnson J.P. A trial of thyroxine in acute renal failure // Kidney Int. 2000. Vol. 57. P. 293—298.
17. Ahmed N., Furth A.J. Failure of common glycation assays to detect glycation by fructose // Clin. Chem. 1992. Vol. 38. N. 7. P. 1301-1303.
18. Ahn C.H., Min S.H., Lee D.H. et al. Hemoglobin glycation index is associated with cardiovascular diseases in people with impaired glucose metabolism // J. Clin. Endocrinol. Metab. 2017. Vol. 102. N. 8. P. 2905-2913.
19. Alkemade A., Friesema E.C., Unmehopa U.A. et al. Neuroanatomical pathways for thyroid hormone feedback in the human hypothalamus // J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 4322-4334.
20. Aramendi I., Burghi G., Manzanares W. Dysglycemia in the critically ill patient: current evidence and future perspectives // Rev. Bras. Ter. Intensiva. 2017. Vol. 29. N. 3. P. 364—372.
21. Arem R.T.J., Deppe S.A. Comparison of thyroid hormone and cortisol measurements with APACHE II and TISS scoring systems as predictors of mortality in the medical intensive care unit //J. Intensive Care Med. 1997. Vol. 12. P. 12—17.
22. Austin G.E., Wheaton R., Nanes M.S.. Rubin J., Mullins R.E. Usefulness of fructosamine for monitoring outpatients with diabetes // Am. J. Med. Sci. 1999. Vol. 318. N. 5. P. 316—323.
23. Baumann M. Advanced glycation endproducts in sepsis and mechanical ventilation: extra or leading man? // Critical. Care. 2009. Vol. 13. P. 164.
24. Becker R.A., Vaughan G.M., Ziegler M.G. et al. Hypermetabolic low triiodothyronine syndrome of burn injury//Crit. Care Med. 1982. Vol. 10. P. 870—875.
25. Bilotta E, Caramia R., Paoloni F.P., Delfini R., Rosa G. Safety and efficacy of intensive insulin therapy in critical neurosurgical patients//Anesthesiology. 2009. Vol. ПО. P. 611—619.
26. Boelen A., Kwakkel J., Thijssen-Timmer D.C., Alkemade A., Fliers E., Wiersinga W.M. Simultaneous changes in central and peripheral components of the hypothalamus-pituitar-ythyroid axis in lipopolysaccharide-induced acute illness in mice // J. Endocrinol. 2004. Vol. 182. P. 315-323.
27. Boelen A.,Wiersinga W.M., Fliers E. Fasting-induced changes in the hypothalamus-pituitary-thyroid axis // Thyroid. 2008. Vol. 18. P. 123—129.
28. Boelen A., Kwakkel J., Fliers E. Beyond low plasma T3: local thyroid hormone metabolism during inflammation and infection // Endocr. Rev. 2011. Vol. 32. P. 670—693.
29. Braithwaite S.S. Glycemic variability in hospitalized patients: choosing metrics while awaiting the evidence // Curr. Diab. Rep. 2013. Vol. 13. N. 1. P. 138—154.
30. Ahmad J. The diabetic foot // Diabetes Metab. Syndr. 2016. Vol. 10. P. 48—60.
31. Ahmed I., Goldstein B. Diabetes mellitus // Clin. Dermatol. 2006. Vol. 24. P. 237—246.
32. Barbato M.T., Criado P.R., Silva A.K., Averbeck E., Guerine M.B., Sa N.B. Association of acanthosis nigricans and skin tags with insulin resistance // An. Bras. Dermatol. 2012. Vol. 87. P. 97-104.
33. Bell H.K., Poston G.J., Vora J., Wilson N.J.E. Cutaneous manifestations of the malignant carcinoid syndrome // Br. J. Dermatol. 2005. Vol. 152. P. 71-75.
34. Ben-Shlomo A., Melmed S. Skin manifestations in acromegaly // Clin. Dermatol. 2006. Vol. 24. P. 256-259.
35. Blank S.K., Helm K.D., McCartney C.R., Marshall J.C. Polycystic ovary syndrome in adolescence //Ann. N. Y. Acad. Sci. 2008. Vol. 1135. P. 76-84.
36. Borlu M., Karaca Z., Yildiz H., Tanriverdi E, Demirel B., Elbuken G. et al. Acromegaly is associated with decreased skin transepidermal water loss and temperature, and increased skin pH and sebum secretion partially reversible after treatment // Growth. Hormon. IGF Res. 2012. Vol. 22. P. 82-86.
37. Boulton A.J., Vileikyte 1., Ragnarson-Tennvall G. Apelqvist. The global burden of diabetic foot disease // Lancet. 2005. Vol. 366. P. 1719-1724.
38. Brazzini B., Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use // Am. J. Clin. Dermatol. 2002. Vol. 3. P. 47—58.
39. Burke W.A., Briggaman R.A., Gammon W.R. Epidermolysis bullosa acquisita in a patient with multiple endocrinopathies syndrome//Arch. Dermatol. 1986. Vol. 122. P. 187—189.
40. Cause M., Kamboj A., Faith E.F. Dermatologic manifestations of endocrine disorders // Transl. Pediatr. 2017. Vol. 6. P. 300-312.
41. Crook MA. Skin tags and the atherogenic lipid profile //J. Clin. Pathol. 2000. Vol. 53. P. 873—874.
42. Dabski K., Winkelmann R.K.. Generalized granuloma annulare. Clinical and laboratory findings in 100 patients //J. Am. Acad. Dermatol. 1989. Vol. 20. P. 39—47.
43. Daoud M.A., Mete O., Al Habeeb A., Ghazarian D. Neuroendocrine carcinoma of the skin-an updated review// Semin. Diagn. Pathol. 2013. Vol. 30. P. 234—244.
44. Darling T.N., Skarulis M.C., Steinberg S.M., Marx S.J., Spiegel A.M., Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1 /1 Arch. Dermatol. 1997. Vol. 133. P. 853-857.
45. Davidovici B., Orion E., Wolf R. Cutaneous manifestations of pituitary gland diseases // Clin. Dermatol. 2008. Vol. 26. P. 288-295.
46. de Laat J.M., van der Luijt R.B., Pieterman C.R., Oostveen M.P., Hermus A.R., Dekkers O.M. et al. MEN1 redefin e.d., a clinical comparison of mutation-positive and mutation-negative patients // BMC Med. 2016. Vol. 14. P. 182.
47. Demirkesen C. Skin manifestations of endocrine diseases // Turk. Patoloji Derg. 2015. Vol. 31. P. 145-154.
48. Diven D.G., Tanus T., Raimer S.S. Cutis verticis gyrata // Int. J. Dermatol. 1991. Vol. 30. P. 710-712.
49. Dumitrescu C.E., Collins M.T. McCune-Albright syndrome // Orphanet. J. Rare Dis. 2008. Vol. 3. P. 12.
50. Erfurt-Berge С., Seitz А.Т., Rehse С., Wollina U., Schwede К., Renner R. Update on clinical and laboratory features in necrobiosis lipoidica: a retrospective multicentre study of 52 patients// Eur. J. Dermatol. 2012. Vol. 22. P. 770-775.
51. Feingold K.R., Elias P.M. Endocrine-skin interactions. Cutaneous manifestations of pituitary disease, thyroid disease, calcium disorders, and diabetes // J. Am. Acad. Dermatol. 1987. Vol. 17. P. 921-940.
52. Ferringer T., Miller F. Cutaneous manifestations of diabetes mellitus // Dermatol. Clin. 2002. Vol. 20. P. 483-492.
53. Fuleihan G.H., Rubeiz N. Dermatologic manifestations of parathyroid-related disorders // Clin. Dermatol. 2006. Vol. 24. P. 281-288.
54. Geerlings S.E., Hoepelman A.I. Immune dysfunction in patients with diabetes mellitus (DM) /I FEMS Immunol. Med. Microbiol. 1999. Vol. 26. P. 259-265.
55. Hanley P., Lord K., Bauer AJ. Thyroid disorders in children and adolescents: a review // JAMA Pediatr. 2016. Vol. 170. P. 1008-1019.
56. Heinzerling L., Raile K., Rochlitz H., ZuberbierT., Worm M. Insulin allergy: clinical manifestations and management strategies // Allergy. 2008. Vol. 63. P. 148—155.
57. Herskovitz I., Tosti A. Female pattern hair loss // Int. J. Endocrinol. Metab. 2013. Vol. 11. P. e9860.
58. Heymann W.R. Cutaneous manifestations of thyroid disease // J. Am. Acad. Dermatol. 1992. Vol. 26. P. 885.
59. Hoerer E., Dreyfuss E, Herzberg M. Carotenem i.c., skin colour and diabetes mellitus //Acta DiabetoL Lat. 1975. Vol. 12. P. 202-207.
60. Horvath A., Stratakis C.A. Carney complex and lentiginosis // Pigment. Cell. Melanoma Res. 2009. Vol. 22. P. 580-587.
61. Ikeda Y., Suehiro T., Abe T., Yoshida T., Shinoki T., Tahara K. et al. Severe diabetic scleredema with extension to the extremities and effective treatment using prostaglandin El // Intern. Med. 1998. Vol. 37. P. 861-864.
62. Jabbour S.A. Cutaneous manifestations of endocrine disorders: a guide for dermatologists // Am. J. Clin. Dermatol. 2003. Vol. 4. P. 315-331.
63. Kanaka-Gantenbein C., Kogia C., Abdel-Naser M.B., Chrousos G.P. Skin manifestations of growth hormone-induced diseases // Rev. Endocr. Metab. Disord. 2016. Vol. 17. P. 259-267.
64. Kasten R., Pfirrmann G., Voigtlander V. Klinefelter’s syndrome associated with mixed connective tissue disease (Sharp’s syndrome) and thrombophilia with postthrombotic syndrome // J. Dtsch. Dermatol. Ges. 2005. Vol. 3. P. 623—626.
65. Kendereski A., Mici D., Sumarac M. et al. White Addison’s disease: what is the possible cause? //J. Endocrinol. Invest. 1999. Vol. 22. P. 395—400.
66. Ko M.J., Chiu H.C., Jee S.H., Hu F.C., Tseng C.H. Postprandial blood glucose is associated with generalized pruritus in patients with type 2 diabetes // Eur. J. Dermatol. 2013. Vol. 23. P. 688-693.
67. Krause W. Skin diseases in consequence of endocrine alterations // Aging. Male. 2006. Vol. 9. P. 81-95.
68. Kutlubay Z., Engin B., Bairamov O., Tuzun Y. Acanthosis nigricans: a fold (intertriginous) dermatosis // Clin. Dermatol. 2015. Vol. 33. P. 466—470.
69. Lan C., Li C., Chen W, Mei X., Zhao J., Hu J. A randomized controlled trial of intralesional glucocorticoid for treating pretibial myxedema//J. Clin. Med. Res. 2015. Vol. 7. P. 862—872.
70. Larsen K., Jensen T., Karlsmark T., Holstein P.E. Incidence of bullosis diabeticorum—a controversial cause of chronic foot ulceration // Int. Wound J. 2008. Vol. 5. P. 591—596.
71. Lee M.R., Shumack S. Prurigo nodularis: a review // Australas J. Dermatol. 2005. Vol. 46. P. 211-218.
72. Leonhardt J.M., Heymann W.R. Thyroid disease and the skin // Dermatol. Clin. 2002. Vol. 20. P. 473-481.
73. Leventhal J.S., Braverman I.M. Skin manifestations of endocrine and neuroendocrine tumors// Semin. Oncol. 2016. Vol. 43. P. 335-340.
74. Levy L., Zeichner J.A. Dermatologic manifestation of diabetes // J. Diabetes. 2012. Vol. 4. P. 68-76.
75. Lima A.L., llling T., Schliemann S., Elsner P. Cutaneous manifestations of diabetes mellitus: a review // Am. J. Clin. Dermatol. 2017. Vol. 18. P. 541—553.
76. Lipsky B.A., Baker P.D., Ahroni J.H. Diabetic bullae: 12 cases of a purportedly rare cutaneous disorder // Int. J. Dermatol. 2000. Vol. 39. P. 196—200.
77. Mahmood T., Bari A., Agha H. Cutaneous manifestations of diabetes mellitus // J. Pak. Assoc. Dermatol. 2005. Vol. 15. P. 227-232.
78. Martin C., Requena L., Manrique K., Manzarbeitia ED., Rovira A. Scleredema diabeticorum in a patient with type 2 diabetes mellitus // Case Rep. Endocrinol. 2011. Vol. 2011. P. 560273.
79. Marx SJ. Hyperparathyroid and hypoparathyroid disorders // N. Engl. J. Med. 2000. Vol. 343. P. 1863-1875.
80. Melmed S. Medical progress: acromegaly // N. Engl. J. Med. 2006. Vol. 355. P. 2558—2573. Muhlbauer J.E. Granuloma annulare //J. Am. Acad. Dermatol. 1980. Vol. 3. P. 217—230. Ngo B.T., Hayes K.D., DiMiao D.J., Srinivasan S.K., Huerter C.J., Rendell M.S.
81. Manifestations of cutaneous diabetic microangiopathy // Am. J. Clin. Dermatol. 2005. Vol. 6. P. 225-237.
82. Noakes R. Lichenoid drug eruption as a result of the recently released sulfonylurea glimepiri-de // Australas J. Dermatol. 2003. Vol. 44. P. 302—303.
83. Oh D.H., Eulau D., Tokugawa D.A., McGuire J.S., Kohler S. Five cases of calciphylaxis and a review of the literature //J. Am. Acad. Dermatol. 1999. Vol. 40. P. 979—987.
84. Parex I. Cutaneous manifestations of diabetes mellitus // J. Am. Acad. Dermatol. 1994. Vol. 30. P. 519-531.
85. Paterson A.J., Lamey P.J., Lewis M.A., Nolan A., Rademaker M. Pemphigus vulgaris precipitated by glibenclamide therapy//J. Oral. Pathol. Med. 1993. Vol. 22. P. 92—95.
86. Perez M.L, Kohn S.R. Cutaneous manifestations of diabetes mellitus // J. Am. Acad. Dermatol. 1994. Vol. 30. P. 519-531.
87. Ratnam K.V, Su W.P., Peters M.S. Purpura simplex (inflammatory purpura without vasculitis): a clinicopathologic study of 174 cases // J. Am. Acad. Dermatol. 1991. Vol. 25. P. 642-647.
88. Regana M.S., Millet P.U. Psoriasis in association with prolactinoma: three cases // Br. J. Dermatol. 2000. Vol. 143. P. 864-867.
89. Resende M., Bolfi E, Nunes Vdos S., Miot H.A. Prevalence of dermatologic disorders in 15 patients with acromegaly // An. Bras. Dermatol. 2012. Vol. 87. P. 166—168.
90. Richardson T., Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies //Am. J. Clin. Dermatol. 2003. Vol. 4. P. 661—667.
91. Safer J. D. Thyroid hormone action on skin // Dermatoendocrinology. 2011. Vol. 3. P. 211—215.
92. Saggini A., Brandi M.L. Skin lesions in hereditary endocrine tumor syndromes // Endocr. Pract. 2011. Vol. 17. P. 47-57.
93. Sahin M.T., Tiirel-Ermertcan A., Oztiirkcan S., Tiirkdogan P. Generalized granuloma annulare in a patient with type II diabetes mellitus: successful treatment with isotretinoin // J. Eur. Acad. Dermatol. Venereol. 2006. Vol. 20. P. 111 — 114.
94. Sehgal V.N., Srivastava G., Aggarwal A.K., Gupta M., Bhattacharya S.N., Verma P. Noninsulin depende n.t., type II diabetes mellitus related dermatoses: part 11 // Skinmed. 2011. Vol. 9. P. 302-308.
95. Seyhan М., Ozcan Н., Sahin I., Bayram N., Karincaoglu Y. High prevalence of glucose metabolism disturbance in patients with lichen planus // Diabetes Res. Clin. Pract. 2007. Vol. 77. P. 198-202.
96. Singh N., Armstrong D.G., Lipsky B.A. Preventing foot ulcers in patients with diabetes // JAMA. 2005. Vol. 293. P. 217-228.
97. Stratakis C.A. Skin manifestations of Cushing’s syndrome // Rev. Endocr. Metab. Disord. 2016. Vol. 17. P. 283-286.
98. Siinkel S., Wichmann-Hesse A., Gartner R., Hesse G. Increasing pigmentation in Schmidt syndrome (polyglandular autoimmune syndrome type 11) // Hautarzt. 2001. Vol. 52. P. 974-976.
99. Torley D., Bellus G.A., Munro C.S. Genes, growth factors and acanthosis nigricans // Br. J. Dermatol. 2002. Vol. 147. P. 1096-1101.
100. Van Hattem S., Bootsma A.H., Thio H.B. Skin manifestations of diabetes // Cleve Clin. J. Med. 2008. Vol. 75. P. 772-777.
101. Verrotti A., Chiarelli E, Amerio P., Morgese G. Necrobiosis lipoidica diabeticorum in children and adolescents: a clue for underlying renal and retinal disease // Pediatr. Dermatol. 1995. Vol. 12. P. 220-223.
102. Wagner G., Sachse M.M. Acquired reactive perforating dermatosis //J. Dtsch. Dermatol. Ges. 2013. Vol. 11. P. 723-729.
103. Wilson BE., Newmark J.J. Severe scleredema diabeticorum and insulin resistance // J. Am. Board. Fam. Pract. 1995. Vol. 8. P. 55—57.
104. Wiwanitkit V Metformin allergy // Indian J. Pharmacol. 2011. Vol. 43. P. 216—217.
105. Wu C.S., Chang W.Y., Lan C.C., Chen G.S., Chiu H.H. Acute generalized exanthematous pustulosis possibly induced by acarbose // Int. J. Dermatol. 2008. Vol. 47. P. 1313—1315.
106. Yildiz B.O. Diagnosis of hyperandrogenism: clinical criteria // Best. Pract. Res. Clin. Endocrinol. Metab. 2006. Vol. 20. P. 167—176.
107. Yosipovitch G., Hodak E., Vardi P., Shraga 1., Karp M., Sprecher E. et al. The prevalence of cutaneous manifestations in DM patients and their association with diabetes risk factors and microvascular complications// Diabetes Care. 1998. Vol. 21. P. 506—509.
108. Ahn С., Kang H.S., Lee J.H., Hong E.J., Jung E.M., Yoo Y.M., Jeung E.B. Bisphenol A and octylphenol exacerbate type 1 diabetes mellitus by disrupting calcium homeostasis in mouse pancreas //Toxicol. Lett. 2018. Vol. 295. P. 162—172.
109. Altamirano G.A., Delconte M.B., Gomez A.L., Ingaramo P.I., Bosquiazzo V.L., Luque E.H., Kass L. Postnatal exposure to a glyphosate-based herbicide modifies mammary gland growth and development in Wistar male rats // Food Chem. Toxicol. 2018. Vol. 118. P. 111-118.
110. Amin М.М., Ebrahim К., Hashemi M., Shoshtari-Yeganeh В., Rafiei N., Mansourian M., Kelishadi R. Association of exposure to Bisphenol Awith obesity and cardiometabolic risk factors in children and adolescents // Int. J. Environ. Health Res. 2019. Vol. 29. N. 1. P. 94-106. https://doi.org/10.1080/09603123.2018.1515896.
111. Attina T.M., Trasande L. Association of exposure to Di-2-ethylhexylphthalate replacements with increased insulin resistance in adolescents from NHANES 2009—2012 // J. Clin. Endocrinol. Metab. 2015. Vol. 100. N. 7. P. 2640-2650. https://doi.org/10.1210/ jc.2015-1686.
112. Attina T.M., Hauser R., Sathyanarayana S., Hunt P.A., Bourguignon J.P., Myers J.P. ... Trasande L. Exposure to endocrine-disrupting chemicals in the USA: a population-based disease burden and cost analysis // Lancet Diabetes Endocrinol. 2016. Vol. 4. N. 12. P. 996-1003. https://doi.org/10.1016/S2213-8587( 16)30275-3.
113. Avgerinos K.I., Spyrou N., Mantzoros C.S., Dalamaga M. Obesity and cancer risk: emerging biological mechanisms and perspectives // Metabolism. 2019. Vol. 92. P. 121 — 135. https:// doi.org/10.1016/j.metabol.2018.11.001.
114. Bai X., Yan L., Ji C., Zhang Q., Dong X., Chen A., Zhao M. A combination of ternary classification models and reporter gene assays for the comprehensive thyroid hormone disruption profiles of 209 polychlorinated biphenyls // Chemosphere. 2018. Vol. 210. P. 312—319. https://doi.Org/l0.1016/j.chemosphere.2018.07.023.
115. Bailey H.D., Fritschi L., Infante-Rivard C., Glass D.C., Miligi L., Dockerty J.D. ... Schuz J. Parental occupational pesticide exposure and the risk of childhood leukemia in the offspring: findings from the childhood leukemia international consortium // Int. J. Cancer. 2014. Vol. 135. N. 9. P. 2157-2172. https://doi.org/10.1002/ijc.28854.
116. Bodin J., Kocbach Bolling A., Wendt A., Eliasson L., Becher R., Kuper E ... Nygaard U.C. Exposure to bisphenol A., but not phthalat e.s., increases spontaneous diabetes type 1 development in NOD mice //Toxicol. Rep. 2015. Vol. 2. P. 99—110. https://doi.Org/10.1016/j. toxrep.2015.02.010.
117. Brook R.D., Cakmak S., Turner M.C., Brook J.R., Crouse D.L., Peters P.A. ... Burnett R.T. Long-term fine particulate matter exposure and mortality from diabetes in Canada // Diabetes Care. 2013. Vol. 36. N. 10. P. 3313-3320. https://doi.org/10.2337/dcl2-2189.
118. Calsolaro V, Pasqualetti G., Niccolai E, Caraccio N., Monzani F. Thyroid disrupting chemicals// Int. J. Mol. Sci. 2017. Vol. 18. N. 12. https://doi.org/10.3390/ijmsl8122583.
119. Costas L., Infante-Rivard C., Zock J.P., Van Tongeren M., Boffetta P., Cusson A. ... de Sanjose S. Occupational exposure to endocrine disruptors and lymphoma risk in a multi-centric European study // Br. J. Cancer. 2015. Vol. 112. N. 7. P. 1251 — 1256. https://doi. org/10.l038/bjc.2015.83.
120. Cowell W., Sjodin A., Jones R.L., Wang Y, Wang S., Whyatt R. ... Herbstman J. Pre and postnatal polybrominated diphenyl ether concentrations in relation to thyroid parameters measured during early childhood // Thyroid. 2019. https://doi.org/10.1089/ thy.2018.0417.
121. de Cock M., de Boer M.R., Govarts E., Iszatt N., Palkovicova L., Lamoree M.H. ... van de Bor M. Thyroid-stimulating hormone levels in newborns and early life exposure to endocrinedisrupting chemicals: analysis of three European mother-child cohorts // Pediatr. Res. 2017. Vol. 82. N. 3. P. 429-437. https://doi.org/10.1038/pr.2017.50.
122. de Souza J.S., Kizys M.M., da Conceicao R.R., Glebocki G., Romano R.M., Ortiga-Carvalho T.M.... Chiamolera M.I. Perinatal exposure to glyphosate-based herbicide alters the thyrotrophic axis and causes thyroid hormone homeostasis imbalance in male rats // Toxicology. 2017. Vol. 377. P. 25-37. https://doi.Org/10.1016/j.tox.2016.ll.005.
123. Defarge N., Takacs E., Lozano V.L., Mesnage R., Spiroux de Vendomois J., Seralini G.E., Szekacs A. Co-formulants in glyphosate-based herbicides disrupt aromatase activity in human cells below toxic levels // Int. J. Environ. Res. Public. Health. 2016. Vol. 13. N. 3. P. 264. https://doi.org/10.3390/ijerphl3030264.
124. Demerath E.W., Choh A.C., Johnson W., Curran J.E., Lee M., Bellis C.... Towne B. The positive association of obesity variants with adulthood adiposity strengthens over an 80-year period: a gene-by-birth year interaction // Hum. Hered. 2013. Vol. 75. N. 2—4. P. 175—185. https://doi.org/10.1159/000351742.
125. Di Ciaula A. Type I diabetes in paediatric age in Apulia (Italy): incidence and associations with outdoor air pollutants // Diabetes. Res. Clin. Pract. 2016. Vol. 111. P. 36—43. https://doi. org/10.1016/j.diabres.2015.10.016.
126. Di Ciaula A. Towards 5G communication systems: are there health implications? // Int. J. Hyg. Environ. Health. 2018. Vol. 221. N. 3. P. 367-375. https://doi.0rg/lO.lOI6/j. ijheh.2018.01.Oil.
127. Di Ciaula A., Portincasa P. Fat, epigenome and pancreatic diseases. Interplay and common pathways from a toxic and obesogenic environment // Eur. J. Intern. Med. 2014. Vol. 25. N. 10. P. 865-873. https://doi.Org/10.1016/j.ejim.2014.10.012.
128. Di Ciaula A., Portincasa P. Diet and contaminants: driving the rise to obesity epidemics? // Curr. Med. Chem. 2017. https://doi.org/10.2174/0929867324666170518095736.
129. Eskander E.F., Estefan S.F., Abd-Rabou A.A. How does long term exposure to base stations and mobile phones affect human hormone profiles? // Clin. Biochem. 2012. Vol. 45. N. 1—2. P. 157—161. https://doi.0rg/lO.lOl6/j.clinbiochem.2Oll.ll.OO6.
130. Esmekaya M.A., Seyhan N., Omeroglu S. Pulse modulated 900 MHz radiation induces hypothyroidism and apoptosis in thyroid cells: a light, electron microscopy and immunohistochemical study // Int. J. Radiat. Biol. 2010. Vol. 86. N. 12. P. 1106—1116. https://d0i.0rg/l O. 3109/09553002.2010.502960.
131. Gallo M.V., Ravenscroft J., Carpenter D.O., Schell L.M., Akwesasne Task Force On The Environment. Persistent organic pollutants as predictors of increased FSH:LH ratio in naturally cycling, reproductive age women // Environ. Res. 2018. Vol. 164. P. 556—564. https://doi.0rg/lO.lOl6/j. envres.2018.03.021.
132. Ghazarian A.A., Trabert B., Robien K., Graubard B.I., McGlynn K.A. Maternal use of personal care products during pregnancy and risk of testicular germ cell tumors in sons // Environ. Res. 2018. Vol. 164. P. 109—113. https://doi.Org/10.1016/j.envres.2018.02.017.
133. Gibson E.A., Siegel E.L., Eniola E, Herbstman J.B., Factor-Litvak P. Effects of polybrominated diphenyl ethers on child cogniti v.e., behavior a.l., and motor development // Int. J. Environ. Res. Public Health. 2018. Vol. 15. N. 8. pii: E1636. https://doi.org/10.3390/ ijerph 15081636.
134. Gore A.C., Chappell V.A., Fenton S.E., Flaws J.A., Nadal A., Prins G.S. ... Zoeller R.T. Executive summary to EDC-2: the Endocrine Society’s second scientific statement on en-docrinedisrupting chemicals // Endocr. Rev. 2015. Vol. 36. N. 6. P. 593—602. https://doi. org/10.1210/er.2015-1093.
135. Howe C.G., Eckel S.P., Habre R., Girguis M.S., Gao L., Lurmann F.W. ... Breton C.V. Association of prenatal exposure to ambient and traffic-related air pollution with newborn thyroid function: findings from the Children’s Health Study // JAMA Netw. Open. 2018. Vol. 1. N. 5. P. el82172. https://doi.org/10.1001/jamanetworkopen.2018.2172.
136. Hu Y, Wen S., Yuan D., Peng L., Zeng R., Yang Z. ... Kang D. The association between the environmental endocrine disruptor bisphenol a and polycystic ovary syndrome: a systematic review and meta-analysis // Gynecol. Endocrinol. 2018. Vol. 34. N. 5. P. 370—377. https://doi.org/10.1080/09513590.2017.1405931.
137. Kasubuchi M., Hasegawa S., Hiramatsu T., Ichimura A., Kimura I. Dietary gut microbial me-tabolit e.s., short-chain fatty aci d.s., and host metabolic regulation // Nutrients. 2015. Vol. 7. N. 4. P. 2839-2849. https://doi.org/10.3390/nu7042839.
138. Kesari К.К., Agarwal A., Henkel R. Radiations and male fertility // Reprod Biol Endocrinol. 2018. Vol. 16. N. 1. P. 118. https://doi.org/10.1186/sl2958-018-0431-l.
139. Kim M.J., Moon S., Oh B.C., Jung D., Choi K., Park YJ. Association between diethylhexyl phthalate exposure and thyroid function: a meta-analysis // Thyroid. 2019. Vol. 29. N. 2. P. 183-192. https://doi.org/10.1089/thy.2018.0051.
140. Koyu A., Cesur G., Ozguner E, Akdogan M., Mollaoglu H., Ozen S. Effects of 900 MHz electromagnetic field on TSH and thyroid hormones in rats//Toxicol. Lett. 2005. Vol. 157. N. 3. P. 257-262. https://doi.Org/10.1016/j.toxlet.2005.03.006.
141. Kubsad D., Nilsson E.E., King S.E., Sadler-Riggleman I., Beck D., Skinner M.K. Assessment of glyphosate induced epigenetic transgenerational inheritance of pathologies and sperm epimutations: generational toxicology // Sci Rep. 2019. Vol. 9. N. 1. P. 6372. https://doi. org/10.1038/ S41598-019-42860-0.
142. Kunkle B., Bae S., Singh K.P., Roy D. Increased risk of childhood brain tumors among children whose parents had farm-related pesticide exposures during pregnancy // JP J. Biostat. 2014. Vol. 11. N. 2. P. 89-101.
143. Lauritzen H.B., Larose T.L., Oien T., Sandanger T.M., Odland J.O., van de Bor M., Jacobsen G.W. Prenatal exposure to persistent organic pollutants and child overweight/ obesity at 5-year followup: a prospective cohort study // Environ. Health. 2018. Vol. 17. N. 1. P. 9. https://doi.org/10.1186/sl2940-017-0338-x.
144. Lavigne E., Ashley-Martin J., Dodds L., Arbuckle T.E., Hystad P., Johnson M.... Fraser W.D. Air pollution exposure during pregnancy and fetal markers of metabolic function: the M1REC Study // Am. J. Epidemiol. 2016. Vol. 183. N. 9. P. 842—851. https://doi. org/10.1093/aje/kwv256.
145. Le Cornet C., Fervers B., Pukkala E., Tynes T., Feychting M., Hansen J. ... Schuz J. Parental occupational exposure to organic solvents and testicular germ cell tumors in their offspring: NORD-TEST Study // Environ. Health Perspect. 2017. Vol. 125. N. 6. P. 067023. https:// doi.org/10.1289/EHP864.
146. Lee H.S., Lee J.C., Lee I.K., Moon H.B., Chang Y.S., Jacobs DR J.r., Lee D.H. Associations among organochlorine pesticid e.s., methanobacterial e.s., and obesity in Korean women // PLoS One. 2011. Vol. 6. N. 11. P. e27773. https://doi.org/10.1371/joumal.pone.0027773.
147. Lerro C.C., Koutros S., Andreotti G., Sandler D.P., Lynch C.F., Louis L.M. ... Beane Freeman L.E. Cancer incidence in the agricultural health study after 20 years of follow-up // Cancer Causes. Control. 2019. Vol. 30. N. 4. P. 311—322. https://doi. org/10.1007/sl0552-019-01140-y.
148. Liu B., Lehmler H.J., Sun Y., Xu G., Liu Y., Zong G. ... Bao W. Bisphenol A substitutes and obesity in US adults: analysis of a population-bas e.d., cross-sectional study // Lancet Planet. Health. 2017. Vol. 1. N. 3. P. e 114—e 122. https://doi.org/10.1016/S2542-5196(17)30049-9.
149. Liu B., Lehmler H.J., Sun Y., Xu G., Sun Q., Snetselaar L.G. ... Bao W. Association of Bisphenol A and its substitut e.s., Bisphenol F and Bisphenol S, with obesity in United States children and adolescents // Diabetes Metab. J. 2019. Vol. 43. N. 1. P. 59—75. https:// doi.org/10.4093/dmj.2018.0045.
150. Luo D., Pu Y., Tian H., Wu W., Sun X., Zhou T. ... Mei S. Association of in utero exposure to organochlorine pesticides with thyroid hormone levels in cord blood of newborns // Environ. Pollut. 2017. Vol. 231. Pt. 1. P. 78—86. https://doi.org/10.1016/j.en-vpol.2017.07.091.
151. Malmqvist E., Larsson H.E., Jonsson I., Rignell-Hydbom A., Ivarsson S.A., Tinnerberg H. ... Rylander L. Maternal exposure to air pollution and type 1 diabetes — accounting for genetic factors// Environ. Res. 2015. Vol. 140. P. 268—274. https://doi.org/10.1016/j.en-vres.2015.03.024.
152. Martini C.N., Gabrielli М., Brandani J.N., Del С., Vila М. Glyphosate inhibits PPAR gamma induction and differentiation of preadipocytes and is able to induce oxidative stress // J. Biochem. Mol. Toxicol. 2016. N. 8. P. 404—413. https://doi.org/10.1002/jbt.21804.
153. Meo S.A., Al Rubeaan K. Effects of exposure to electromagnetic field radiation (EMFR) generated by activated mobile phones on fasting blood glucose // Int. J. Occup. Med. Environ. Health. 2013. Vol. 26. N. 2. P. 235-241. https://doi.org/10.2478/sl3382-013-0107-l.
154. Meo S.A., Alsubaie Y, Almubarak Z., Almutawa H., AIQasem Y, Hasanato R.M. Association of Exposure to radio-frequency electromagnetic field radiation (RF-EMFR) generated by Mobile Phone Base stations with glycated hemoglobin (HbAlc) and risk of type 2 diabetes mellitus // Int. J. Environ. Res. Public Health. 2015. Vol. 12. N. 11. P. 14519—14528. https://doi.org/10.3390/ijerphl211145l9.
155. Mortazavi S.M., Owji S.M., Shojaei-Fard M.B., Ghader-Panah M., Mortazavi S.A., Tavakoli-Golpayegani A. ... Koohi O. GSM 900 MHz microwave radiation-induced alterations of insulin level and histopathological changes of liver and pancreas in rat // J. Biomed. Phys. Eng. 2016. Vol. 6. N. 4. P. 235-242.
156. Nevoral J., Kolinko Y, Moravec J., Zalmanova T., Hoskova K., Prokesova S.... Kralickova M. Longterm exposure to very low doses of bisphenol S affects female reproduction // Reproduction. 2018. Vol. 156. N. 1. P. 47—57. https://doi.org/10.1530/REP-18-0092.
157. Nowak K., Jablonska E., Ratajczak-Wrona W. Immunomodulatory effects of synthetic endocrine disrupting chemicals on the development and functions of human immune cells // Environ. Int. 2019. Vol. 125. P. 350-364. https://doi.Org/10.1016/j.envint.2019.01.078.
158. Owagboriaye F.O., Dedeke G.A., Ademolu K.O., Olujimi O.O., Ashidi J.S., Adeyinka A.A. Reproductive toxicity of roundup herbicide exposure in male albino rat // Exp. Toxicol. Pathol. 2017. Vol. 69. N. 7. P. 461-468. https://doi.Org/10.1016/j.etp.2017.04.007.
159. Park J., Park S.K., Choi YH. Environmental pyrethroid exposure and diabetes in U.S. adults // Environ. Res. 2018. Vol. 172. P. 399—407. https://doi.Org/10.1016/j.envres.2018.12.043.
160. Perego M.C., Caloni E, Cortinovis C., Schutz L.F., Albonico M., Tsuzukibashi D., Spicer L.J. Influence of a roundup formulation on glyphosate effects on steroidogenesis and proliferation of bovine granulosa cells in vitro // Chemosphere. 2017. Vol. 188. P. 274—279. https:// doi.org/10.1016/j.chemosphere.2017.09.007.
161. Ren X., Li R., Liu J., Huang K., Wu S., Li Y, Li C. Effects of glyphosate on the ovarian function of pregnant mi c.e., the secretion of hormones and the sex ratio of their fetuses // Environ. Pollut. 2018. Vol. 243. Pt. В. P. 833—841. https://doi.org/10.1016Zj.en-vpol.2018.09.049.
162. RiJk I., van Duursen E.R.T., van den Berg M. Health costs that may be associated with endocrine disrupting chemicals. Utrech: Institute for Risk Assessment Scien c.e., University of Utrecht, 2016.
163. Rundle A., Hoepner L., Hassoun A., Oberfield S., Freyer G., Holmes D. ... Whyatt R. Association of childhood obesity with maternal exposure to ambient air polycyclic aromatic hydrocarbons during pregnancy // Am. J. Epidemiol. 2012. Vol. 175. N. 11. P. 1163—1172. https://doi.org/10.1093/aje/kwr455.
164. Shrestha S., Parks C.G., Goldner W.S., Kamel E, Umbach D.M., Ward M.H.... Sandler D.P. Pesticide use and incident hypothyroidism in pesticide applicators in the agricultural health study // Environ. Health Perspect. 2018. Vol. 126. N. 9. P. 97008. https://doi.org/10.1289/ EHP3194.
165. Sidorkiewicz L, Zareba K., Wolczynski S., Czerniecki J. Endocrine-disrupting chemi-cals-mechanisms of action on male reproductive system // Toxicol. Ind. Health. 2017. Vol. 33. N. 7. P. 601-609. https://doi.org/10.1177/0748233717695160.
166. Skarha J., Minguez-Alarcon L., Williams P.L., Korevaar T.I.M., de Poortere R.A., Broeren M A.C. ... Braun J.M. Cross-sectional associations between urinary triclosan and serum thyroid function biomarker concentrations in women // Environ. Int. 2019. Vol. 122. P. 256—262. https://doi.Org/10.1016/j.envint.2018.ll.015.
167. Song Y., Chou E.L., Baecker A., You N.C., Song Y, Sun Q., Liu S. Endocrine-disrupting chemica l.s., risk of type 2 diabet e.s., and diabetes-related metabolic traits: a systematic review and meta. 3-analysis // J. Diabetes. 2016. Vol. 8. N. 4. P. 516—532. https://doi. org/10.1111/1753-0407.12325.
168. Starling A.P., Umbach D.M., Kamel E, Long S., Sandler D.P., Hoppin J.A. Pesticide use and incident diabetes among wives of farmers in the Agricultural Health Study // Occup. Environ. Med. 2014. Vol. 71. N. 9. P. 629—635. https://doi.org/10.1136/ oemed-2013-101659.
169. Su P.H., Chen H.Y., Chen S.J., Chen J.Y., Liou S.H., Wang S.L. Thyroid and growth hormone concentrations in 8-year-old children exposed in utero to dioxins and polychlorinated biphenyls//J. Toxicol. Sci. 2015. Vol. 40. N. 3. P. 309—319. https://doi.org/10.2131/ jts.40.309.
170. Thiering E., Cyrys J., Kratzsch J., Meisinger C., Hoffmann B., Berdel D.... Heinrich J. Longterm exposure to traffic-related air pollution and insulin resistance in children: results from the GINIplus and LISAplus birth cohorts // Diabetologia. 2013. Vol. 56. N. 8. P. 1696— 1704. https://doi.org/10.1007/s00125-013-2925-x.
171. Trasande L. Further limiting bisphenol a in food uses could provide health and economic benefits // Health Aff. (Millwood). 2014. Vol. 33. N. 2. P. 316—323. https://doi.org/10.1377/ hlthaff.2013.0686.
172. Trasande L., Spanier A.J., Sathyanarayana S., AttinaT.M., Blustein J. Urinary phthalates and increased insulin resistance in adolescents // Pediatrics. 2013. Vol. 132. N. 3. P. e646— e655. https://doi.org/10.1542/peds.2012-4022.
173. Trasande L., Zoeller R.T., Hass U., Kortenkamp A., Grandjean P., Myers J.P. ... Heindel J.J. Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European union //J. Clin. Endocrinol. Metab. 2015. Vol. 100. N. 4. P. 1245—1255. https://doi.org/10.1210/jc.2014-4324.
174. Vafeiadi M., Georgiou V, Chalkiadaki G., Rantakokko P., Kiviranta H., Karachaliou M. ... Chatzi L. Association of Prenatal Exposure to persistent organic pollutants with obesity and Cardiometabolic traits in early childhood: The Rhea mother-child cohort (Crete, Greece) // Environ. Health Perspect. 2015. Vol. 123. N. 10. P. 1015—1021. https://doi. org/10.1289/ehp. 1409062.
175. Williams G.P., Darbre P.D. Low-dose environmental endocrine disrupto r.s., increase aromatase activi t.y., estradiol biosynthesis and cell proliferation in human breast cells // Mol. Cell. Endocrinol. 2019. Vol. 486. P. 55-64. https://doi.Org/10.1016/j.mce.2019.02.016.
176. Xu J., Huang G., Nagy T., Guo T.L. Bisphenol A alteration of type 1 diabetes in non-obese diabetic (NOD) female mice is dependent on window of exposure // Arch. Toxicol. 2019. Vol. 93. N. 4. P. 1083-1093. https://doi.org/10.1007/s00204-019-02419-4.
177. Yorita Christensen K.L. Metals in blood and uri n.e., and thyroid function among adults in the United States 2007-2008 // Int. J. Hyg. Environ. Health. 2013. Vol. 216. N. 6. P. 624-632. https://doi.Org/10.l016/j.ijheh.2012.08.005.
178. Zama A.M., Uzumcu M. Epigenetic effects of endocrine-disrupting chemicals on female reproduction: an ovarian perspective // Front. Neuroendocrinol. 2010. Vol. 31. N. 4. P. 420— 439. https://doi.Org/10.10l6/j.yfrne.20l0.06.003.
179. Zhang H., DiBaise J.K., Zuccolo A., Kudrna D., Braidotti M., Yu Y.... Krajmalnik-Brown R. Human gut microbiota in obesity and after gastric bypass // Proc. Natl. Acad. Sci USA. 2009. Vol. 106. N. 7. P. 2365-2370. https://doi.org/10.1073/pnas.0812600106.
180. Zhang Y.F., Ren X.M., Li Y.Y., Yao X.F., Li C.H., Qin Z.F., Guo L.H. Bisphenol A alternatives bisphenol S and bisphenol F interfere with thyroid hormone signaling pathway in vitro and in vivo // Environ. Pollut. 2018. Vol. 237. P. 1072—1079. https://doi.0rg/lO.lOI6/j. envpol.2017.11.027.
181. Zheng J., He C.T., Chen S.J., Yan X., Guo M.N.,Wang M.H. ... Mai B.X. Disruption of thyroid hormone (TH) levels and TH-regulated gene expression by polybrominated diphenyl ethers (PBDEs), polychlorinated biphenyls (PCBs), and hydroxylated PCBs in e-waste recycling workers// Environ. Int. 2017. Vol. 102. P. 138—144. https://doi.Org/10.1016/j. envint.2017.02.009.
182. Ziv-Gal A., Flaws J.A. Evidence for bisphenol А-induced female infertility: a review (2007— 2016) U Fertil. Steril. 2016. Vol. 106. N. 4. P. 827-856. https://doi.org/10.1016Zj.fertn-stert.2016.06.027.
183. Brealey D., Brand M., Hargreaves I. et al. Association between mitochondrial dysfunction and severity and outcome of septic shock // Lancet. 2002. Vol. 360. P. 219—223.
184. Capes S.E., Hunt D., Malmberg K. et al. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview // Stroke. 2001. Vol. 32. P. 2426-2432.
185. Carre J.E., Orban J.C., Re L. et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis //Am. J. Respir. Crit. Care Med. 2010. Vol. 182. P. 745—751.
186. Casaer М.Р., Mesotten D., Hermans G. et al. Early versus late Parenteral Nutrition in Critcally Ill Adults// N. Engl. J. Med. 2011. Vol. 365. P. 506-517.
187. Chan T.M. The permissive effects of glucocorticoid on hepatic gluconeogenesis. Glucagon stimulation of glucose-suppressed gluconeogenesis and inhibition of 6-phosphofructo-1-kinase in hepatocytes from fasted rats // J. Biol. Chem. 1984. Vol. 259. N. 12. P. 7426—432.
188. Choi Y.S., Kwak Y.L., Kim J.C., Chun D.H., Hong S.W., Shim J.K. Peri-operative oral triiodothyronine replacement therapy to prevent postoperative low triiodothyronine state following valvular heart surgery // Anaesthesia. 2009. Vol. 64. P. 871—877.
189. Choi Y.S., Shim J.K., Song J.W., Song Y, Yang S.Y., Kwak Y.L. Efficacy of perioperative oral triiodothyronine replacement therapy in patients undergoing off-pump coronary artery bypass grafting // J. Cardiothorac. Vase. Anesth. 2013. Vol. 27. P. 1218—1223.
190. Coester A., Neumann C.R., Schmidt M.I. Intensive insulin therapy in severe traumatic brain injury: a randomized trial //J. Trauma. 2010. Vol. 68. P. 904—911.
191. Cohen R.M., Holmes Y.R., Chenier T.C., Joiner C.H. Discordance between HbAlc and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy // Diabetes Care. 2003. Vol. 26. N. 1. P. 163-167.
192. Diamanti-Kandarakis E., Chatzigeorgiou A., Papageorgiou E., Koundouras D., Koutsilieris M. Advanced glycation end-products and insulin signaling in granulosa cells // Exp. Biol. Med. 2016. Vol. 241. N. 13. P. 1438-1445.
193. Dixit K., Iwen A., Lehmphul I., Hoefig C., Kohrle J., Brabant G. Treatment of central hypothyroidism with recombinant human TSH — a pilot study // Eur. Thyroid. J. 2013. Vol. 2. Suppl. 1. P. 75-194.
194. Dungan K., Braithwaite S.S., Preiser JC. Stress hyperglycemia // Lancet. 2009. Vol. 373. P. 1798-1807.
195. Egi M., Bellomo R., Stachowski E., French C.J., Hart G. Variability of blood glucose concentration and short-term mortality in critically ill patients // Anesthesiology. 2006. Vol. 105. N. 2. P. 244-252.
196. Egi M., Bellomo R., Stachowski E., French C., Hart G., Taori G. Hypoglycemia and outcome in critically ill patients // Mayo Clin. Proc. 2010. Vol. 85. P. 217—224.
197. Farrokhi E, Chandra P., Smiley D. et al. Glucose variability is an independent predictor of mortality in hospitalized patients treated with total parenteral nutrition // Endocr. Pract. 2014. Vol. 20. N. l.P. 41-45.
198. Fekete C., Lechan R.M. Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: role of neuronal afferents and type 2 deiodi-nase // Front. Neuroendocrinol. 2007. Vol. 28. P. 97—114.
199. Fekete C., Lechan R.M. Central regulation of hypothalamic-pituitary-thyroid axis under physiological and pathophysiological conditions // Endocr. Rev. 2014. Vol. 35. P. 159—194.
200. Fekete C., Gereben B., Doleschall M. et al. Lipopolysaccharide induces type 2 iodothyronine deiodinase in the mediobasal hypothalamus: implications for the nonthyroidal illness syndrome // Endocrinology. 2004. Vol. 145. P. 1649—1655.
201. Finfer S., Chittock D.R., Su S.Y et al. Intensive versus conventional glucose control in critically ill patients // N. Engl. J. Med. 2009. Vol. 360. P. 1283-1297.
202. Finfer S., Liu B., Chittock D. et al. Hypoglycemia and risk of death in critically ill patients // N. Engl. J. Med. 2012. Vol. 367. P. 1108-1118.
203. Finfer S., Chittock D., Li Y. et al. Intensive versus conventional glucose control in critically ill patients with traumatic brain injury: long-term follow-up of a subgroup of patients from the NICE-SUGAR study // Intensive Care Med. 2015. Vol. 41. P. 1037—1047.
204. Fliers E., Guldenaar S.E., Wiersinga W.M., Swaab D.F. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with nonthyroidal illness // J. Clin. Endocrinol. Metab. 1997. Vol. 82. P. 4032-4036.
205. Fliers Е., Alkemade A., Wiersinga W.M., Swaab D.F. Hypothalamic thyroid hormone feedback in health and disease // Prog. Brain. Res. 2006. Vol. 153. P. 189—207.
206. Fliers E., Bianco A.C., Langouche L., Boelen A. Endocrine and metabolic considerations in critically ill patients 4: thyroid function in critically ill patients // Lancet Diabetes Endocrinol. 2015. Vol. 3. N. 10. P. 816-825.
207. Fu Y, Sun Y., Jiankun Zhang J., Cheng Y. Intensive glucose control for critically ill patients: an updated meta-analysis // Endocr. Connect. 2018. Vol. 7. P. 1288—1298.
208. Gsede P., Lund-Andersen H., Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes // N. Engl. J. Med. 2008. Vol. 358. N. 6. P. 580—591.
209. Galton V.A., Hernandez A., St Germain D.L. The 50-deiodinases are not essential for the fastinginduced decrease in circulating thyroid hormone levels in male mice: possible roles for the type 3 deiodinase and tissue sequestration of hormone // Endocrinology. 2014. Vol. 155. P. 3172-3181.
210. Garruti G., De Pergola G., Cignarelli M. et al. 34-day total fast in an adult man // Int. J. Obes. Relat. Metab. Disord. 1995. Vol. 19. N. 1. P. 46-49.
211. Geller A.I., Shehab N., Lovegrove M.C., Kegler S.R., Weidenbach K.N., Ryan G.J. et al. National estimates of insulin-related hypoglycaemia and errors leading to emergency department visits and hospitalizations // JAMA Intern. Med. 2014. Vol. 174. P. 678—686.
212. Gerdes A.M., lervasi G. Thyroid replacement therapy and heart failure // Circulation. 2010. Vol. 122. P. 385-393.
213. Goossens C., Weckx R., Sarah Derde S. et al. Adipose tissue protects against sepsis-induced muscle weakness in mice: from lipolysis to ketones // Critical. Care. 2019. Vol. 23. P. 236.
214. Hagar J.A., Edin M.L., Lih F.B. et al. Lipopolysaccharide potentiates insulin-driven hypoglycemic shock //J. Immunol. 2017. Vol. 199. N. 10. P. 3634—3643.
215. Hamilton A., Zhang Q., Salehi A. et al. Adrenaline stimulates glucagon secretion by Tpc2-dependent Ca2+ mobilization from acidic stores in pancreatic a-cells // Diabetes. 2018. Vol. 67. N. 6. P. 1128-1139.
216. Hermanides J., Bosman R., Vriesendorp T. et al. Hypoglycemia is associated with intensive care unit mortality // Crit. Care Med. 2010. Vol. 38. P. 1430—1434.
217. Huang S.A., Bianco A.C. Reawakened interest in type 111 iodothyronine deiodinase in critical illness and injury // Nat. Clin. Pract. Endocrinol. Metab. 2008. Vol. 4. P. 148—155.
218. Kalfon P., Giraudeau B., Ichai C. et al. Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial // Intensive Care Med. 2014. Vol. 40. P. 171 — 181.
219. Kaptein E.M., Kaptein J.S., Chang E.I., Egodage P.M., Nicoloff J.T., Massry S.G. Thyroxine transfer and distribution in critical nonthyroidal illness e.s., chronic renal failu r.e., and chronic ethanol abuse //J. Clin. Endocrinol. Metab. 1987. Vol. 65. P. 606—616.
220. Kerr D.E., Wenham T., Newell-Price J. Endocrine problems in the critically ill. 2: endocrine emergencies // BJA Education. 2017. Vol. 17. N. 11. P. 377—382.
221. Kim J.T., Jahan R., Saver J.L. et al. Impact of glucose on outcomes in patients treated with mechanical thrombectomy: a post hoc analysis of the solitaire flow restoration with the intention for thrombectomy study // Stroke. 2016. Vol. 47. P. 120—127.
222. Koga M., Kasayama S. Clinical impact of glycated albumin as another glycemic control marker // Endocr. J. 2010. Vol. 57. N. 9. P. 751—762.
223. Kosiborod M., Rathore S.S., Inzucchi S.E. et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes // Circulation. 2005. Vol. 111. P. 3078—3086.
224. Krinsley J. Glycemic variability: a strong independent predictor of mortality in critically ill patients // Crit. Care Med. 2008. Vol. 36. P. 3008—3013.
225. Krinsley J.S. Glycemic control in the critically ill: what have we learned since NICE-SUGAR? // Hosp. Pract. 2015. Vol. 43. N. 3. P. 191-197.
226. Krinsley J., Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes // Crit. Care Med. 2007. Vol. 35. P. 2262-2267.
227. Krinsley J.S., Preiser J.C. Time in blood glucose range 70 to 140 mg/dL >80% is strongly associated with increased survival in non-diabetic critically ill adults // Crit. Care. 2015. Vol. 19. P. 179.
228. Kumar E., McCurdy M.T., Koch C.A., Hamadah A., Fiilop T., Gharaibeh K.A. Impairment of thyroid function in critically ill patients in the intensive care units // Am. J. Med. Sci. 2018. Vol. 355. N.3.P. 281-285.
229. Kwakkel J., Surovtseva O.V., de Vries E.M., Stap J., Fliers E., Boelen A. A novel role for the thyroid hormone-activating enzyme type 2 deiodinase in the inflammatory response of macrophages // Endocrinology. 2014. Vol. 155. P. 2725—2734.
230. Lang C.H., Dobrescu C., Bagby G J. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output // Endocrinology. 1992. Vol. 130. N. 1. P. 43-52.
231. Langouche L., Vander Perre S., Marques M. et al. Impact of early nutrient restriction during critical illness on the nonthyroidal illness syndrome and its relation with outcome: a randomiz e.d., controlled clinical study // J. Clin. Endocrinol. Metab. 2013. Vol. 98. P. 1006-1013.
232. Lechan R.M., Fekete C. Feedback regulation of thyrotropin-releasing hormone (TRH): mechanisms for the non-thyroidal illness syndrome // J. Endocrinol. Investig. 2004. Vol. 27 (Suppl). P. 105-119.
233. Lee S.A., Cho S.J., Jeong M.H. et al. Hypoglycemia at admission in patients with acute myocardial infarction predicts a higher 30-day mortality in patients with poorly controlled type 2 diabetes than in well-controlled patients // Diabetes Care. 2014. Vol. 37. P. 2366—2373.
234. Longo V.D., Mattson M.P. Fasting: molecular mechanisms and clinical applications // Cell. Metab. 2014. Vol. 19. P. 181-192.
235. Marchesini G., Veronese G., Forlani G., Forlani G., Ricciardi L.M., Fabbri A. et al. The management of severe hypoglycemia by the emergency system: the hypothesis study // Nutr. Metab. Cardiovasc. Dis. 2014. Vol. 24. P. 1181 — 1188.
236. Meertens J.H., Nienhuis H.L., Lefrandt J.D. et al. The course of skin and serum biomarkers of advanced glycation endproducts and its association with oxidative stress, inflammation, disease severity, and mortality during ICU admission in critically ill patients: results from a prospective pilot study // PLoS One. 2016. Vol. 11. N. 8. P. e0160893.
237. Michalaki M., Vagenakis A.G., Makri M., Kalfarentzos E, Kyriazopoulou V. Dissociation of the early decline in serum T3 concentration and serum IL-6 rise and TNFalpha in nonthyroidal illness syndrome induced by abdominal surgery // J. Clin. Endocrinol. Metab. 2001. Vol. 86. P. 4198-4205.
238. Mukai N., Ohara T., Hata J. et al. Alternative measures of hyperglycemia and risk of Alzheimer’s disease in the community: the hisayama study // J. Clin. Endocrinol. Metab. 2017. Vol. 102. N. 8. P. 3002-3010.
239. Natali A., Ribeiro R., Baldi S., Tulipani A., Rossi M., Venturi E., Mari A., Macedo M.P., Ferrannini E. Systemic inhibition of nitric oxide synthesis in non-diabetic individuals produces a significant deterioration in glucose tolerance by increasing insulin clearance and inhibiting insulin secretion // Diabetologia. 2013. Vol. 56. N. 5. P. 1183—1191.
240. NICE-SUGAR Study Investigato r.s., Finfer S., Chittock D.R., Su S.Y., Blair D., Foster D., Dhingra V. et al. Intensive versus conventional glucose control in critically ill patients // N. Engl. J. Med. 2009. Vol. 360. N. 13. P. 1283-1297.
241. Omar A.S., Salama A., Allam M., Elgohary Y., Mohammed S., Tuli A.K. et al. Association of time in blood glucose range with outcomes following cardiac surgery // BMC Anesthesiol. 2015. Vol. 15. P. 14.
242. Peeters R.P., van der Geyten S., Wouters P.J. et al. Tissue thyroid hormone levels in critical illness //J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 6498—6507.
243. Penning S., Chase J.G., Preiser J.C., Pretty C.G., Signal M., МёкН C. et al. Does the achievement of an intermediate glycemic target reduce organ failure and mortality? A post hoc analysis of the Glucontrol trial // J. Crit. Care. 2014. Vol. 29. N. 3. P. 374—379.
244. Ribeiro R.T., Macedo M.P., Raposo J.F. HbAlc, fructosami n.e., and glycated albumin in the detection of dysglycaemic conditions // Curr. Diabetes Rev. 2016. Vol. 12. N. 1. P. 14-19.
245. Roberts G.W., Quinn S.J., Valenine N. et al. Relative hyperglycem i.a., a marker of critical illness: introducing the stress hyperglycemia ratio // J. Clin. Endocrinol. Metab. 2015. Vol. 100. P. 4490-4497.
246. Rodriguez-Segade S., Rodriguez J., Garcia Lopez J.M., Casanueva F.F., Camina F. Estimation of the glycation gap in diabetic patients with stable glycemic control // Diabetes Care. 2012. Vol. 35. N. 12. P. 2447-2450.
247. Rondeau P., Bourdon E. The glycation of albumin: structural and functional impacts // Biochimie. 2011. Vol. 93. N. 4. P. 645-658.
248. Selvin E., Rawlings A., Grams M. et al. Prognostic utility of fructosamine and glycated albumin for incident diabetes and microvascular complications // Lancet Diabetes Endocrinol. 2014. Vol. 2. N.4. P. 279-288.
249. Shenkin A. Micronutrients in health and disease // Postgrad. Med. J. 2006. Vol. 82. P. 559-567.
250. Shepard J.G., Airee A., Dake A.W., McFarland M.S., Vora A. Limitations of Ale interpretation // South. Med. J. 2015. Vol. 108. N. 12. P. 724-729.
251. Signal M., Le Compte A., Shaw G.M., Chase J.G. Glycemic levels in critically ill patients: are normoglycemia and low variability associated with improved outcomes? // J. Diabetes Sci Technol. 2012. Vol. 6. N. 5. P. 1030-1037.
252. Singer M., De Santis V, Vitale D., Jeffcoate W. Multiorgan failure is an adapti v.e., endo-crine-mediated metabolic response to overwhelming systemic inflammation // Lancet. 2004. Vol. 364. P. 545-548.
253. Soeters M.R., Soeters P.B. The evolutionary benefit of insulin resistance // Clin. Nutr. 2012. Vol. 31. P. 1002.
254. Stentz F.B., Umpierrez G.E., Cuervo R. et al. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises // Diabetes. 2004. Vol. 53. N. 8. P. 2079—2086.
255. van den Berghe G., Wouters P., Weekers F. et al. Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropinreleasing hormone in patients with protracted critical illness // J. Clin. Endocrinol. Metab. 1999. Vol. 84. P. 1311-1323.
256. van den Berghe G., Wouters P., Weekers F. et al. Intensive insulin therapy in critically ill New England//J. Med. 2001. Vol. 345. P. 1359-1367.
257. van den Berghe G., Wilmer A., Hermans G. et al. Intensive insulin therapy in the medical ICU 11 N. Engl. J. Med. 2006. Vol. 354. P. 449-461.
258. Vanhorebeek L, Van den Berghe G. Diabetes of injury: novel insights // Endocrinol. Metab. Clin. N. Am. 2006. Vol. 35. P. 859-872.
259. Wang Y, Zhou S., Bao J., Pan S., Zhang X. Low T3 levels as a predictor marker predict the prognosis of patients with acute ischemic stroke // Int. J. Neurosci. 2017. Vol. 127. N. 7. P. 559-566.
260. Wang L., Zhou Z., Tian X. et al. Impact of relative blood glucose changes on mortality risk of patient with acute ischemic stroke and treated with mechanical thrombectomy // J. Stroke Cerebrovasc. Dis. 2019. Vol. 28. N. 1. P. 213-219.
261. Wartofsky L., Burman K.D. Alterations in thyroid function in patients with systemic illness: the «euthyroid sick syndrome» // Endocr. Rev. 1982. Vol. 3. P. 164—217.
262. Yang M., Guo Q., Zhang X. et al. Intensive insulin therapy on infection rate, days in NICU, inhospital mortality and neurological outcome in severe traumatic brain injury patients: a randomized controlled trial // Int. J. Nurs. Stud. 2009. Vol. 46. P. 753—758.
263. Levy M.J., Matharu M.S., Meeran K., Powell M., Goadsby P.J. The clinical characteristics of headache in patients with pituitary tumours // Brain. 2005. Vol. 128. P. 1921 — 1930.
264. Loriaux L. Diagnosis and differential diagnosis of Cushing’s syndrome // N.. Engl. J. Med. 2017. Vol. 376. P. 1451-1459.
265. Meschia J.F., Bushnell C., Boden-Albala B., Braun L.T., Bravata D.M. et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association // Stroke. 2014. Vol. 45. P. 3754-3832.
266. Minguez-Olaondo A., Irimia P., Friihbeck G. Obesity and the nervous system: more questions 11 Lancet. Neurol. 2017. Vol. 16. P. 773.
267. Molitch M.E. Diagnosis and treatment of pituitary adenomas: a review // JAMA. 2017. Vol. 7. N. 317. P. 516-524.
268. Munshi M.N. Cognitive dysfunction in older adults with diabetes: what a clinician needs to know // Diabetes Care. 2017. Vol. 40. P. 461—7.
269. O’Brien P.D., Hinder L.M., Callaghan B.C., Feldman E.L. Neurological consequences of obesity// Lancet Neurol. 2017. Vol. 16. P. 465-477.
270. Orrell R.W. Endocrine myopathies// Handb. Clin. Neurol. 2007. Vol. 86. P. 343—355.
271. Andela C.D., van Haaleb ЕМ., Ragnarsson О., Papakokkinou Е., Johansson G., Santos A. et al. Cushing’s sindrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance studies // Eur. J. Endocrinol. 2015. Vol. 173. P. R1-R14.
272. Arlt W., Allolio B. Adrenal insufficiency// Lancet. 2003. Vol. 361. P. 1881 — 1893.
273. Arlt W., Willis D.S., Wild S.H., Krone N., Doherty E.J., Hahner S. et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients // J. Clin. Endocrino.l Metab. 2010. Vol. 95. P. 5110-5121.
274. Atwi S., McMahon D., Scharfman H., MacLusky N J. Androgen modulation of hippocampal structure and function // Neuroscientist. 2016. Vol. 22. P. 46—60.
275. Aydogan U., Aydogdu A., Akbulut H., Sonmez A., Yuksel S., Basaran Y. et al. Increased frequency of anxie t.y., depressi o.n., quality of life and sexual life in young hypogonadotrop-ic hypogonadal males and impacts of testosterone replacement. Therapy on these conditions // Endocr. J. 2012. Vol. 59. P. 1099-1105.
276. Barbuti M., Carvalho A.F., Kohler C.A., Murru A., Verdolini N., Guiso G. et al. Thyroid autoimmunity in bipolar disorder: a systematic review // J. Affect. Disord. 2017. Vol. 221. P. 97—106.
277. Bauer M., Goetz T., Glenn T., Whybrow P.C. The thyroid-brain interaction in thyroid disorders and mood disorders // J. Neuroendocrinol. 2008. Vol. 20. P. 1101 — 1114.
278. Bhasin S., Cunningahm G.R., Hayes F.J., Matsumoto A.M., Snyder P.J., Swerdloff R.S. et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline //J. Clin. Endocrinol. Metab. 2010. Vol. 95. P. 2536—2559.
279. Bilezikian J.P., Bandeira L., Khan A., Cusano N.E. Hyperparathyroidism // Lancet. 2018. Vol. 391. P. 168-178.
280. Bommer M., Eversmann T., Pickardt R., Leonhardt A., Naber D. Psychopathological and neuropsychological symptoms in patients with subclinical and remitted hyperthyroidism // Klin. Wochenschr. 1990. Vol. 68. P. 552-558.
281. Bray G., Kim K.K., Wilding J.P.H., World Obesity Federation Position Statement. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation // Obes. Rev. 2017. Vol. 18. P. 715-723.
282. Brown J.S Jr. Cases of remission of psychosis following resection of pheochromocytoma or paraganglioma // Schizophr. Res. 2016. Vol. 176. P. 304—306.
283. Buchmann L., Ashby S., Cannon R.B., Hunt J.P. Psychosocial distress in patients with thyroid cancer// Otolaryngol. Head. Neck. Surg. 2015. Vol. 152. P. 644—649.
284. Butwicka A., Frisen L., Almqvist C., Zethelius B., Lichtenstein P. Risks of psychiatric disorders and suicide attempts in children and adolescents with type 1 diabetes: a population-based cohort study // Diabetes Care. 2015. Vol. 38. P. 453—459.
285. Calcia M.A., Bonsall D.R., Bloomfield P.S., Selvaraj S., Barichello T., Howes O.D. Stress and neuroinflammation: a systematic review of the effects of stress on microglia and the implications for mental illness // Psychopharmacology. 2016. Vol. 233. P. 1637—1650.
286. Capatina C., Christodoulides C., Fernandez A., Cudlip S., Grossman A.B., Wass J.A.H. et al. Current treatment protocols can offer a normal or near-normal quality of life in the majority of patients with non-functioning pituitary adenomas // Clin. Endocrinol. 2013. Vol. 78. P. 86-93.
287. Carle A., Andersen S.L., Boelaert K., Laurberg P. Management of endocrine disease: subclinical thyrotoxicosis: prevalen c.e., causes and choice of therapy // Eur. J. Endocrinol. 2017. Vol. 176. P. R325- R337.
288. Castanon N., Lasselin J., Capuron L. Neuropsychiatry comorbidity in obesity: role of inflammatory processes // Front. Endocrinol. 2014. Vol. 5. P. 74.
289. Qelik S., Kayar Y, Akgakaya R.O., Uyar T.E., Kalkan K., Yazisiz V. et al. Correlation of binge eating disorder with level of depresion and glycemic control in type 2 diabetes mellitus patients // Gen. Hosp. Psychiatry. 2015. Vol. 37. P. 116—119.
290. Conner S.H., Solomon S.S. Psychiatric manifestations of endocrine disorders // J. Hum. Endocrinol. 2017. Vol. 2. P. 7.
291. De Groot M., Golden S.H., Wagner J. Psychological conditions in adults with diabetes // Am. Psychol. 2016. Vol. 71. P. 552-562.
292. Ducat L., Phillipson L.H., Anderson B.J. The mental health comorbidities of diabetes // JAMA. 2014. Vol. 312. P. 691-692.
293. Engberg H., Butwicka A., Nordestrom A., Hirschberg A.L., Falhammar H., Lichtenstein P. et al. Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: a total population study // Psychoneuroendocrinology. 2015. Vol. 60. P. 195-205.
294. Falhammar H., Butwicka A., Landen M., Lichtenstein P., Norenskjold A., Frisen L. Increased psychiatric morbidity in men with congenital adrenal hyperplasia due to 21 -hydroxylae deficiency //J. Clin. Endocrinol. Metab. 2014. Vol. 99. P. E554- E560.
295. Feldman A.Z., Shrestha R.T., Hennesey J.V. Neuropsychiatric manifestations of thyroid disease // Endocrinol. Metab. Clin. N. Am. 2013. Vol. 42. P. 453—476.
296. Ferlov-Schwensen C., Brix Т.Н., Hegediis L. Death by suicide in Graves’ disease and Graves’ orbitopathy: a nationwide Danish register study //Thyroid. 2017. Vol. 27. P. 1475—1480.
297. Fernandez-Real J.M., Serino M., Blasco G., Puig J., Daunis-i-Estadella J. et al. Gut microbiota interacts with brain microstructure and function // J. Clin. Endocrinol. Metab. 2015. Vol. 100. P. 4505-4513.
298. Fleseriu M., Hshim LA., Melmed S., Murad M.H., Salvatori R., Samuels M.H. Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline // J. Clin. Endocrinol. Metab. 2016. Vol. 101. P. 3888-3921.
299. Galea L.A.M., Duarte-Guterman P. Hormones and the regulation of adult neurogenesis in the hippocampus and beyond: where are we now? // Front. Neuroendocrinol. 2016. Vol. 41. P. 1-2.
300. Gariepy G., Nitka D., Schmitz N. The association between obesity and anxiety disorders in the population: a systematic review and meta-analysis // Int. J. Obes. 2010. Vol. 34. P. 407—419.
301. Geraedts V.J., Dimopulou C., Auer M., Schopohl J., Stalla G.K., Sievers C. Health outcomes in acromegaly: depression and anxiety are promising targets for improving reduced quality of life // Front. Endocrinol. 2015. Vol. 5. P. 229.
302. Gilsanz P., Karter A.J., Beeri M.S., Quesenberry C.P. Jr., Whitmer R.A. The bidirectional association between depression and severe hypoglycemic and hyperglycemic events in type 1 diabetes// Diabetes Care 2017. Vol. 18. pii: de 171566. https://doi.org/10.2337/dcl7-1566. | Epub. ahead of print].
303. Joborn C., Hetta J., Rastad J., Agren H., Akerstrom G., Ljunghall S. Psychiatric symptoms and cerebrospinal fluid monoamine metabolites in primary hyperparathyroidism // Biol. Psychiatry. 1988. Vol. 23. P. 149-158.
304. Joffe R.T., Pearce E.N., Hennessey J.V., Ryan J.J., Stern R.A. Subclinical hypothyroidism, mood, and cognition in older adults: a review // Int. J. Geriatr. Psychiatry. 2013. Vol. 28. P. 111-118.
305. Joffe H., Crawford S.L., Freeman M.P., White D.P., Bianchi M.T., Kim S. et al. Independent contributions of nocturnal hot flashes and sleep disturbance to depression in estrogen-deprived women //J. Clin. Endocrinol. Metab. 2016. Vol. 101. P. 3847—3855.
306. Kecklund G., Axelsson J. Health consequences of shift work and insufficient sleep // BMJ. 2016. Vol. 355. P. i5210.
307. Kelly J.R., Clarke G., Cryan J.F., Dinan T.G. Brain-gut-microbiota axis: challenges for translation in psychiatry // Ann. Epidemiol. 2016. Vol. 26. P. 366—372.
308. Kulshreshtha B., Mehta M., Gupta N., Ammini A.C. Behavioral aggressiveness in boys with sexual precocity// Indian J. Endocrinol. Metab. 2012. Vol. 16. P. 395—399.
309. Lecube A., Monereo S., Rubio M.A., Marti'nez-de-Icaya P., Marti A., Salvador J. et al. Prevention, diagnosis, and treatment of obesity. 2016 position statement of the Spanish Society for the Study of Obesity // Endocrinol. Diabetes Nutr. 2017. Vol. 64. Suppl. I. P. 15-22.
310. Leistner S.M., Klotsche J., Dimopoulou C., Athanasoulia A.P., Roemmler-Zehrer J., Pieper L. et al. Reduced sleep quality and depression associate with decreased quality of life in patients with pituitary adenomas // Eur. J. Endocrinol. 2015. Vol. 172. P. 733-743.
311. Lenders J.W., Eisenhofer G., Mannelli M., Pacak K. Phaeochromocytoma // Lancet. 2005. Vol. 366. P. 665-675.
312. Leyhe T., Miissig K. Cognitive and affective dysfunctions in autoimmune thyroiditis // Brain. Behav. Immun. 2014. Vol. 41. P. 261—266.
313. Liao W-T, Bai Y-M. Major depressive disorder induced by prolactinoma. A case report // Gen. Hosp. Psychiatry. 2014. Vol. 36. P. 125.el-125.e2.
314. Marie N.P., Doknic M., Pavlovic D., Pekic S., Stojanovic M., Jasovic-Gasic M. et al. Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy // J. Endocrinol. Investig. 2010. Vol. 33. P. 770-775.
315. Mauas V, Kopala-Sibley D.C., Zuroff D.C. Depressive symptoms in the transition to menopause: the roles of irritabili t.y., personality vulnerability and self-regulation // Arch. Womens Ment. Health. 2014. Vol. 17. P. 279—289.
316. McEwen B.S. Neurobiological and systemic effects of chronic stress // Chronic. Stress. 2017. Vol. 1. P. I.
317. Menon V., Subramanian K., Thamizh J.S. Psychiatric presentations heralding Hashimoto’s encephalopathy: a systematic review and analysis of cases reported in literature //J. Neurosci Rural. Pract. 2017. Vol. 8. P. 261-267.
318. Allison D.B., Gallagher D., Нео М., Pi-Sunyer F.X., Heymsfield S.B. Body mass index and all-cause mortality among people age 70 and over: the Longitudinal Study of Aging // Int. J. Obes. Relat. Metab. Disord. [Internet|. 1997. Jun. [cited 2019. Aug. 311. Vol. 21. N. 6. P. 424—431.
319. Anderson L.J., Liu H., Garcia J.M. Sex differences in muscle wasting // Advances in experimental medicine and biology [Internet]. 2017 [cited 2019. Jul. 21]. P. 153—97.
320. Barsony J., Sugimura Y., Verbalis J.G. Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss //J. Biol. Chem. [Internet]. 2011. Mar. 25 [cited 2017. Dec. 30]. Vol. 286. N. 12. P. 10864—10875.
321. Baulieu E.E., Thomas G., Legrain S., Lahlou N., Roger M., Debuire B. et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue // Proc. Natl. Acad. Sci USA [Internet]. 2000 Apr. 11 [cited 2017. Dec. 30]. Vol. 97. N. 8. P. 4279—4284.
322. Britton A., Shipley M., Singh-Manoux A., Marmot M.G. Successful aging: the contribution of earlylife and midlife risk factors // J. Am. Geriatr. Soc. [Internet], 2008. Jun. [cited 2017. Apr. 5]. Vol. 56. N. 6. P. 1098—1105.
323. Cohen L.S., Soares C.N., Joffe H. Diagnosis and management of mood disorders during the menopausal transition // Am. J. Med. [Internet]. 2005. Dec. 19 [cited 2017. Dec. 28]. Vol. 118. Suppl. 12B. N. 12. P. 93—97.
324. Crandall C.J., Manson J.E., Hohensee C., Horvath S., Wactawski-Wende J., LeBlanc E.S. et al. Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women’s Health Initiative Study // Menopause [Internet]. 2017. Mar. [cited 2019. Jul. 19]. Vol. 24. N. 3. P. 252-261.
325. Davidson J.M., Chen J.J., Crapo L., Gray G.D., Greenleaf W.J., Catania J.A. Hormonal changes and sexual function in aging men J/ J. Clin. Endocrinol. Metab. [Internet]. 1983. Jul. [cited 2017. Dec. 29]. Vol. 57. N. 1. P. 71—77.
326. Davison S.L., Bell R., Donath S., Montalto J.G., Davis S.R. Androgen levels in adult females: changes with a g.e., menopau s.e., and oophorectomy // J. Clin. Endocrinol. Metab. [Internet], 2005. Jul. [cited 2017. Dec. 30]. Vol. 90. N. 7. P. 3847-3853.
327. Dennerstein L., Dudley E.C., Hopper J.L., Guthrie J.R., Burger H.G. A prospective population-based study of menopausal symptoms // Obstet. Gynecol. [Internet]. 2000. Sep. [cited 2017. Dec. 22]. Vol. 96. N. 3. P. 351-358.
328. Derby C.A., Crawford S.L., Pasternak R.C., Sowers M., Sternfeld B., Matthews K.A. Lipid changes during the menopause transition in relation to age and weight: the Study of Women’s Health Across the Nation // Am. J. Epidemiol. [Internet]. 2009. Jun. 1 [cited 2017. Dec. 28]. Vol. 169. N. 11. P. 1352—1361.
329. Feldman H.A., Longcope C., Derby C.A., Johannes C.B., Araujo A.B., Coviello A.D. et al. Age trends in the level of serum testosterone and other hormones in Middle-aged men: longitudinal results from the Massachusetts male aging study // J. Clin. Endocrino.l Metab. [Internet], 2002. Feb. [cited 2017. Dec. 29]. Vol. 87. N. 2. P. 589-598.
330. Freedman R.R. Physiology of hot flashes // Am. J. Hum. Biol. [Internet], 2001. Jul. [cited 2019. Jul. 19]. Vol. 13. N. 4. P. 453—464.
331. Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R. Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men // J. Clin. Endocrinol. Metab. [Internet]. 2001. Feb. [cited 2017. Dec. 29]. Vol. 86. N. 2. P. 724—731.
332. Harris S.S., Soteriades Е., Coolidge J.A., Mudgal S., Dawson-Hughes В. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population // J. Clin. Endocrinol. Metab. [Internet], 2000. Nov. [cited 2018. Jan. 2]. Vol. 85. N. 11. P. 4125— 4130.
333. Hegstad R., Brown R.D., Jiang N.S., Kao P., Weinshilboum R.M., Strong C. et al. Aging and aldosterone//Am. J. Med. [Internet]. 198.3 Mar. [cited 2017. Dec. 18]. Vol. 74. N. 3. P. 442-448.
334. Hellstrom W.J.G., Overstreet J.W., Sikka S.C., Denne J., Ahuja S., Hoover A.M. etal. Semen and sperm reference ranges for men 45 years of age and older// J. Androl. [Internet]. 2006. Feb. 10 [cited 2017. Dec. 28|. Vol. 27. N. 3. P. 421—428.
335. Houmard J.A., Weidner M.D., Dolan P.L., Leggett-Frazier N., Gavigan K.E., Hickey M.S. et al. Skeletal muscle GLUT4 protein concentration and aging in humans // Diabetes [Internet]. 1995. May [cited 2017. Dec. 29]. Vol. 44. N. 5. P. 555—560.
336. Houston D.K., Tooze J.A., Garcia K., Visser M., Rubin S., Harris T.B. et al. Protein intake and mobility limitation in community-dwelling older adults: the health ABC study // J. Am. Geriatr. Soc. [Internet]. 2017. Aug. [cited 2019. Aug. 30]. Vol. 65. N. 8. P. 1705-1711.
337. Hua J.T., Hildreth K.L., Pelak VS. Effects of testosterone therapy on cognitive function in aging: a systematic review // Cogn. Behav. Neurol. [Internet]. 2016. Sep. [cited 2017. Dec. 11]. Vol. 29. N. 3. P. 122—138.
338. Ishikawa Se.S., Saito T., Fukagawa A., Higashiyama M., Nakamura T., Kusaka I. et al. Close association of urinary excretion of aquaporin-2 with appropriate and inappropriate arginine vasopressin-dependent antidiuresis in hyponatremia in elderly subjects // J. Clin. Endocrinol. Metab. [Internet|. 2001. Apr. [cited 2017. Dec. 30]. Vol. 86. N. 4. P. 1665— 1671.
339. Kim M.J., Morley J.E. The hormonal fountains of youth: myth or reality? // J. Endocrinol. Invest. [Internet]. 2005 [cited 2017. Dec. 14]. Vol. 28. Suppl. Proceedings. 11. P. 5—14.
340. Kim Y, Triolo M., Hood D.A. Impact of aging and exercise on mitochondrial quality control in skeletal muscle // Oxid. Med. Cell. Longev. [Internet], 2017 [cited 2017. Dec. 11]. Vol. 2017. P. 3165396.
341. Krall E.A., Sahyoun N., Tannenbaum S., Dallal G.E., Dawson-Hughes B. Effect of vitamin D intake on seasonal variations in parathyroid hormone secretion in postmenopausal women // N. Engl. J. Med. [Internet]. 1989. Dec. 28 [cited 2018. Jan. 2]. Vol. 321. N. 26. P. 1777-1783.
342. LeBlanc E.S., Nielson C.M., Marshall L.M., Lapidus J.A., Barrett-Connor E., Ensrud K.E. et al. The effects of serum testostero n.e., estradi o.L, and sex hormone binding globulin levels on fracture risk in older men // J. Clin. Endocrinol. Metab. [Internet]. 2009. Sep. [cited 2017. Dec. 29]. Vol. 94. N. 9. P. 3337—3346.
343. Leng S.X., Cappola A.R., Andersen R.E., Blackman M.R., Koenig K., Blair M. et al. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty //Aging. Clin. Exp. Res. [Internet]. 2004. Apr. [cited 2017. Dec. 30]. Vol. 16. N. 2. P. 153—157.
344. Leong D.P., Teo K.K., Rangarajan S., Kutty V.R., Lanas E, Hui C. et al. Reference ranges of handgrip strength from 125,462 healthy adults in 21 countries: a prospective urban rural epidemiologic (PURE) study // J. Cachexia Sarcopenia Muscle [Internet]. 2016 (cited 2019. Aug. 30]. Vol. 7. N. 5. P. 535—546.
345. Liu H., Bravata D.M., Olkin 1., Nayak S., Roberts B., Garber A.M. et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly // Ann. Intern. Med. [Internet], 2007. Jan. 16 [cited 2017. Dec. 29]. Vol. 146. N. 2. P. 104—115.
346. Mauras N., Hayes V, Welch S., Rini A., Helgeson K., Dokler M. et al. Testosterone deficiency in young men: marked alterations in whole body protein kineti c.s., streng t.h., and adiposity // J. Clin. Endocrinol. Metab. [Internet]. 1998. Jun. [cited 2017. Dec. 29]. Vol. 83. N. 6. P. 1886—1892.
347. Newman A.B., Arnold A.M., Sachs M.C., Ives D.G., Cushman M., Strotmeyer E.S. et al. Long-term function in an older cohort—the cardiovascular health study all stars study // J. Am. Geriatr. Soc. | Internet]. 2009. Mar. [cited 2017. Dec. 29]. Vol. 57. N. 3. P. 432—440.
348. Passeri G., Pini G., Troiano L., Vescovini R., Sansoni P., Passeri M. et al. Low vitamin D status, high bone turnover, and bone fractures in centenarians //J. Clin. Endocrinol. Metab. [Internet]. 2003. Nov. [cited 2018. Jan. 2]. Vol. 88. N. 11. P. 5109—5115.
349. Pattanaungkul S., Riggs B.L., Yergey A.L., Vieira N.E., O’Fallon W.M., Khosla S. Relationship of intestinal calcium absorption to 1,25-dihydroxyvitamin D [1,25(OH)2D] levels in young versus elderly women: evidence for age-related intestinal resistance to 1,25(OH)2D action // J. Clin. Endocrinol. Metab. [Internet]. 2000. Nov. [cited 2018. Jan. 2]. Vol. 85. N. 11. P. 4023—4027.
350. Rodriguez A., Becerril S., Ezquerro S., Mendez-Gimenez L., Friihbeck G. Cross-talk between adipokines and myokines in fat browning // Acta Physiol. (Oxford) [Internet]. 2017. Vol. 219. N. 2. P. 362—381.
351. Shimokata H., Muller D.C., Fleg J.L., Sorkin J., Ziemba A.W., Andres R. Age as independent determinant of glucose tolerance // Diabetes [Internet]. 1991. Jan. [cited 2017. Dec. 29]. Vol. 40. N. 1. P. 44—51.
352. Soares C.N. Tailoring strategies for the management of depression in midlife years // Menopause [Internet]. 2017. Jun. 1 [cited 2017. Dec. 4]. Vol. 24. N. 6. P. 699—701.
353. Sternfeld B.,Wang H., Quesenberry C.P., Abrams B., Everson-Rose S.A., Greendale G.A. et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women’s Health Across the Nation // Am. J. Epidemiol. [Internet]. 2004. Nov. 1 [cited 2017. Dec. 28]. Vol. 160. N. 9. P. 912—922.
354. Stott D.J., McLellan A.R., Finlayson J., Chu P., Alexander W.D. Elderly patients with suppressed serum TSH but normal free thyroid hormone levels usually have mild thyroid overactivity and are at increased risk of developing overt hyperthyroidism // Q. J. Med. [Internet]. 1991. Jan. [cited 2017. Dec. 29]. Vol. 78. N. 285. P. 77—84.
355. Tabatabaie V, Surks M.I. The aging thyroid // Curr. Opin. Endocrinol. Diabetes Obes. [Internet], 2013. Oct. [cited 2017. Dec. 18]. Vol. 20. N. 5. P. 455-459. (UK) NCC for Wand C.H. Menopause [Internet], Menopause: Full Guideline. National Institute for Health and Care Excellence (UK). Vol. 2015 [cited 2017. Dec. 28].
356. Unamuno X., Gomez-Ambrosi J., Rodriguez A., Becerril S., Friihbeck G., Catalan V. Adipokine dysregulation and adipose tissue inflammation in human obesity // Eur. J. Clin. Invest. |Internet|. 2018. Sep. 1 [cited 2018. Nov. 8]. Vol. 48. N. 9. P. e!2997.
357. van Coevorden A., Mockel J., Laurent E., Kerkhofs M., L’Hermite-Baleriaux M., Decoster C. et al. Neuroendocrine rhythms and sleep in aging men // Am. .1. Physiol. 11 nternet |. 1991. Apr. [cited 2017. Dec. 17]. Vol. 260. N. 4 Pt. 1. P. E651— E66I.
358. Veldhuis J.D. Altered pulsatile and coordinate secretion of pituitary hormones in aging: evidence of feedback disruption //Aging. (Milano) [Internet], 1997 [cited 2017. Dec. 22]. Vol. 9. Suppl. 4. P. 19—20.
359. Verbalis J.G., Barsony J., Sugimura Y, Tian Y., Adams D.J., Carter E.A. et al. Hyponatremia-induced osteoporosis //J. Bone Miner. Res. [Internet], 2010 Mar. [cited 2017. Dec. 30]. Vol. 25. N. 3. P. 554-563.
360. Wannamethee S.G., Shaper A.G., Lennon L., Whincup P.H. Decreased muscle mass and increased central adiposity are independently related to mortality in older men // Am. J. Clin. Nutr. [Internet], 2007. Nov. 1 [cited 2019. Aug. 311. Vol. 86. N. 5. P. 1339-1346.
361. Willcox B.J., Willcox D.C., He Q., Curb J.D., Suzuki M. Siblings of Okinawan centenarians share lifelong mortality advantages // J. Gerontol. A. Biol. Sci Med. Sci [Internet], 2006a. Apr. 1 [cited 2019. Jul. 19]. Vol. 61. N. 4. P. 345—354.
362. Willcox D.C., Willcox B.J., Todoriki H., Curb J.D., Suzuki M. Caloric restriction and human longevity: what can we learn from the Okinawans? // Biogerontology [Internet]. 2006b. Jun. 30 [cited 2019. Jul. 19]. Vol. 7. N. 3. P. 173-177.
363. Woodard G.A., Brooks M.M., Barinas-Mitchell E., Mackey R.H., Matthews K.A., Sutton-Tyrrell K. Lipids, menopause, and early atherosclerosis in Study of Women’s Health Across the Nation Heart women // Menopause [Internet]. 2011. Apr. [cited 2017. Dec. 28]. Vol. 18. N. 4. P. 376—384.
364. Woods N.F., Mitchell E.S. Symptoms during the perimenopause: prevalen c.e., severi t.y., trajecto r.y., and significance in women’s lives // Am. J. Med. [Internet]. 2005. Dec. 19 [cited 2017. Dec. 14|. Vol. 118. Suppl. 12. P. 14—24.
365. Wu F.C.W., Tajar A., Pye S.R., Silman A.J., Finn J.D., O’Neill T.W. et al. Hypothalamic -pituitarytesticular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study // J. Clin. Endocrinol. Metab. [Internet]. 2008. Jul. [cited 2017. Dec. 28]. Vol. 93. N. 7. P. 2737—2745.
366. Wurtman R.J. Age-related decreases in melatonin secretion — clinical consequences // J. Clin. Endocrinol. Metab. [Internet], 2000. Jun. [cited 2017. Dec. 18]. Vol. 85. N. 6. P. 2135-2136.
367. Nacinovich R., Buzi E, Oggiano S., Rossi S., Spada S., Broggi F. Body experiences and psychopathology in idiopathic central precocious and early puberty // Minerva Pediatr. 2016. Vol. 68. P. 11-18.
368. Neovius M., Bruze G., Jacobson P., Sjoholm K., Johansson K., Granath F. et al. Risk of suicide and non-fatal self-harm after bariatric surgery: results from two matched cohort studies // Lancet Diabetes Endocrinol. 2018. Vol. 6. P. 197—207.
369. Norkett E.M., Lincoln S.H., Gonzalez-Heydrich J., D’Angelo E.J. Social cognitive impairment in 22q 11 deletion syndrome: a review // Psychiatry Res. 2017. Vol. 253. P. 99—106.
370. Peterhansel C., Petroff D., KJinitzke G., Kersting A., Wagner B. Risk of completed suicide after bariatric surgery: a systematic review // Obes. Rev. 2013. Vol. 14. P. 369—382.
371. Pivonello R., Simeoli C., De Martino M.C., Cozzolino A., de Leo M., lacuaniello D. et al. Neuropsychiatric disorders in Cushing’s syndrome // Front. Neurosci. 2015. Vol. 9. P. 129.
372. Pope H.G., Wood R.L, Rogol A., Nyberg E, Bowers L., Bhasin S. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement // Endocr. Rev. 2014. Vol. 35. P. 341-375.
373. Rajan T.M., Menon V. Psychiatric disorders and obesity: a review of association studies //J. Postgrad. Med. 2017. Vol. 63. P. 182-190.
374. Riecher-Rdssler A. Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses // Lancet Psychiatry. 2017. Vol. 4. P. 63—72.
375. Riecher-Rdssler A., Rybakowski J.K., Pflueger M.O., Beyrau R., Kahn R.S., Malik P. et al. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis // Psychol. Med. 2013. Vol. 43. P. 2571-2582.
376. Robinson D.J., Luthra M., Vallis M. Diabetes and mental health // Can. J. Diabetes. 2013. Vol. 37. Suppl. 1. P. S87- S92.
377. Rodrigues K.C., Toledo R.A., Coutinho F.L., Nunes A.B., Maciel R.M.B., Hoff A.O. et al. Assessment of depression., anxiety., quality of life, and coping in long-standing multiple endocrine neoplasia type 2 patients // Thyroid. 2017. Vol. 27. P. 693—706.
378. Rosen-Reynoso М., Alegria М., Chen C.N., Laderman М., Roberts R. The relationship between obesity and psychiatric disorders across ethnic and racial minority groups in the United States // Eat.. Behav. 2011. Vol. 12. P. 1—8.
379. Ryan C.M., van Duinkerken E., Rosano C. Neurocognitive consequences of diabetes // Am. Psychol. 2016. Vol. 71. P. 563-576.
380. Sahingdz M., Uguz E, Gezginc K., Korucu D.G. Axis I and axis 11 diagnoses in women with PCOS//Gen. Hosp. Psychiatry. 2013. Vol. 35. P. 508-511.
381. Scaruffi E., Gambineri A., Cattaneo S., Turra J., Vettor R., Mioni R. Personality and psychiatric disorders in women affected by polycystic ovary sindrome // Front. Endocrinol. 2014. Vol. 5. P. 185.
382. Schoelwer M.J., Donahue K.L., Bryk K., Didrick P., Berenbaum S.A., Eugster E.A. Psychological assessment of mothers and their daughters at the time of diagnosis of precocious puberty 11 Int. J. Pediatr. Endocrinol. 2015. Vol. 2015. P. 5.
383. Sievers C., Ising M., Pfister H., Dimopoulou C., Schneider H.J., Roemmier J. et al. Personality in patients with pituitary adenomas is characterized by increased anxiety-related traits: comparison of 70 acromegalic patients with patients with non-functioning pituitary adenomas and age- and gender-matched controls // Eur. J. Endocrinol. 2009a. Vol. 160. P. 367-373.
384. Sievers C., Dimopoulou C., Pfister H., Lieb R., Steffin B., Roemmier J. et al. Prevalence of mental disorders in acromegaly: a cross-sectional study in 81 acromegalic patients // Clin. Endocrinol. 2009b. Vol. 71. P. 691-701.
385. Sievers C., Samann P.G., Pfister H., Dimopoulou C., Czisch M., Roemmier J. et al. Cognitive function in acromegaly: description and brain volumetric correlates // Pituitary. 2012. Vol. 15. P. 350-357.
386. Simon G.E., Von KorffM., Saunders K., Miglioretti D.L., Crane P.K., van Belle G. et al. Association between obesity and psychiatric disorders in the US adult population // Arch. Gen. Psychiatry. 2006. Vol. 63. P. 824-830.
387. Sonino N., Fava G.A. Psychological aspects of endocrine disease // Clin. Endocrinol. 1998. Vol. 49. P. 1-7.
388. Sonino N., Tomba E., Genesia M.L., Bertello C., Mulatero P., Veglio F. et al. Psychological assessment of primary aldosteronism: a controlled study // J. Clin. Endocrinol. Metab. 2011. Vol. 96. P. E878- E883.
389. Starkman M.N. Neuropsychiatric findings in Cushing’s syndrome and exogenous glucocorticoid administration // Endocrinol. Metab. Clin. N. Am. 2013. Vol. 42. P. 477—488.
390. Studd J. Hormone therapy for reproductive depression in women // Post. Reprod. Health. 2014. Vol. 20. P. 132-137.
391. Sukor N., Kogovsek C., Gordon R.D., Robson D., Stowasser M. Improved quality of li f.e., blood pressure and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism//J. Clin. Endocrinol. Metab. 2010. Vol. 95. P. 1360-1364.
392. Szczesniak D., Jawiarczyk-Przybylowska A., Rymaszewska J. The quality of life and psychologic a.l., social and cognitive functioning of patients with acromegaly // Adv. Clin. Exp. Med. 2015. Vol. 24. P. 167-172.
393. Thomsen A.F., Kvist T.K., Andersen P.K., Kessing L.V. The risk of affective disorders in patients with adrenocortical insufficiency // Psychoneuroendocrinology. 2006. Vol. 31. P. 614-622.
394. Underbjerg L., Sikjaer T., Mosekilde L., Rejnmark L. Postsurgical hypoparathyroidism — risk of fractures., psychiatric diseases, cancer, catara c.t., and infections //J. Bone Miner. Res. 2014. Vol. 29. P. 2504-2510.
395. Vargas K.G., Milic J., Zaciragic A., Wen K.X., Jaspers L., Nano J. et al. The functions of estrogen receptor beta in the female brain: a systematic review // Maturitas. 2016. Vol. 93. P. 41—57.
396. Wang В., An X., Shi X., Zhang J. Management of endocrine disease: suicide risk in patients with diabetes: a systemic review and meta-analysis // Eur. J. Endocrinol. 2017. Vol. 177. P. R169- R18I.
397. Webb S.M. How good is perceived health-related quality of life in patients treated for non-functioning pituitary adenomas? // Clin. Endocrinol. 2013. Vol. 78. P. 21—22. 2016. Vol. 93. P. 41-57.
398. Weber T., Keller M., Hense 1., Pietsch A., Hinz U., Schilling T. et al. Effect of parathyroidectomy on quality of life and neuropsychological symptoms in primary hyperparathyroidism //World J. Surg. 2007. Vol. 31. P. 1202-1209.
399. Wedrychowicz A., Zajqc A., Pilecki M., Koscielniak B., Tomasik P.J. Peptides from adipose tissue in mental disorders // World. J. Psychiatry. 2014. Vol. 4. P. 103—111.
400. Wilhelm S.M., Lee J., Prinz R.A. Major depression due to primary hyperparathyroidism: a frequent and correctable disorder // Am. Surg. 2004. Vol. 70. P. 175—179.
401. Wojniusz S., Callens N., Siitterlin S., Andersson S., De Schepper J., Gies I. et al. Cognitive, emotional, and psychosocial functioning of girls treated with pharmacological puberty blockage for idiopathic central precocious puberty // Front. Psychol. 2016. Vol. 7. P. 1053.
402. Yen Y-C, Huang C-K, Tai C-M. Psychiatric aspects of bariatric surgery // Curr. Opin. Psychiatry. 2014. Vol. 27. P. 374—379.
403. Young-Hyman D., de Groot M., Hill-Briggs E, Gonzalez J.S., Hood K., Peyrot M. Psychosocial care for people with diabetes: a position statement of the American Diabetes Association // Diabetes Care. 2016. Vol. 39. P. 2126—2140.
404. Poewe W, Djamshidian-Tehrani A. Movement disorders in systemic diseases // Neurol. Clin. 2015. Vol. 33. P. 269-297.
405. Samarasinghe S., Emanuele M.A., Mazhari A. Neurology of the pituitary // Handb. Clin. Neurol. 2014. Vol. 120. P. 685-701.
406. The International Classification of Headache Disorde r.s., 3rd edition (beta version). Headache Classification Committee of the International Headache Society (IHS) // Cephalalgia. 2013. Vol. 33. P. 629-808.
407. Viau М., Renaud М.С., Gregoire J., Sebastianelli A., Plante M. Paraneoplastic syndromes associated with gynecological cancers: a systematic review // Gynecol. Oncol. 2017. Vol. 146. P. 661-671.
408. Wood-Allum C.A., Shaw P.J. Thyroid disease and the nervous system // Handb. Clin. Neurol. 2014. Vol. 120. P. 703-735.
409. Yu J. Endocrine disorders and the neurologic manifestations // Ann. Pediatr. Endocrinol. Metab. 2014. Vol. 19. P. 184-190.
410. Besedovsky H.O., del Rey A.E., Sorkin E. Immune-neuroendocrine interactions // J. Immunol. 1985. Vol. 135. P. 750—754.
411. Boettger M.K., Weber K., Grossmann D., Gajda M., Bauer R., Bar K.J. et al. Spinal tumor necrosis factor alpha neutralization reduces peripheral inflammation and hyperalgesia and suppresses autonomic responses in experimental arthritis: a role for spinal tumor necrosis factor alpha during induction and maintenance of peripheral inflammation // Arthritis Rheum. 2010. Vol. 62. P. 1308-1318.
412. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R. et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin // Nature. 2000. Vol. 405. P. 458-462.
413. Bosmann M., Meta E, Ruemmler R., Haggadone M.D., Sarma J.V., Zetoune F.S. et al. Regulation of IL-17 family members by adrenal hormones during experimental sepsis in mice //Am. J. Pathol. 2013. Vol. 182. P. 1124-1130.
414. Bourne H.R., Lichtenstein L.M., Melmon K.L., Henney C.S., Weinstein Y., Shearer G.M. Modulation of inflammation and immunity by cyclic AMP. Receptors for vasoactive hormones and mediators of inflammation regulate many leukocyte functions // Science. 1974. Vol. 184. P. 19-28.
415. Bynoe M.S., Grimaldi C.M., Diamond B. Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive В cells // Proc. Natl. Acad. Sci USA. 2000. Vol. 97. P. 2703—2708.
416. Capellino S., Cosentino M., Wolff C., Schmidt M., Grifka J., Straub R.H. Catecholamine-producing cells in the synovial tissue during arthritis: modulation of sympathetic neurotransmitters as new therapeutic target // Ann. Rheum. Dis. 2010. Vol. 69. P. 1853—1860.
417. Carlsten FL, Nilsson N., Jonsson R., Backman K., Holmdahl R., Tarkowski A. Estrogen accelerates immune complex glomerulonephritis but ameliorates T cell-mediated vasculitis and sialadenitis in autoimmune MRL 1pr/lpr mice 86 // Cell. Immunol. 1992. Vol. 144. P. 190-202.
418. Chabbi-Achengli Y, Coman T., Collet C., Callebert J., Corcelli M., Lin H. et al. Serotonin is involved in autoimmune arthritis through Thl7 immunity and bone resorption // Am. J. Pathol. 2016. Vol. 186. P. 927-937.
419. Chang Y, Albright S., Lee F. Cytokines in the central nervous system: expression of macrophage colony stimulating factor and its receptor during development // J. NeuroimmunoL 1994. Vol. 52. P. 9-17.
420. Chikanza ЕС., Grossman А.В. Reciprocal interactions between the neuroendocrine and immune systems during inflammation // Rheum. Dis. Clin. N. Am. 2000. Vol. 26. P. 693—711.
421. Conde J., Scotece M., Abella V., Lopez V., Pino J., Gomez-Reino J.J. et al. An update on leptin as immunomodulator // Expert. Rev. Clin Immunol. 2014. Vol. 10. P. 1165—1170.
422. Croffbrd L.J., Sano H., Karalis K., Friedman T.C., Epps H.R., Remmers E.F. et al. Corticotropinreleasing hormone in synovial fluids and tissues of patients with rheumatoid arthritis and osteoarthritis//J. Immunol. 1993. Vol. 151. P. 1587—1596.
423. Cutolo M., Maestroni G.J. The melatonin-cytokine connection in rheumatoid arthritis // Ann. Rheum. Dis. 2005. Vol. 64. P. 1109—1111.
424. Cutolo M., Straub R.H. Polymyalgia rheumatica: evidence for a hypothalamic-pituitary-adrenal axisdriven disease // Clin. Exp. Rheumatol. 2000. Vol. 18. P. 655—658.
425. Cutolo M., Wilder R.L. Different roles for androgens and estrogens in the susceptibility to autoimmune rheumatic diseases // Rheum. Dis. Clin. N. Am. 2000. Vol. 26. P. 825—839.
426. Cutolo M., Balleari E., Giusti M., Monachesi M., Accardo S. Sex hormone status of male patients with rheumatoid arthritis: evidence of low serum concentrations of testosterone at baseline and after human chorionic gonadotropin stimulation // Arthritis Rheum. 1988. Vol. 31. P. 1314-1317.
427. Cutolo M., Kirkham B.C., Sany B.J., Scott D., Brooks P., Forre O. et al. Loading/main-tenance doses approach to neutralization of TNF by Lenercept (TNFR55-IgGl, Ro 45-2081) in patients with rheumatoid arthritis treated for 3 months: results of double-blind placebo controlled phase II trial //Arthritis Rheum. 1996. Vol. 39 (Supplement). P. S243.
428. Cutolo M., Foppiani L., Prete C., Ballarino P., Sulli A., Villaggio B. et al. Hypothalamic-pituitaryadrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids //J. Rheumatol. 1999. Vol. 26. P. 282—288.
429. Cutolo M., Sulli A., Pizzomi C., Craviotto C., Prete C., Foppiani L. et al. Cortisol., dehydroepiandrosterone sulfa t.e., and androstenedione levels in patients with polymyalgia rheumatica during twelve months of glucocorticoid therapy// N. YAcad. Sci. 2002. Vol. 966. P. 91—96.
430. Cutolo M., Capellino S., Montagna P., Villaggio B., Sulli A., Seriolo B. et al. New roles for estrogens in rheumatoid arthritis // Clin. Exp. Rheumatol. 2003a. Vol. 21. P. 687—690.
431. Cutolo M., Sulli A., Pizzorni C., Craviotto C., Straub R.H. Hypothalamic-pituitary-adrenocortical and gonadal functions in rheumatoid arthritis // Ann. N. Y. Acad. Sci. 2003b. Vol. 992. P. 107-117.
432. Cutolo M., Capellino S., Montagna P., Villaggio B., Sulli A., Seriolo B. et al. New roles for estrogens in rheumatoid arthritis // Clin. Exp. Rheumatol. 2003c. Vol. 21. P. 687—690.
433. Cutolo M., Straub R.H., Buttgereit F. Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside // Ann. Rheum. Dis. 2008. Vol. 67. P. 905-908.
434. Cutolo M., Hopp M., Liebscher S., Dasgupta B., Buttgereit F. Modified-release prednisone for polymyalgia rheumatica: a multicent r.e., randomis e.d., active-control! e.d., dou-ble-bli n.d., parallelgroup study // RMD Open. 2017. Vol. 3. P. e000426.
435. Dailey M.O., Schreurs J., Schulman H. Hormone receptors on cloned T lymphocytes. Increased responsiveness to histami n.e., prostaglandins and |3-adrenergic agents as a late stage in T cell activation // J. Immunol. 1988. Vol. 140. P. 2931—2936.
436. De Souza E.B., Webster E.L., Grigoriadis D.E., Tracey D.E. Corticotropin-releasing factor (CRF) and interleukin-1 (IL-1) receptors in the brain-pituitary-immune axis // Psychopharmacol. Bull. 1989. Vol. 25. P. 299—305.
437. Dekkers J.C., Geenen R., Godaert G.L., Glaudemans K.A., Lafeber F.P., van Doornen L.J. et al. Experimentally challenged reactivity of the hypothalamic pituitary adrenal axis in patients with recently diagnosed rheumatoid arthritis // J. Rheumatol. 2001. Vol. 28. P. 1496-1504.
438. Dicou Е., Perrot S., Menkes C.J., Masson C., Nerriere V. Nerve growth factor (NGF) autoantibodies and NGF in the synovial fluid: implications in spondylarthropathies // Autoimmunity. 1996. Vol. 24. P. 1—9.
439. Ernestam S., Hafstrom 1.,WernerS., Carlstrom K., Tengstrand B. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function // J. Rheumatol. 2007. Vol. 34. P. 1451 — 1458.
440. Forrest C.M., Mackay G.M., Stoy N.. Stone T.W., Darlington L.G. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin // Br. J. Clin. Pharmacol. 2007. Vol. 64. P. 517-526.
441. Galant S.P., Remo R.A. Beta-adrenergic inhibition of human T lymphocyte rosettes // J. Immunol. 1975. Vol. 114. P. 512-513.
442. Gillette S., Gillette R. Changes in thymic estrogen receptor expression following orchidectomy // Cell. Immunol. 1979. Vol. 42. P. 194—196.
443. Gisler R.H., Schenkel-Hulliger L. Hormonal regulation of the immune response. II. Influence of pituitary and adrenal activity on immune responsiveness in vitro // Cell. Immunol. 1971. Vol. 2. P. 646-657.
444. Guirao X., Kumar A., Katz J., Smith M., Lin E., Keogh C. et al. Catecholamines increase monocyte TNF receptors and inhibit TNF through beta 2-adrenoreceptor activation // Am. J. Phys. 1997. Vol. 273. P. E1203—E1208.
445. Guo E, Yu J., Jae Jung H., Abruzzi K.C., Lu o.W., Griffith L.C. et al. Circadian neuron feedback controls the Drosophila sleep—activity profile // Nature. 2016. Vol. 536. P. 292—297.
446. Hadden J.W., Hadden E.M., Middleton E.J. Lymphocyte blast transformation. Demonstration of adrenergic receptors in human peripheral lymphocytes // Cell. Immunol. 1970. Vol. 1. P. 583-595.
447. Harbuz M.S., Rees R.G., Eckland D., Jessop D.S., Brewerton D., Lightman S.L. Paradoxical responses of hypothalamic corticotropin-releasing factor (CRF) messenger ribonucleic acid (mRNA) and CRF-41 peptide and adenohypophysial propiomelanocortin mRNA during chronic inflammatory stress//Endocrinology. 1992. Vol. 130. P. 1394—1400.
448. Harle P., Straub R.H., Wiest R., Mayer A., Scholmerich J., Atzeni F. et al. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pitui-tary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems // Ann. Rheum. Dis. 2006. Vol. 65. P. 51-56.
449. Harle P., Pongratz G., Albrecht J., Tarner I.H., Straub R.H. An early sympathetic nervous system influence exacerbates collagen-induced arthritis via CD4+CD25+ cells // Arthritis Rheum. 2008. Vol. 58. P. 2347-2355.
450. Hazum E., Chang K.J., Cuatrecasas P. Specific nonopiate receptors for beta endorphins // Science. 1979. Vol. 205. P. 1033-1035.
451. Helderman J.H., Strom T. Specific insulin binding site on T and В lymphocytes as a marker of cell activation // Nature. 1978a. Vol. 274. P. 62—63.
452. Helderman J.H., Strom T. Specific insulin binding site on T and В lymphocytes as a marker of cell activation // Nature. 1978b. Vol. 274. P. 62—63.
453. Hench P.S. The ameliorating effect of pregnancy on chronic atrophic (infectious, rheumatoid) arthritis., fibrositis, and intermittent hydrarthrosis // Proc. Staff. Meet. Mayo Clin. 1938. Vol. 13. P. 161-167.
454. Herxheimer H., Rosa L. The protective effect of sympathicomimetic amines and of aminophylline in the anaphylactic microshock of the Guinea-pig // Br. J. Pharmacol. Chemother. 1953. Vol. 8. P. 177-180.
455. Imrich R., Bosak V, Rovensky J. Polymyalgia rheumatica and temporal arteritis: the endocrine relations and the pathogenesis // Review Endocr. Regul. 2006. Vol. 40. P. 83—89.
456. Jara L.J., Medina G., Saavedra M.A., Vera-Lastra О., Navarro C. Prolactin and autoimmunity // Clin. Rev. Allergy Immunol. 2011. Vol. 40. P. 50—59.
457. Jenei-Lanzl Z., Zwingenberg J., Lowin T., Anders S., Straub R.H. Proinflammatory receptor switch from Gas to Gai signaling by |3-arrestin-mediated PDE4 recruitment in mixed RA synovial cells // Brain. Behav. Immun. 2015. Vol. 50. P. 266—274.
458. Jiang H., Shen X., Chen Z., Liu F.,Wang T., Xie Y, Ma C. Nociceptive neuronal fc-gamma receptor I is involved in IgG immune complex induced pain in the rat // Brain. Behav. Immun. 2017. Vol. 62. P. 351-361.
459. Johnson E.O., Moutsopoulos H.M. Neuroendocrine manifestations in Sjogren’s syndrome. Relation to the neurobiology of stress // Ann. N. Y. Acad. Sci. 2000. Vol. 917. P. 797—808.
460. Kassi E., Vlachoyiannopoulos P.G., Kominakis A., Kiaris H., Moutsopoulos H.M., Moutsatsou P. Estrogen receptor alpha gene polymorphism and systemic lupus erythematosus: a possible risk? // Lupus. 2005. Vol. 14. P. 391—398.
461. Kinouchi K., Brown G., Pasternak G., Donner D.B. Identification and characterization of receptors for tumor necrosis factor-alpha in the brain // Biochem. Biophys. Res. Commun. 1991. Vol. 18. P. 1532-1538.
462. Koller M.D., Tempi E., Riedl M., Clodi M., Wagner O., Smolen J.S. et al. Pituitary function in patients with newly diagnosis untreated systemic lupus erythematosus // Ann. Rheum. Dis. 2004. Vol. 63. P. 1677-1680.
463. Koopman F.A., Chavan S.S., Miljko S. Grazio S4 Sokolovic S5 Schuurman P.R. et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis // Proc. Natl. Acad. Sci USA. 2016. Vol. 113. P. 8284—8289.
464. Lago R., Gomez R., Lago E, Gomez-Reino J., Gualillo O. Leptin beyond body weight regulation— current concepts concerning its role in immune function and inflammation // Cell. Immunol. 2008. Vol. 252. P. 139-145.
465. Lahita R.G. Sex and age in systemic lupus erythematosus. Systemic lupus erythematosus. New York: Wiley, 1986. P. 523-539.
466. Lahita R.G., Bradlow H.L., Kunkel H.G., Fishman J. Alterations of estrogen metabolism in systemic lupus erythematosus //Arthritis Rheum. 1979. Vol. 22. P. 1195—1198.
467. Lahita R.G., Bradlow H.L., Ginzler E., Pang S., New M. Low plasma androgens in women with systemic lupus erythematosus// Arth. Rheum. 1987. Vol. 30. P. 241—248.
468. Landmann R M.A., Bittiger H., Biihler F.R. High affinity beta-2-adrenergic receptors in mononuclear leucocytes: similar density in young and old normal subjects // Life Sci. 1981. Vol. 29. P. 1761-1771.
469. Le Moine O., Stordeur P., Schandene L., Marchant A., De Groote D., Goldman M. et al. Adenosine enhances IL-10 secretion by human monocytes // J. Immunol. 1996. Vol. 156. p. 4408-4414.
470. Lechner O., Hu Y, Jafarian-Tehrani M., Dietrich H., Schwarz S., Herold M. et al. Disturbed immunoendocrine communication via the hypothalamo-pituitary-adrenal axis in murine lupus // Brain. Behav. Immun. 1996. Vol. 10. P. 337—359.
471. Lechner O., Dietrich H., Oliveira dos Santos A., Wiegers G.J., Schwarz S., Harbutz M. et al. Altered circadian rhythms of the stress hormone and melatonin response in lupus-prone MRL/MP- fas (Lpr) mice //J. Autoimmun. 2000. Vol. 14. P. 325—333.
472. Lee Y.C., Raychaudhuri S., Cui J., De V.I., Ding B., Alfredsson L. et al. The PRL-1149G/T polymorphism and rheumatoid arthritis susceptibility // Arthritis Rheum. 2009. Vol. 60. P. 1250-1254.
473. Levine Y.A., Koopman F.A., Faltys M., Caravaca A., Bendele A., Zitnik R. et al. Neurostimulation of the cholinergic anti-inflammatory pathway ameliorates disease in rat collagen-induced arthritis // PLoS One. 2014. Vol. 9. P. e 104530.
474. Lorton D., Bellinger D.L. Molecular mechanisms underlying β-adrenergic receptor-mediated crosstalk between sympathetic neurons and immune cells // Int. J. Mol. Sci. 2015. Vol. 16. P. 5635-5665.
475. Masi A.T., Imrich R., Cutolo M. Hypothesis: can neuroendocrine immune (NEI) testing of individual RA patients guide benefits to harms ratio in glucocorticoid therapy? // Arthritis Care Res. (Hoboken). 2017. Vol. 26.
476. Mastorakos G., Chrousos G.P., Weber J.S. Recombinant interleukin-6 activates the hypo-thalamicpituitary-adrenal axis in humans // J. Clin. Endocrinol. Metab. 1993. Vol. 77. P. 1690-1694.
477. Matera L., Mori M., Geuna M., Buttiglieri S., Palestro G. Prolactin in auto-immunity and antitumor defence //J. Neuroimmunol. 2000. Vol. 109. P. 47—55.
478. Miller L.E., Justen H.P., Scholmerich J., Straub RH. The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages // FASEB J. 2000. Vol. 14. P. 2097-2107.
479. Miller L.E., Grifka J., Scho Imerich J., Straub R.H. Norepinephrine from synovial tyrosine hydroxylase positive cells is a strong indicator of synovial inflammation in rheumatoid arthritis // J. Rheumatol. 2002. Vol. 29. P. 427-435.
480. Ohmichi M., Hirota K., Koike K., Kurachi H., Ohtsuka S., Matsuzaki N. et al. Binding sites for interleukin-6 in the anterior pituitary gland // Neuroendocrinology. 1992. Vol. 55. P. 199-203.
481. O'Shaughnessy M.C., Vetsika E.K., Inglis J.J., Carleson J., Haigh R., Kidd B.L. et al. The effect of substance P on nitric oxide release in a rheumatoid arthritis model // Inflamm. Res. 2006. Vol. 55. P. 236-240.
482. Paolino S., Cutolo M., Pizzorni C. Glucocorticoid management in rheumatoid arthritis: morning or night low dose? // Reumatologia. 2017. Vol. 55. P. 189—197.
483. Pereira da Silva J.A., Carmo-Fonseca M. Peptide containing nerves in human synovium: immunohistochemical evidence for decreased innervation in rheumatoid arthritis // J. Rheumatol. 1990. Vol. 17. P. 1592-1599.
484. Platzer C., Meisel C., Vogt K., Platzer M., Volk H.D. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs // Int. Immunol. 1995. Vol. 7. P. 517-523.
485. Pool A.J., Whipp B.J., Skasick A.J., Alavi A., Bland J.M., Axford J.S. Serum cortisol reduction and abnormal prolactin and CD4[i/CD8f> T-cell response as a result of controlled exercise in patients with rheumatoid arthritis and systemic lupus erythematosus despite unaltered muscle energetics // Rheumatology (Oxford). 2004. Vol. 43. P. 43—48.
486. Procaccini C., La Rocca C., Carbone E, De Rosa V, Galgani M., Matarese G. Leptin as immune mediator: interaction between neuroendocrine and immune system // Dev. Comp. Immunol. 2017. Vol. 66. P. 120-129.
487. Richman D.P., Arnason B.G. Nicotinic acetylcholine receptor: evidence for a functionally distinct receptor on human lymphocytes // Proc. Natl. Acad. Sci USA. 1979. Vol. 76. P. 4632-4635.
488. Rivier C., Vale W. In the rat, interleukin-1 alpha acts at the level of the brain and the gonads to interfere with gonadotropin and sex steroid secretion // Endocrinology. 1989. Vol. 124. P. 2105-2109.
489. Russell D.H., Matrision L., Kibler R., Larson D., Poulps B., Magun B. Prolactin receptor on human lymphocytes and their modulation by cyclosporin // Biochem. Biophys. Res. Commun. 1984. Vol. 121. P. 899-906.
490. Schaible H.G. Nociceptive neurons detect cytokines in arthritis // Arthritis Res. Ther. 2014. Vol. 16. P. 470.
491. Schmidt P., Holsboer F. Spengler D. beta(2)-adrenergic receptors potentiate glucocorticoid receptor transactivation via g protein betagamma-subunits and the phosphoinositide 3-kinase pathway// Mol. Endocrinol. 2001. Vol. 15. P. 553—564.
492. Schramm C.M. Beta-adrenergic relaxation of rabbit tracheal smooth muscle: a receptor deficit that improves with corticosteroid administration // J. Pharmacol. Exp. Ther. 2000. Vol. 292. P. 280-287.
493. Severn A., Rapson N.T., Hunter C.A., Liew F.Y. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists // J. Immunol. 1992. Vol. 148. p. 3441-3445.
494. Shim G.J., Warner M., Kim H.J., Andersson S., Liu L., Ekman J. et al. Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjogren’s syndrome // Proc. Natl. Acad. Sci USA. 2004. Vol. 101. P. 12628—12633.
495. Silva C.A., Deen M.E., Febronio M.V., Oliveira S.K., Terreri M.T., Sacchetti S.B. et al. Hormone profile in juvenile systemic lupus erythematosus with previous or current amenorrhea // Rheumatol. Int. 2011. Vol. 31. P. 1037—1043.
496. Smith L.R., Brown S.L., Blalock J.E. Interleukin-2 induction of ACTH secretion: presence of an interleukin-2 receptor alpha-chain- like molecule on pituitary cells//J. Neuroimmunol. 1989. Vol. 21. P. 249-254.
497. Spies C.M., Schaumann D.H., Berki T., Mayer K., Jakstadt M., Huscher D. et al. Membrane glucocorticoid receptors (mGCR) are down-regulated by glucocorticoids in patients with systemic lupus erythematosus and use a caveolin-1 independent expression pathway // Ann. Rheum. Dis. 2006. Vol. 65. P. 1139-1146.
498. Srinivasan V, Spence D.W., Trakht I., Pandi-Perumal S.R., Cardinali D.P., Maestroni G.J. Immunomodulation by melatonin: its significance for seasonally occurring diseases // Neuroimmunomodulation. 2008. Vol. 15. P. 93—101.
499. Stark K., Schmidt M., Rovensky J., Blazickova S., Lowin T., Straub R.H. Influence of CYB5A gene variants on risk of rheumatoid arthritis and local endocrine function in the joint // Brain. Behav. Immun. 2013. Vol. 29 (Suppl). P. S12— S13.
500. Sternberg E.M., Hill J.M., Chrousos G.P., Kamilaris T., Listwak S.J., Gold P.W. et al. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats // Proc. Natl. Acad. Sci USA. 1989. Vol. 86. P. 2374-2378.
501. Straub R.H. The complex role of estrogens in inflammation // Endocr. Rev. 2007. Vol. 28. P. 521-574.
502. Straub R.H., Cutolo M. Involvement of the hypothalamic — pituitary — adrenal/gonadal axis and the peripheral nervous system in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role // Arthritis Rheum. 2001. Vol. 44. P. 493—507.
503. Straub R.H., Cutolo M. Glucocorticoids and chronic inflammation // Rheumatology (Oxford). 2016. Vol. 55. P. ii6—iil4.
504. Straub R.H., Konecna L., Hrach S., Rothe G., Kreutz M., Scholmerich J. et al. Serum dehydroepiandrosterone (DHEA) and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence // J. Clin. Endocrinol. Metab. 1998a. Vol. 83. P. 2012—2017.
505. Straub R.H., Konecna L., Hrach S., Rothe G., Kreutz M., Scholmerich J. et al. Serum DHEA and DHEA sulfate are negatively correlated with serum interleukin-6 (IL-6), and DHEA inhibits IL-6 secretion from mononuclear cells in man in vitro: possible link between endocrinosenescence and immunosenescence // J. Clin. Endocrinol. Metab. 1998b. Vol. 83. P. 2012-2017.
506. Straub R.H., Gliick T., Cutolo M., Georgi J., Helmke K., Scholmerich J. et al. The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica // Rheumatology (Oxford). 2000. Vol. 39. P. 624—631.
507. Straub R.H., Giinzler C., Miller L.E., Cutolo M., Scholmerich J., Schill S. Anti-inflammatory cooperativity of corticosteroids and norepinephrine in rheumatoid arthritis synovial tissue in vivo and in vitro // FASEB J. 2002a. Vol. 16. P. 993-1000.
508. Straub R.H., Paimela L., Peltomaa R., Scholmerich J., Leirisalo-Repo M. Inadequately low serum levels of steroid hormones in relation to IL-6 and TNF in untreated patients with early rheumatoid arthritis and reactive arthritis // Arthritis Rheum. 2002b. Vol. 46. P. 654-662.
509. Straub R.H., Pongratz G., Scholmerich J., Kees E, Schaible T.F., Antoni C. et al. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion // Arthritis Rheum. 2003. Vol. 48. P. 1504-1512.
510. Straub R.H., Weidler C., Demmel B., Herrmann M., Kees E, Schmidt M. et al. Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus // Rheum. Dis. 2004. Vol. 63. P. 961—968.
511. Straub R.H., Bijlsma J.W., Masi A., Cutolo M. Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases-the 10-year update // Semin. Arthritis Rheum. 2013. Vol. 43. P. 392—404.
512. Suehiro R.M., Borba E.F., Bonfa E., Okay T.S., Cocuzza M., Soares P.M. et al. Testicular Sertoli cell function in male systemic lupus erythematosus // Rheumatology (Oxford). 2008. Vol. 47. P. 1692-1697.
513. Szabo G., Girouard L., Mandrekar P., Catalano D. Regulation of monocyte IL-12 production: augmentation by lymphocyte contact and acute ethanol treatme n.t., inhibition by elevated intracellular cAMP // Int. J. Immunopharmacol. 1998. Vol. 20. P. 491—503.
514. Tai P., Wang J., Jin H., Song X., Yan J., Kang Y. et al. Induction of regulatory T cells by physiological level estrogen //J. Cell. Physiol. 2008. Vol. 214. P. 456—464.
515. Tengstrand B., Carlstrom K., Hafstrom I. Bioavailable testosterone in men with rheumatoid arthritishigh frequency of hypogonadism // Rheumatology (Oxford). 2002. Vol. 41. P. 285-289.
516. Tengstrand B., Carlstrom K., Hafstrom I. Gonadal hormones in men with rheumatoid arthritis — from onset through 2 years // J. Rheumatol. 2009. Vol. 36. P. 887—892.
517. Torres-Ruiz J., Sulli A., Cutolo M., Air Travel S.Y. Circadian rhythms/hormon e.s., and autoimmunity // Clin. Rev. Allergy Immunol. 2017. Vol. 53. P. 117—125.
518. Tsigos C., Papanicolaou D.A., Defensor R., Mitsiadis C.S., Kyrou L, Chrousos G.P. Dose effects of recombinant human interleukin-6 on pituitary hormone secretion and energy expenditure // Neuroendocrinology. 1997. Vol. 66. P. 54—62.
519. van der Goes M.C., Bossema E.R., Hartkamp A., Godaert G.L., Jacobs J.W., Kruize A.A. Cortisol during the day in patients with systemic lupus erythematosus or primary Sjogren’s syndrome // J. Rheumatol. 2011. Vol. 38. P. 285—288.
520. Verghese M.W., McConnell R.T., Strickland A.B., Gooding R.C., Stimpson S.A., Yamall D.P. et al. Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors // J. Pharmacol. Exp. Ther. 1995. Vol. 272. P. 1313-1320.
521. Walker S.E., Jacobson J.D. Roles of prolactin and gonadotropin-releasing hormone in rheumatic diseases // Rheum. Dis. Clin. N. Am. 2000a. Vol. 26. P. 713—736.
522. Walker S.E., Jacobson J.D. Roles of prolactin and gonadotropin-releasing hormone in rheumatic diseases // Rheum. Dis. Clin. N. Am. 2000b. Vol. 26. P. 713—736.
523. Webster E.L., Barrientos R.M., Contoreggi C., Isaac M.G., Ligier S., Gabry K.E. et al. Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation // J. Rheumatol. 2002. Vol. 29. P. 1252—1261.
524. Weidler C., Holzer C., Harbuz M., Hofbauer R., Angele P., Scholmerich J. et al. Low density of sympathetic nerve fibres and increased density of brain derived neurotrophic factor positive cells in RA synovium // Ann. Rheum. Dis. 2005. Vol. 64. P. 13—20.
525. Werb Z., Foley R., Munck A. Interaction of glucocorticoids with macrophages. Identification of glucocorticoid receptors in monocytes and macrophages //J. Exp. Med. 1978. Vol. 147. P. 1684-1694.
526. Wybran J., Appelboom T., Famaey J.P., Govaerts A. Suggestive evidence for morphin and methionine-enkephalin receptor-like structures on normal blood T lymphocytes // J. Immunol. 1979. Vol. 123. P. 1068-1070.
527. Zietz B., Reber T., Oertel M., Gluck T., Scholmerich J., Straub RH. Altered function of the hypothalamic stress axes in patients with moderately active systemic lupus erythematosus. II. Dissociation between androstenedio n.e., cortis o.l., or dehydroepiandrosterone and interleukin 6 or tumor necrosis factor // J. Rheumatol. 2000. Vol. 27. P. 911—918.
528. Abd-Elnabi Н., El-Gamasy М., Abd-Elhafez М. Thyroid dysfunctions in a sample of Egyptian children and adolescents with SLE: relation to disease activity and duration // Egypt. J. Immunol. 2016. Vol. 23. N. 2. P. 65-73.
529. Al Saleh J., Sayed M., Jassim V., Mohammed N., Khan N. Hypothyroidism determines the clinical and immunological manifestations of Arabs with lupus // Lupus. 2008. Vol. 17. N. 3. P. 215-220.
530. Albrecht K., Luque Ramos A., Hoffmann E, Redeker 1., Zink A. High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data// Rheumatology. 2018. Vol. 57. N. 2. P. 329—336.
531. Aloush V., Litinsky I., Caspi D., Elkayam O. Propylthiouraci induced autoimmune syndromes: two distinct clinical presentations with different course and management // Semin. Arthritis. Rheum. 2006. Vol. 36. P. 4—9.
532. Alvarez-Nemegyei J., Cobarrubias-Cobos A., Escalante-Triay E, Sosa-Muiioz J., Miranda J.M., Jara L.J. Bromocriptine in systemic lupus erythematosus: a double-bli n.d., randomized., placebocontrolled study// Lupus. 1998. Vol. 7. N. 6. P. 414—419.
533. Anaya J.M., Rojas-Villarraga A., Mantilla R.D., Arcos-Burgos M., Sarmiento-Monroy J.C. Polyautoimmunity in Sjogren syndrome // Rheum. Dis. Clin. N. Am. 2016. Vol. 42. P. 457-472.
534. Antohe J I., Bili A., Sartorius J.A., Kirchner H.L., Morris S.J., Dancea S.,Wasko MCM. Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor a therapy // Arthritis Care Res. 2012. Vol. 64. N. 2. P. 215—221.
535. Antonelli A., Fallahi P., Mosca M., Ferrari S.M., Ruffilli I., Corti A. ... Bombardieri S. Prevalence of thyroid dysfunction in SLE // Metabolism. 2010. Vol. 59. P. 896—900.
536. Balavoine A.S., Glinoer D., Dubucquoi S., Wemeau J.L. Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? // Thyroid. 2015. Vol. 25. N. 12. P. 1273—1281.
537. Banon S., Isenberg D.A. Rheumatological manifestations occurring in patients with diabetes mellitus// Scand. J. Rheumatol. 2013. Vol. 42. P. 1—10.
538. Bengtsson C., Padyukov L., Kallberg H., Saevarsdottir S. Thyroxin substitution and the risk of developing rheumatoid arthritis: results from the Swedish population based EIRA study // Ann. Rheum. Dis. 2014. Vol. 73. P. 1096-1100.
539. Bilge S.Y., Korkmaz C. Calcium metabolism disorders simulating rheumatologic diseases // Rheumatol. Int. 2012. Vol. 32. P. 1503-1505.
540. Boelaert K., Newby P.R., Simmonds M.J., Holder R.L., Carr-Smith J.D., Heward J.M. ... Lazarus J.H. Prevalence and relative risk of the autoimmune diseases in subjects with autoimmune thyroid disease // Am. J. Med. 2010. Vol. 123. N. 2. P. el— e 183.
541. Boswell S.B., Patel D.B., White E.A., Gottsegen C.J., Forrester D.M., Masih S., Matcuk G.R. Musculoskeletal manifestations of endocrine disorders // Clin Imaging. 2014. Vol. 38. P. 384-396.
542. Bouchard B., Ormandy C J., Di Santo J.P., Kelly P.A. Immune system development and function in prolactin receptor-deficient mice //J. Immunol. 1999. Vol. 163. N. 2. P. 576—582.
543. Bruce I.N., Urowitz M.B., Gladman D., Bafiez D., Steiner G. Risk factors for coronary heart disease in women with SLE arthritis and rheumatism // Arthritis Rheum. 2003. Vol. 48. N. 11. P. 3159-3167.
544. Caramaschi Р., Biasi D., Caimmi С., Scambi С., Pieropan S., Barausse G., Adami S. The co-occurrence of Hashimoto thyroiditis in primary Sjogren’s syndrome defines a subset of patients with milder clinical phenotype // Rheumatol. Int. 2013. Vol. 33. N. 5. P. 1271 — 1275.
545. Chakravarty S.D., Markenson J.A. Rheumatic manifestations of endocrine disease // Curr. Opin. Rheumatol. 2013. Vol. 25. N. 1. P. 37—43.
546. Charles P.J., Plant D., Chowdhury M., Worthington J., Venables P. Antibodies to thyroglobulin and thyroperoxidase in rheumatoid arthritis: environmental and genetic associations // Ann. Rheum. Dis. 2011. Vol. 70. Suppl. 2. P. A88-A89.
547. Chen L.H., Li C.Y., Kuo L.C., Wang L.Y., Kuo K.N., Jou I.M., Hou WH. Risk of hand syndromes in patients with diabetes mellitus // Medicine. 2015a. Vol. 94. N. 41. P. e 1575.
548. Chen Y.M., Lin C.H., Lan Т.Н., Chen H.H., Chang S.N., Chen Y.H. ... Chen D.Y. Hydroxycholoroquine reduces risk of incident diabetes mellitus in lupus patients in a dose dependent manner: a population-based cohort study // Rheumatology. 2015b. Vol. 54. P. 1244-1249.
549. Chen H.H., Chen D.Y, Lin C.C., Chen Y.M., Lai K.L., Lin C.H. Association between use of disease modifying antirheumatic drugs and diabetes in patients with ankylosing spondylitis, RA and psoriasis\PSA: a nationwide population-based cohort study // Ther. Clin. Risk. Manag. 2017. Vol. 13. P. 583-592.
550. Chung C.P., Oeser A., Solus J.F., Avalos I., Gebretsadik T., Shintani A. ... Stein C.M. Prevalence of the metabolic syndrome is increased in rheumatoid arthritis and is associated with coronary atherosclerosis // Atherosclerosis. 2008. Vol. 196. N. 2. P. 756—763.
551. Cortes S., Chambers S., Jeronimo A., Isenberg D. Diabetes mellitus complicating systemic lupus erythematosus-analysis of the UCL lupus cohort and review of the literature // Lupus. 2008. Vol. 17. P. 977-980.
552. Costanza M., Binart N., Steinman L., Pedotti R. Prolactin: a versatile regulator of inflammation and autoimmune pathology // Autoimmun. Rev. 2015. Vol. 14. N. 3. P. 223—230.
553. Courties A., Sellam J. Osteoarthritis and type 2 diabetes mellitus: what are the links? // Diabetes Res. Clin. Pract. 2016. Vol. 122. P. 198.
554. Crepaldi G., Scirfe C.A., Carrara G., Sakellariou G., Caporali R., Hmamouchi I. ... Montecucco C. Cardiovascular comorbidities relate more than others with disease activity in rheumatoid arthritis // PLoS One. 2016. Vol. 11. N. 1. P. e0146991.
555. den Uyl D., van Raalte D.H., Nurmohamed M.T., Lems W.F., Bijlsma J W.J., Hoes J.N. ... Diamant M. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction // Arthritis Rheum. 2012. Vol. 64. N. 3. P. 639-646.
556. Dougados M., Soubrier M., Antunez A., Balint P., Balsa A., Buch M.H. ... Kay J. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) //Ann. Rheum. Dis. 2014. Vol. 73. N. I. P. 62—68.
557. Dowart B.B., Schumacher H.R. Joint effusions and chodrocalcinosis in hypothyroidism // Arthritis Rheum. 1975. Vol. 18. N. 5. P. 529.
558. El Miedany Y.M., Ahmed L, Moustafa H., El Baddini M. Hyperprolactinemia in Sjogren syndrome: a patient subset or a disease manifestation? // Joint. Bone Spine. 2004. Vol. 71. N. 3. P. 203-208.
559. Elfving Р., Puolakka К., Kautiainen Н., Virta L.J., Pohjolainen T., Kaipiainen-Seppanen О. Drugs used in incident systemic lupus erythematosus-results from the Finnish nationwide register 2000-2007 // Lupus. 2016. Vol. 25. N. 6. P. 666-670.
560. Elnady B.M., Kamal N.M., Shaker R.H., Soliman A.F., Hasan W.A., Alghamdi H.A. ... Jajah M.B. Prevalence and clinical significance of non-organ specific antibodies in patients with autoimmune thyroiditis as predictor markers for rheumatic diseases // Medicine. 2016. Vol. 95. N. 38. P. e4336.
561. Emamifar A., Hangaard J., Hansen I.M. Thyroid disorders in patients with newly diagnosed rheumatoid arthritis is associated with poor initial treatment response evaluated by disease activity score in 28 joint C-reactive protein (DAS-28 CRP) // Medicine. 2017. Vol. 96. N. 43. P. e8357.
562. Fallahi P., Ferrari S.M., Ruffilli 1., Elia G., Biricotti M., Vita R. ... Antonelli A. The association of other autoimmune diseases in patients with autoimmune thyroiditis: review of the literature and report of a large series of patients // Autoimmun. Rev. 2016. Vol. 15. N. 12. P. 1125-1128.
563. Gamstedt A., Holm-Glad J., Ohlson C.G., Sundstrom M. Hand abnormalities are strongly associated with the duration of diabetes mellitus // J. Intern. Med. 1993. Vol. 234. N. 2. P. 189-193.
564. Gao H., Li C., Mu R., Guo Y.Q., Liu T., Chen S. ... Li Z.G. Subclinical hypothyroidism and its association with lupus nephritis: a case control study in a large cohort of Chinese systemic lupus erythematosus patients// Lupus. 2011. Vol. 20. N. 10. P. 1035—1041.
565. Gerrits E.G., Landman G.W., Bilo H .J., Nijenhuis-Rosien L. Limited joint mobility syndrome in diabetes mellitus: a mini review//World. J. Diabetes. 2015. Vol. 6. N. 9. P. 1108—1112.
566. Gherghe A.M., Dougados M., Combe B., Landewe R., Mihai C., Berenbaum F. ... van der Heijde D. Cardiovascular and selected comorbidities in early arthritis and early spondyloarthritis, a comparative study: results from the ESPOIR and DESIR cohorts // RMD Open. 2015. Vol. 1. N. I. P. e000128.
567. Ha Y.J., Lee K.H., Jung S.J., Lee S.W., Lee S.K., Park Y.B. Glucocorticoid induced diabetes mellitus in patients with SLE treated with high dose glucocorticoid therapy // Lupus. 2011. Vol. 20. N. 10. P. 1027-1034.
568. Hage M.P., Al-Badri M.R., Azar S.T. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role // Ther. Adv. Endocrinol. Metab. 2014. Vol. 5. N. 4. P. 77-85.
569. Hansen B.U., Ericsson U.B., Henricsson V., Larsson A., Manthorpe R., Warfvinge G. Autoimmune thyroiditis and primary Sjogren’s syndrome: clinical and laboratory evidence of the coexistence of the two diseases // Clin. Exp. Rheumatol. 1991. Vol. 9. N. 2. P. 137— 141.
570. Hochberg M.C., Silman A.J., Smolen J.S., Weisman M., Weinblatt M. Rheumatology. Vol. 2. 6th ed. Philadelphia: Mosby-Elsevier, 2015.
571. Innala L., Sjoberg C., Moller B., Ljung L., Smedby T., Sodergren A. ... WSllberg-Jonsson S. Comorbidity in patients with early rheumatoid arthritis-inflammation matters // Arthritis Res. Ther. 2016. Vol. 18. N. 1. P. 33.
572. Jacobi A.M., Rohd e.W., Ventz M., Riemekasten G., Burmester G.R., Hiepe F. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity // Lupus. 2001. Vol. 10. N. 8. P. 554—561.
573. Jafri K., Bartels C.M., Shin D., Gelfand J.M., Ogdie A. Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study // Arthritis Care Res. 2017. Vol. 69. N. 1. P. 51-57.
574. Jara L., Cruz-Cruz Р., Saavedra М., Medina G., Garcia-Flores A., Angeles U., Miranda-Lim6n J. Bromocriptine during pregnancy in SLE. A pilot clinical trial // Ann. N. Y. Acad. Sci. 2007a. Vol. 1110. N. 1. P. 297-304.
575. Jara L.J., Pacheco-Reyes H., Medina G., Angeles U., Cruz-Cruz P., Saavedra MA. Prolactin levels are associated with lupus activi t.y., lupus anticoagula n.t., and poor outcome in pregnancy//Ann. N. Y. Acad. Sci. 2007b. Vol. 1108. N. I. P. 218—226.
576. Jara L.J., Medina G., Saavedra M.A., Jara L.J., Medina G., Saavedra M.A. ... Espinoza L.R. Prolactin had a pathogenic role in systemic lupus erythematosis // Immunol. Res. 2017. Vol. 65. P. 512-513.
577. Jiang P., Li H., Li X. Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis//Clin. Exp. Rheumatol. 2015. Vol. 33. N. I. P. 115—121.
578. Joshi P., Agarwal A., Vyas S., Kumar R. Prevalence of hypothyroidism in rheumatoid arthritis and its correlation with disease activity // Trop. Doct. 2017. Vol. 47. N. 1. P. 6—10.
579. Kaklamanos M., Thomas D., Pikazis D., Kaltsas G. Thyroid specific changes flowing treatment with biological therapies in patients with rheumatic diseases // Endocrine. 2015. Vol. 50. N. 1. P. 146-153.
580. Kiss C., Szilagyi M., Paksy A., Poor G. Risk factors for diffuse idiopathic skeletal hyperostosis: a case-control study// Rheumatology. 2002. Vol. 41. P. 27—30.
581. Koller M., Tempel E., Riedl M., Clodi M., Wagner O., Smolen J.S., Luger A. Pituitary function in patients with newly diagnosed untreated systemic lupus erythematosus // Ann. Rheum. Dis. 2004. Vol. 63. N. 12. P. 1677-1680.
582. Koszarny A., Majdan M., Suszek D., Wielosz E., Dryglewska M. Relationship between rheumatoid arthritis activity and anti thyroid antibodies // Pol. Arch. Intern. Med. 2013. Vol. 123. N. 7-8. P. 394-400.
583. Kota S.K., Meher L.K., Jammula S., Kota S.K., Modi K.D. Clinical profile of coexisting conditions in type 1 diabetes mellitus patients // Diabetes Metab. Syndr. Clin. Res. Rev. 2012. Vol. 6. N. 2. P. 70-76.
584. Kramer C.K., Tourinho T.F., de Castro W.P., da Costa Oliveira M. Association between systemic lupus erythematosus., rheumatoid arthritis., hyperprolactinemia and thyroid autoantibodies//Arch. Med. Res. 2005. Vol. 36. N. 1. P. 54—58.
585. Kuo C.F., Grainge M.J., Valdes A.M., See L.C., Luo S.F., Yu K.H. ... Doherty M. Familial aggregation of SLE and coaggregation of autoimmune diseases in affected families // JAMA Intern. Med. 2015. Vol. 175. N. 9. P. 1518-1526.
586. KuoC-F, Grainge M.J., Valdes A.M., See L-C, Yu K-H, ShawS.W.S.... Doherty M. Familial aggregation of rheumatoid arthritis and co-aggregation of autoimmune diseases in affected families: a nationwide population-based study // Rheumatology. 2017. Vol. 56. N. 6. P. 928-933.
587. Larouche V, Correa J.A., Cassidy P., Beauregard C., Garfield N., Rivera J. Prevalence of autoimmune disease in patients with prolactinomas and non-functioning pituitary adenoma // Pituitary. 2016. Vol. 19. N. 2. P. 202-209.
588. Lazurova I., Benhatchi K., Rovensky J., Kozakovd D., Wagnerova H., Tajtdkova M. ... Macejova Z. Autoimmune thyroid diseases and autoimmune rheumatic disorders: a two sided analysis //Ann. N. Y. Acad. Sci. 2009. Vol. 1173. N. 1. P. 211—216.
589. Laziirova L, Jochmanova L, Benhatchi K., Sotak §. Autoimmune thyroid disease and rheumatoid arthritis: relationship and the role of genetics // Immunol. Res. 2014. Vol. 60. N. 2—3. P. 193-200.
590. Lee Y.H., Bae S.C., Song G.G. Meta-analysis of associations between functional prolactin-1149 G/T polymorphism and susceptibility to rheumatoid arthritis and systemic lupus erythematosus//Clin. Rheumatol. 2015. Vol. 34. N. 4. P. 683—690.
591. LeRiche N.G., Bell D.A. Hashimoto thyroiditis and polyarthritis: a possible subset of seronegative polyarthritis//Ann. Rheum. Dis. 1984. Vol. 43. P. 594—598.
592. Liao K.P., Gunnarsson M., Kallberg H., Ding B., Plenge R.M., Padyukov L.... Alfredsson L. Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis//Arthritis Rheum. 2009. Vol. 60. N. 3. P. 653—660.
593. Lin W., Chang C.L., Fu L.S., Lin C.H., Lin H.K. Systemic lupus erythematosus and thyroid disease: a 10-year study //J. Microbiol. Immunol. Infect. 2015. Vol. 48. P. 676—683.
594. Lu M-C, Yin W-Y, Tsai T-Y, Koo M., Lai N-S. Increased risk of primary Sjogren’s syndrome in female patients with thyroid disorders: a longitudinal population-based study in Taiwan // PLoS One. 2013. Vol. 8. N. 10. P. e77210.
595. Lu M-C, Yan S-T, Yin W-Y, Koo M., Lai N-S. Risk of rheumatoid arthritis in patients with type 2 diabetes: a nationwide population-based case-control study // PLoS One. 2014. Vol. 9. N. 7. P. e 101528.
596. Mader R., Mishail S., Adawi M., Lavi L, Luboshitzky R. Thyroid dysfunction in patients with systemic lupus erythematosus (SLE): relation to disease activity // Clin. Rheumatol. 2007. Vol. 26. N. II. P. 1891-1894.
597. Mavragani C., Fragoulis G., Moutsopoulos H. Endocrine alternations in primary Sjogren’s syndrome: an overview // J. Autoimmun. 2012. Vol. 39. P. 354—358.
598. McCoy S.S., Crowson C.S., Gabriel S.E., Matteson E.L. Hypothyroidism as a risk factor for development of cardiovascular disease in patients with rheumatoid arthritis // J. Rheumatol. 2012. Vol. 39. N. 5. P. 954-958.
599. McMurray R.W., Weidensaul D., Allen S.H., Walker S.E. et al. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus // J. Rheumatol. 1995. Vol. 22. N. II. P. 2084-2091.
600. Merashli M., Chowdhury T.A., Jawad ASM. Musculoskeletal manifestations of diabetes mellitus//Int. J. Med. 2015. Vol. 108. N. 11. P. 853-857.
601. Miller F.W., Moore G.F., Weintraub B.D., Steinberg A.D. Prevalence of thyroid disease and abnormal thyroid function test results in patients with systemic lupus erythematosus // Arthritis Rheum. 1987. Vol. 30. N. 10. P. 1124—1131.
602. Miyake C.N., Gualano B., Dantas W.S., Pereira R.T., Neves W., Zambelli V.O. ... Borba E. Increased insulin resistance and glucagon levels in mild\inactive systemic lupus patients despite normal glucose tolerance // Arthritis Care Res. 2017.
603. Morita S., Arima T., Matsuda M. Prevalence of non-thyroid specific autoantibodies in autoimmune thyroid diseases //J. Clin. Endocrinol. MetaboL 1995. Vol. 80. N. 4. P. 1203—1206.
604. Movahedi M., Beauchamp M-E, Abrahamowicz M., Ray D.W., Michaud K., Pedro S., Dixon W.G. Risk of incident diabetes associated with dose and duration of oral glucocorticoid therapy in patients with rheumatoid arthritis // Arthritis Rheumatol. 2015. Vol. 68. N. 5. P. 1089-1098.
605. Nicolau J., Lequerre T., Bacquet H., Vittecoq O. Rheumatoid arthritis., insulin resistan c.e., and diabetes //Joint. Bone Spine. 2017. Vol. 84. N. 4. P. 411—416.
606. Notsu K., Note S., Nabeya N. Antinuclear antibodies in childhood diabetes // Endocrinol. Japon. 1983. Vol. 30. N. 4. P. 469-473.
607. Ogata A., Morishima A., Hirano T., Hishitani Y, Hagihara K., Shima Y. ... Tanaka T. Improvement of HbAlc during treatment with humanised anti-interleukin 6 receptor an-tibo d.y., tocilizumab//Ann. Rheum. Dis. 2011. Vol. 70. N. 6. P. 1164-1165.
608. Oruk G., Tarhan Е, Argin М., Ozmen М. Is every joint symptom related to acromegaly? // Endocrine. 2013. Vol. 43. N. 2. P. 404-411.
609. Ozen G., Pedro S., Holmqvist M.E., Avery M., Wolfe E, Michaud K. Risk of diabetes mel-litus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis //Ann. Rheum. Dis. 2017. Vol. 76. N. 5. P. 848—854.
610. Pan X.P., Gu J.Q., Shan Z.Y. Increased risk of thyroid autoimmunity in rheumatoid arthritis: a systematic review and meta-analysis // Endocrine. 2015. Vol. 50. P. 79—86.
611. Parker B., Urowitz M.B., Gladman D.D., Lunt M., Bae S.C., Sanchez-Guerrero J. ... Bernatsky S. Clinical associations of the metabolic syndrome in SLE: data form an international inception cohort // Ann. Rheum. Dis. 2013. Vol. 72. N. 8. P. 1308—1314.
612. Penn S.K., Kao A.H., Schott L.L., Elliott J.R., Toledo F.G., Kuller L. ... Wasko M.C. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus//!. Rheumatol. 2010. Vol. 37. N. 6. P. 1136—1142.
613. Petri M., Purvey S., Fang H. Predictors of organ damage in SLE: the Hopkins lupus cohort // Arthritis Rheum. 2012. Vol. 64. N. 12. P. 4021-4028.
614. Podgorski M., Robinson B.,Weissberger A., Stiel J.,Wang S., Brooks P.M. Articular manifestations of acromegaly//Aust. NZ. J. Med. 1988. Vol. 18. N. 1. P. 28—35.
615. Pourmemari M.H., Shiri R. Diabetes as a risk factor for carpal tunnel syndrome: a systematic review and meta-analysis // Diabet. Med. 2016. Vol. 33. N. 1. P. 10—16.
616. Proto R.F., Proietta M., Koverech A. Hypercalcemia in systemic lupus erythematosis // Lupus. 2011. Vol. 20. P. 758-762.
617. Punzi L., Michelotto M., Pianon M., Bertazzolo N.. Fagiolo U., Betterle C. ... Todesco S. Clinical laboratory and immunogenetic aspects of arthritis associated with chronic lymphocytic thyroiditis // Clin. Exp. Rheumatol. 1997. Vol. 15. N. 4. P. 373—380.
618. Pyne D., Isenberg DA. Autoimmune thyroid disease in SLE //Ann Rheum Dis. 2002. Vol. 61. N. I. P. 70-72.
619. Ralston S.H., Frases W.D., Jankowski J. Hypercalemia in Rheuamtoid arthritis revisited // Ann. Rheum. Dis. 1990. Vol. 49. P. 22—24.
620. Ramos-Casals M., Garcia-Carrasco M., Cervera R. Thyroid disease in primary Sjogren syndrome. Study in a series of 160 patients // Medicine. 2000. Vol. 79. N. 2. P. 103—108.
621. Rasmussen U.F. Increased risk of thyroid autoimmunity in rheumatoid arthritis // Endocrine. 2015. Vol. 50. P. 4-5.
622. Raterman H.G., Nurmohamed M.T. Hypothyroidism in rheumatoid arthritis-to screen or not to screen//J Rheumatol. 2012. Vol. 399. P. 885—886.
623. Raterman H.G., Van Halm V.P., Voskuyl A.E., Simsek S., Dijkmans B.A.C., Nurmohamed M.T. Rheumatoid arthritis is associated with a high prevalence of hypothyroidism that amplifies its cardiovascular risk //Ann. Rheum. Dis. 2008. Vol. 67. N. 2. P. 229—232.
624. Raterman H.G., Van Eijk I.C., Voskuyl A.E., Peters M.J.L., Dijkmans B.A.C., Van Halm VP. ... Nurmohamed M.T. The metabolic syndrome is amplified in hypothyroid rheumatoid arthritis patients: a cross sectional study // Ann. Rheum. Dis. 2010. Vol. 69. P. 39-42.
625. Raterman H.G., Jamnitski A., Lems W.F., Voskuyl A.E., Dijkmans B.A., Bos W.H. ... de Koning M.H., Nurmohamed M.T. Improvement of thyroid function in hypothyroid patients with rheumatoid arthritis after 6 months of adalimumab treatment: a pilot study // J. Rheumatol. 2011. Vol. 38. N. 2. P. 247-251.
626. Rempenault C., Combe B., Barnetche T., Gaujoux-Viala C., Lukas C., Morel J., Hua C. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis // Ann. Rheum. Dis. 2018. Vol. 77. N. I. P. 98-103.
627. Rojas-Villarraga A., Toro С.Е., Espinosa G. Factors influencing polautommmunity in SLE // Autoimmun. Rev. 2010. Vol. 9. P. 229—232.
628. Ruiz-Arruza I., Ugarte A., Cabezas-Rodriguez I., Medina J.A., Moran M.A., Ruiz-Irastorza G. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus // Rheumatology. 2014. Vol. 53. N. 8. P. 1470—1476.
629. Ruscitti P., Ursini E, Cipriani P., Ciccia E, Liakouli V., Carubbi F. ... Giacomelli R. Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: results from a cross-sectional study // Medicine. 2017a. Vol. 96. N. 34. P. e7896.
630. Ruscitti P., Ursini E, Cipriani P., Liakouli V, Carubbi E, Berardicurti O. ... Giacomelli R. Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: a 1-year, single-centre., longitudinal study // PLoS One. 2017b. Vol. 12. N. 7. P. e0181203.
631. Senanayake H.M.S., Dedigama A.D., De Alwis R.P., Thirumavalavan K. Hoffmann syndrome: a case report // Int. Arch. Med. 2014. Vol. 7. N. 1. P. 2.
632. Sencan D., Elden H., Nacitarhan V., Sencan M., Kaptanoglu E. The prevalence of diffuse idiopathic skeletal hyperostosis in patients with diabetes mellitus // Rheumatol. Int. 2005. Vol. 25. N. 7. P. 518-521.
633. Shahin D., Eltoraby E., Mesbah A., Houssen M. Insulin resistance in early untreated rheumatoid arthritis patients // Clin. Biochem. 2010. Vol. 43. N. 7—8. P. 661—665.
634. Shimizu M., Kawata M., Okada T., Yuu H., Kurahashi T., Yamanaka K., Umezu K. Concomitant Cushing’s syndrome due to adrenal adenoma in a patient with systemic lupus erythematosus // Intern. Med. 2002. Vol. 41. N. 11. P. 1044—1046.
635. Shiroky J. B., Cohen M., Ballachey M.L., Neville C. Thyroid dysfunction in rheumatoid arthritis: a controlled prospective survey // Ann. Rheum. Dis. 1993. Vol. 52. N. 6. P. 454—456.
636. Siebert S., Lyall D.M., Mackay D.F., Porter D., Mclnnes I.B., Sattar N., Pell J.P. Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK biobank participants // RMD Open. 2016. Vol. 2. N. 1. P. e000267.
637. Simard J.F., Mittleman M.A. Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older // J. Rheumatol. 2007. Vol. 34. N. 3. P. 469—73.
638. Solomon D.H., Massarotti E., Garg R., Liu J., Canning C., Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis // JAMA. 2011. Vol. 305. N. 24. P. 2525.
639. Stagnaro-Green A., Akhter E., Yim C., Davies T.F., Magder L.S., Petri M. Thyroid disease in pregnant women with SLE: increase preterm delivery// Lupus. 2011. Vol. 20. N. 7. P. 690—699.
640. Tagoe C.E., Zezon A., Khattri S. Rheumatic manifestations of autoimmune thyroid disease: the other autoimmune disease //J. Rheumatol. 2012. Vol. 39. N. 6. P. 1125—1129.
641. Takaya K., Kimura N., Hiyoshi T. Antithyroid arthritis syndrome: report and review of the literature // Intern. Med. 2016. Vol. 55. N. 24. P. 3627—3633.
642. Tang M.W., Garcia S., Gerlag D.M., Так P.P., Reedquist KA. Insight into the endocrine system and the immune system: of the inflammatory role of prolactin in rheumatoid arthritis and psoriatic arthritis // Front. Immunol. 2017. Vol. 8. P. 720.
643. Tektonidou M.G., Anapliotou M., Vlachoyiannopoulos P., Moutsopoulos HM. Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases // Ann. Rheum. Dis. 2004. Vol. 63. N. 9. P. 1159—1161.
644. Ugarte-Gil М.Е, Gamboa-Cdrdenas R., Zevallos Е, Medina М., Cucho-Venegas J.M., Perich-Campos R.A., Alfaro-Lozano J.L. ... Pastor-Asurza C.A. High prolactin levels are independently associated with damage accrual in SLE patients // Lupus. 2014. Vol. 23. N. 10. P. 969-974.
645. Ulff-Moller C.J., Simonsen J., Kyvik K.O., Jacobsen S., Frisch M. Family history of SLE and risk of autoimmune disease: nationwide cohort study in Denmark 1977—2013 // Rheumatology. 2017. Vol. 56. P. 957—964.
646. Urowitz M.B., Gladman D., Ibanez D., Fortin P., Sanchez-Guerrero J., Bae S.... Wallace D. Clinical manifestations and coronary artery risk factors at diagnosis of SLE: data form an international inception cohort // Lupus. 2007. Vol. 16. N. 9. P. 731—735.
647. Urowitz M.B., Gladman D., Ibanez D. Atherosclerosis vascular events in multinational inception cohort of SLE // Arthritis Care Res. 2010. Vol. 62. N. 6. P. 881—887.
648. Urowitz M.B., Gladman D.D., Anderson N.M., Su J., Romero-Diaz J., Bae S.C. ... Gordon C. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort // Lupus. Sci Med. 2016. Vol. 3. N. 1. P. e000143.
649. Ursini E, Russo E., D’Angelo S., Arturi E, Hribal M.L., D’Antona L. ... Grembiale R.D. Prevalence of undiagnosed diabetes in rheumatoid arthritis: an OGTT study // Medicine. 2016. Vol. 95. N. 7. P. e2552.
650. Uthman L, Sendeal J.L. Onset of rheumatoid arthritis after surgical treatment of Cushings disease//J. Rheumotol. 1995. Vol. 22. N. 10. P. 1964-1966.
651. Vera-Lastra O., Mendez C., Jara L.J., Cisneros M., Medina G., Ariza R., Espinoza L.R. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment //J. Rheumatol. 2003. Vol. 30. N. 10. P. 2140-2146.
652. Walker S.E. Bromocriptine treatment of systemic lupus erythematosus // Lupus. 2001. Vol. 10. N. 10. P. 762-768.
653. Wallace D.J., Hahn B.H. Dubois’ lupus erythematosus. 7th edition, 2006.
654. Wang X., Bao. W, Liu J., Ouyang Y-Y, Wang D., Rong S. ... Liu L-G. Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis // Diabetes Care. 2013. Vol. 36. N. 1. P. 166-175.
655. Wasko M.C.M., Hubert H.B., Lingala V.B., Elliott J.R., Luggen M.E., Fries J.F., Ward M.M. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis // JAMA. 2007. Vol. 298. N. 2. P. 187.
656. Wen H.Y., Schumacher H.J., Zhang LY. Parathyroid disease // Rheum. Dis. Clin. N. Am. 2010. Vol. 36. N.4. P. 647-664.
657. Yakushiji E, Kita M., Hiroi N., Ueshiba H., Monma L, Miyachi Y. Exacerbation of rheumatoid arthritis after removal of adrenal adenoma in Cushing’s syndrome // Endocr. J. 1995. Vol. 42. N. 2. P. 219-223.
658. Zelissen P M.J., Bast E., Croughs R.J.M. Associated autoimmunity in Addison’s disease // J. Autoimmun. 1995. Vol. 8. N. 1. P. 121 — 130.
659. Zhang Z.I., Wang Y., Zhou W., Hao Y.J. Addison’s disease secondary to connective tissue disease: a report of six cases // Rheumatol. Int. 2009. Vol. 29. N. 6. P. 647—650.
660. Zonana-Nacach A., Barr S.G., Magder L.S., Petri M. Damage in SLE and its association with corticosteroids //Arthritis Rheum. 2000. Vol. 43. N. 8. P. 1801 — 1808.
661. Zriek N.H., Malik R.A., Charalambous P.C. Adhesive capsulitis of the shoulder and diabetes: a metaanalysis of prevalence // Muscle Ligaments Tendons J. 2016. Vol. 6. N. 1. P. 26—34.
662. An Y, Хи Е, Le W„ Ge Y, Zhou M., Chen H. et al. Renal histologic changes and the outcome in patients with diabetic nephropathy // Nephrol. Dial. Transplant. 2015. Vol. 30. N. 2. P. 257-266. PubMed PMID: 25063425. Epub. 2014/07/27.
663. Barnett A.H., Bain S.C., Bouter P., Karlberg B., Madsbad S., Jervell J. et al. Angiotensinreceptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy // N. Engl. J. Med. 2004. Vol. 351. N. 19. P. 1952-1961. PubMed PMID: 15516696. Epub. 2004/11/02.
664. Bhaskaran K., Douglas I., Forbes H., dos-Santos-Silva I., Leon D.A., Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults // Lancet (London, England). 2014. Vol. 384. N. 9945. P. 755-765. PubMed PMID: 25129328. Pubmed Central PMCID: PMC4151483. Epub. 2014/08/19.
665. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis // J. Am. Soc. Nephrol. 2004. Vol. 15. N. 8. P. 2208-2218. PubMed PMID: 15284307. Epub. 2004/07/31.
666. Carrero J.J., Stenvinkel P. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype // Nephrol. Dial. Transplant. 2012. Vol. 27. N. 11. P. 4030—4041. PubMed PMID: 22962412. Epub. 2012/09/11.
667. Carrero J.J., Qureshi A.R., Nakashima A., Arver S., Parini P., Lindholm B. et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease // Nephrol. Dial. Transplant. 2011. Vol. 26. N. 1. P. 184-190. PubMed PMID: 20624775. Epub. 2010/07/14.
668. Chang A., Horn L.V., Jacobs D.R., Liu K., Muntner P., Newsome B., Shoham D.A., Durazo-Arvizu R., Bibbins-Domingo K., Reis J., Kramer H. Lifestyle-related facto r.s., obesi t.y., and incident microalbuminuria: The CARDIA (Coronary Artery Risk Development in Young Adults) study // Am. J. Kidney Dis. 2013. Vol. 62. N. 2. P. 267—275.
669. Chagnac A., Herman M., Zingerman B., Erman A., Rozen-Zvi B., Hirsh J. et al. Obesity-induced glomerular hyperfiltration: its involvement in the pathogenesis of tubular sodium reabsorption // Nephrol. Dial. Transplant. 2008. Vol. 23. N. 12. P. 3946—3952. PubMed PMID: 18622024. Epub. 2008/07/16.
670. Conserva E, Gesualdo L., Papale M. A systems biology overview on human diabetic nephropathy: from genetic susceptibility to post-transcriptional and post-translational modifications //J. Diabetes. Res. 2016. Vol. 2016. P. 7934504. PubMed PMID: 26798653. Pubmed Central PMCID: PMC4698547. Epub. 2016/01/23.
671. de Boer I.H., Rue T.C., Hall Y.N., Heagerty P.J., Weiss N.S., Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States // JAMA. 2011. Vol. 305. N. 24. P. 2532-2539. PubMed PMID: 21693741. Pubmed Central PMCID: PMC3731378. Epub. 2011/06/23.
672. den Hollander J.G., Wulkan R.W., Mantel M.J., Berghout A. Correlation between severity of thyroid dysfunction and renal function // Clin. Endocrinol. 2005. Vol. 62. N. 4. P. 423— 427. PubMed PMID: 15807872. Epub. 2005/04/06.
673. Di lorgi N., Napoli E, Allegri A.E., Olivieri I., Bertelli E., Gallizia A. et al. Diabetes insipidus — diagnosis and management // Horm. Res. Paediatr. 2012. Vol. 77. N. 2. P. 69—84. PubMed PMID: 22433947. Epub. 2012/03/22.
674. Dluhy R.G., Lifton R.P. Glucocorticoid-remediable aldosteronism // J. Clin. Endocrinol. Metab. 1999. Vol. 84. N. 12. P. 4341-4344. PubMed PMID: 10599685. Epub. 1999/12/22.
675. Duckworth W., Abraira C., Moritz T., Reda D., Emanuele N., Reaven P.D. et al. Glucose control and vascular complications in veterans with type 2 diabetes // N. Engl. J. Med. 2009. Vol. 360. N. 2. P. 129-139. PubMed PMID: 19092145. Epub. 2008/12/19.
676. Ellison D.H., Berl T. Clinical practice. The syndrome of inappropriate antidiuresis // N. Engl. J. Med. 2007. Vol. 356. N. 20. P. 2064-2072. PubMed PMID: 17507705. Epub. 2007/05/18.
677. Fiorentino M., Bolignano D., Tesar V., Pisano A., Biesen W.V., Tripepi G. et al. Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies // Nephrol. Dial. Transplant. 2017. Vol. 32. N. 1. P. 97-110. PubMed PMID: 27190327. Epub. 2016/05/18. eng.
678. Fioretto P., Steffes M.W., Sutherland D.E., Goetz F.C., Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation // N. Engl. J. Med. 1998. Vol. 339. N. 2. P. 69-75. PubMed PMID: 9654536. Epub. 1998/07/09.
679. Inzucchi S.E., Lipska K.J., Mayo H., Bailey C.J., McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review // JAMA. 2014. Vol. 312. N. 24. P. 2668-2675. PubMed PMID: 25536258. Pubmed Central PMCID: PMC4427053. Epub. 2014/12/24.
680. Isakova Т., Nickolas T.L., Denburg М., Yarlagadda S., Weiner D.E., Gutierrez O.M. et al. KDOQI US commentary on the 2017 KD1GO clinical practice guideline update for the diagnos i.s., evaluati o.n., preventi o.n., and treatment of chronic kidney disease-mineral and bone disorder (CKDMBD) // Am. J. Kidney Dis. 2017. Vol. 70. N. 6. P. 737-751. PubMed PMID: 28941764. Epub. 2017/09/25.
681. Ismail-Beigi E, Craven T., Banerji M.A., Basile J., Calles J., Cohen R.M. et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial // Lancet (London, England). 2010. Vol. 376. N. 9739. P. 419-430. PubMed PMID: 20594588. Pubmed Central PMCID: PMC4123233. Epub. 2010/07/03.
682. Kanasaki K., Kitada M., Kanasaki M., Koya D. The biological consequence of obesity on the kidney // Nephrol Dial Transplant. 2013. Vol. 28, Suppl. 4. P. ivl— iv7. PubMed PMID: 23743020. Epub. 2013/06/08. KDOQI Clinical Practice Guideline for Diabetes and CKD. Update //Am. J. Kidney Dis. 2012. Vol. 60. N. 5. P. 850-886. PubMed PMID: 23067652. Epub. 2012/10/17.
683. Kimmel M., Braun N., Alscher M.D. Influence of thyroid function on different kidney function tests // Kidney Blood. Press. Res. 2012. Vol. 35. N. I. P. 9—17. PubMed PMID: 21849794. Epub. 2011/08/19.
684. Komaba H., Fukagawa M. FGF23-parathyroid interaction: implications in chronic kidney disease // Kidney Int. 2010. Vol. 77. N. 4. P. 292-298. PubMed PMID: 20010546. Epub. 2009/12/17.
685. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A. et al. Prevalence of abnormal serum vitamin D., PTH., calcium., and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease // Kidney Int. 2007. Vol. 71. N. I. P. 31-38. PubMed PMID: 17091124. Epub. 2006/11/09.
686. Lim V.S. Thyroid function in patients with chronic renal failure // Am. J. Kidney Dis. 2001. Vol. 38. N. 4. Suppl. 1. P. S80- S84. PubMed PMID: 11576928. Epub. 2001/09/29.
687. Lo J.C., Chertow G.M., Go A.S., Hsu C.Y. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease // Kidney Int. 2005. Vol. 67. N. 3. P. 1047-1052. PubMed PMID: 15698444. Epub. 2005/02/09.
688. Lu J.L., Kalantar-Zadeh K., Ma J.Z., Quarles L.D., Kovesdy C.P. Association of Body Mass Index with Outcomes in Patients with CKD // J. Am. Soc. Nephrol. 2014. Vol. 25. N. 9. P. 2088-2096.
689. Lu J.L., Molnar M.Z., Naseer A., Mikkelsen M.K., Kalantar-Zadeh K., Kovesdy C.P. Association of age and BMI with kidney function and mortality: a cohort study // The Lancet Diabetes & Endocrinology. 2015. Vol. 3. N. 9. P. 704—714.
690. Makaryus A.N., McFarlane S.l. Diabetes insipidus: diagnosis and treatment of a complex disease // Cleve Clin. J. Med. 2006. Vol. 73. N. 1. P. 65-71. PubMed PMID: 16444918. Epub. 2006/02/01.
691. Mann J.F., Schmieder R.E., McQueen M., Dyal L., Schumacher H., Pogue J. et al. Renal outcomes with telmisartan., ramipril., or both., in people at high vascular risk (the ONTARGET study): a multicentre., randomised., double-blind., controlled trial // Lancet (London, England). 2008. Vol. 372. N. 9638. P. 547-553. PubMed PMID: 18707986. Epub. 2008/08/19.
692. Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F., Nauck M.A. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes // N. Engl. J. Med. 2016. Vol. 375. N. 4. P. 311-322. PubMed PMID: 27295427. Pubmed Central PMCID: PMC4985288. Epub. 2016/06/14.
693. Mazzucco G., Bertani T., Fortunato M., Bernardi M., Leutner M., Boldorini R. et al. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies // Am. J. Kidney Dis: the official journal of the National Kidney Foundation. 2002. Vol. 39. N. 4. P. 713-720. PubMed PMID: 11920336. Epub. 2002/03/29.
694. Nielsen S., Chou C.L., Marples D., Christensen E.I., Kishore B.K., Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aqua-porin-CD water channels to plasma membrane // Proc Natl. Acad. Sci. 1995. Vol. 92. N. 4. P. 1013-1017. PubMed PMID: 7532304. Pubmed Central PMC1D: PMC42627. Epub. 1995/02/14.
695. Nishikawa T., Edelstein D., Du XL Y.S., Matsumura T., Kaneda Y. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage // Nature. 2000. Vol. 404. N. 6779. P. 787-790. PubMed PMID: 10783895. Epub. 2000/04/28.
696. Palmer B.F. Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease // Adv. Ren. Replace Ther. 2003. Vol. 10. N. 1. P. 48—60. PubMed PMID: 12616463. Epub. 2003/03/05.
697. Palmer B.F., Alpern RJ. Liddle’s syndrome //Am. J. Med. 1998. Vol. 104. N. 3. P. 301—309. PubMed PMID: 9552093. Epub. 1998/04/29.
698. Pontrelli P., Conserva E, Papale M., Granger A., Barozzino M., Vocino G. et al. Lysine 63 ubiquitination is involved in the progression of tubular damage in diabetic nephropathy // FASEB J. 2017. Vol. 31. N. 1. P. 308-319. PubMed PMID: 27881486. Epub. 2016/11/25.
699. Praga M., Hernandez E., Morales E., Campos A.P., Valero M.A., Martinez M.A. et al. Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis // Nephrol. Dial. Transplant. 2001. Vol. 16. N. 9. P. 1790—1798. PubMed PMID: 11522860. Epub. 2001/08/28.
700. Rathi M., Ramachandran R. Sexual and gonadal dysfunction in chronic kidney disease: pathophysiology // Indian J. Endocrinol. Metab. 2012. Vol. 16. N. 2. P. 214—219. PubMed PMID: 22470857. Pubmed Central PMCID: PMC3313738. Epub. 2012/04/04.
701. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies // Lancet (London, England). 2008. Vol. 371. N. 9612. P. 569—578. PubMed PMID: 18280327. Epub. 2008/02/19.
702. Riepe F.G. Pseudohypoaldosteronism // Endocrine development. 2013. Vol. 24. P. 86—95. PubMed PMID: 23392097. Epub. 2013/02/09.
703. Rodriguez Soriano J. Renal tubular acidosis: the clinical entity // J. Am. Soc. Nephrol. 2002. Vol. 13. N. 8. P. 2160-2170. PubMed PMID: 12138150. Epub. 2002/07/26.
704. Romero-Aroca P., Baget-Bemaldiz M., Reyes-Torres J., Fernandez-Ballart J., Plana-Gil N., Mendez-Marin I. et al. Relationship between diabetic retinopat h.y., microalbuminuria and overt nephropathy., and twenty-year incidence follow-up of a sample of type 1 diabetic patients //J. Diabetes Complicat. 2012. Vol. 26. N. 6. P. 506—512. PubMed PMID: 22921286. Epub. 2012/08/28.
705. Rosas S.E., Joffe M., Franklin E., Strom B.L., Kotzker W., Brensinger C. et al. Prevalence and determinants of erectile dysfunction in hemodialysis patients // Kidney Int. 2001. Vol. 59. N. 6. P. 2259-2266. PubMed PMID: 11380829. Epub. 2001/06/16.
706. Ruggenenti P., Remuzzi G. Proteinuria: is the ONTARGET renal substudy actually off target? // Nat. Rev. Nephrol. 2009. Vol. 5. N. 8. P. 436-437. PubMed PMID: 19639016. Epub. 2009/07/30.
707. Scales C.D Jr., Smith A.C., Hanley J.M., Saigal C.S. Prevalence of kidney stones in the United States // Eur. Urol. 2012. Vol. 62. N. 1. P. 160-165. PubMed PMID: 22498635. Pubmed Central PMCID: PMC3362665. Epub. 2012/04/14.
708. Schena F.P., Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy // J. Am. Soc. Nephrol. 2005. Vol. 16. Suppl. 1. P. S30- S33. PubMed PMID: 15938030. Epub. 2005/06/07.
709. Sousa A.G., Cabral J.V., El-Feghaly W.B., de Sousa L.S., Nunes A.B. Hyporeninemic hypoaldosteronism and diabetes mellitus: pathophysiology assumptions., clinical aspects and implications for management // World J. Diabetes. 2016. Vol. 7. N. 5. P. 101 — 111. PubMed PM1D: 26981183. Pubmed Central PMCID: PMC4781902. Epub. 2016/03/17.
710. Tervaert T.W., Mooyaart A.L., Amann K., Cohen A.H., Cook H.T., Drachenberg C.B. et al. Pathologic classification of diabetic nephropathy // J. Am. Soc. Nephrol. 2010. Vol. 21. N. 4. P. 556-563. PubMed PMID: 20167701. Epub. 2010/02/20.
711. van Bommel E.J., Muskiet M.H., Tonneijck L., Kramer M.H., Nieuwdorp M., van Raalte D.H. SGLT2 inhibition in the diabetic kidney-from mechanisms to clinical outcome // Clin. J. Am. Soc. Nephrol. 2017. Vol. 12. N. 4. P. 700-710. PubMed PMID: 28254770. Pubmed Central PMCID: PMC5383382. Epub. 2017/03/04.
712. Verbalis J.G., Greenberg A., Burst V., Haymann J.P., Johannsson G., Peri A. et al. Diagnosing and treating the syndrome of inappropriate antidiuretic hormone secretion // Am. J. Med. 2016. Vol. 129. N. 5. P. 537, e9-e23. PubMed PMID: 26584969. Epub. 2015/11/21.
713. Weiner I.D., Wingo C.S. Hypokalemia — consequences., causes., and correction //J. Am. Soc. Nephrol. 1997. Vol. 8. N. 7. P. 1179-1188. PubMed PMID: 9219169. Epub. 1997/07/01.
714. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the epidemiology of diabetes interventions and complications (EDIC) study // JAMA. 2003. Vol. 290. N. 16. P. 2159-2167. PubMed PMID: 14570951. Pubmed Central PMCID: PMC2622725. Epub. 2003/10/23.
715. Zheng S.L., Roddick A.J., Aghar-Jaffar R., Shun-Shin M.J., Francis D., Oliver N. et al. Association between use of sodium-glucose cotransporter 2 inhibito r.s., glucagon-like peptide 1 agonis t.s., and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis // JAMA. 2018. Vol. 319. N. 15. P. 1580-1591. PubMed PMID: 29677303. Pubmed Central PMCID: PMC5933330. Epub. 2018/04/21.
716. Addison Т. On the constitutional and local effects of disease of the suprarenal capsules. London: Samuel Highley, 1855.
717. Akashi Y.J., Nef H.M., Lyon A.R. Epidemiology and pathophysiology of Takotsubo syndrome // Nat. Rev. Cardiol. 2015. Vol. 12. P. 387—397.
718. Al-Hussaini A., Adlam D. Spontaneous coronary artery dissection // Heart. 2017. Vol. 103. P. 1043-1051.
719. Arany Z., Elkayam U. Peripartum cardiomyopathy // Circulation. 2016. Vol. 133. P. 1397— 1409.
720. Auer J., Scheibner P., Mische T., Langsteger W., Eber O., Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation // Am. Heart. J. 2001. Vol. 142. P. 838—842. 0002-8703(01 )88809-8 [pii],
721. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., Peto R., Barnes E.H., Keech A., Simes J., Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta analysis of data from 170,000 participants in 26 randomised trials// Lancet. 2010. Vol. 376. P. 1670-1681.
722. Basaria S., Coviello A.D., Travison T.G., Storer T.W., Farwell W.R., Jette A.M., Eder R., Tennstedt S., Ulloor J., Zhang A., Choong K., Lakshman K.M., Mazer N.A., Miciek R., Krasnoff J., Elmi A., Knapp P.E., Brooks B., Appleman E., Aggarwal S., Bhasin G., HedeBrierley L., Bhatia A, Collins L., LeBrasseur N., Fiore L.D., Bhasin S. Adverse events associated with testosterone administration // N. Engl. J. Med. 2010. Vol. 363. P. 109-122.
723. Best C.A.E., Krishnan R., Malvankar-Mehta M.S., MacNeil S.D. Echocardiogram changes following parathyroidectomy for primary hyperparathyroidism: a systematic review and meta-analysis// Medicine (Baltimore). 2017. Vol. 96. P. e7255.
724. Bhattacharyya S., Toumpanakis C., Chilkunda D., Caplin M.E., Davar J. Risk factors for the development and progression of carcinoid heart disease // Am. J. Cardiol. 2011. Vol. 107. P. 1221-1226.
725. Bush N., Nelson-Piercy C., Spark P., Kurinczuk J.J., Brocklehurst P., Knight M. Myocardial infarction in pregnancy and postpartum in the UK // Eur. J. Prev. Cardiol. 2013. Vol. 20. P. 12-20.
726. Chaker L., van den Berg M.E., Niemeijer M.N., Franco O.H., Dehghan A., Hofman A., Rijnbeek P.R., Deckers J.W., Eijgelsheim M., Stricker B.H., Peeters R.P. Thyroid function and sudden cardiac death: a prospective population-based cohort study // Circulation. 2016. Vol. 134. P. 713-722.
727. Colao A., Vitale G., Pivonello R., Ciccarelli A., Di SC, Lombardi G. The heart: an end-organ of GH action // Eur. J. Endocrinol. 2004. Vol. 151. Suppl. I. P. S93—S101.
728. Coleman R.L., Stevens R.J., Retnakaran R., Holman R.R. Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes // Diabetes Care. 2007. Vol. 30. P. 1292-1293.
729. Connolly H.M., Schaff H.V., Abel M.D. et al. Early and late outcomes of surgical treatment in carcinoid heart disease // J. Am. Coll. Cardiol. 2015. Vol. 66. P. 2189—2196.
730. Edwards N.C., Yuan M., Nolan O., Pawade T.A., Oelofse T., Singh H., Mehrzad H., Zia Z., Geh J.I., Palmer D.H., May C.J., Ayuk J., Shah T., Rooney S.J., Steeds R.P. Effect of valvular surgery in carcinoid heart disease: an observational cohort study // J. Clin. Endocrinol. Metab. 2016. Vol. 101. P. 183—190.
731. Elkayam U., Jalnapurkar S., Barakkat M.N., Khatri N., Kealey A.J., Mehra A., Roth A. Pregnancyassociated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011 //Circulation. 2014. Vol. 129. P. 1695—1702.
732. Ferreira V.M., Marcelino M., Piechnik S.K., Marini C., Karamitsos T.D., Ntusi N.A.B, Francis J.M., Robson M.D., Arnold J.R., Mihai R., Thomas J.D.J., Herincs M., Hassan-Smith Z.K., Greiser A., Arlt W., Korbonits M., Karavitaki N., Grossman A.B., Wass J.A.H., Neubauer S. Pheochromocytoma is characterized by catecholamine-mediated myocarditis, focal and diffuse myocardial fibrosis, and myocardial dysfunction // J. Am. Col.l Cardiol. 2016. Vol. 67. P. 2364-2374.
733. Geelhoed J.J., van D.C., van Osch-Gevers L., Steegers E.A., Hofman A., Helbing W.A., Jaddoe V.W. Glucocorticoid receptor-9beta polymorphism is associated with systolic blood pressure and heart growth during early childhood. The generation R study // Early Hum. Dev. 2011. Vol. 87. P. 97-102.
734. Gerstein H.C., Yusuf S., Bosch J., Pogue J., Sheridan P., Dinccag N., Hanefeld M., Hoogwerf B., Laakso M., Mohan V., Shaw J., Zinman B., Holman R.R. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial // Lancet. 2006. Vol. 368. P. 1096—1105.
735. Granger С.В., Califf R.M., Young S., Candela R., Samaha J., Worley S., Kereiakes D.J., Topol E.J. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) study group // J. Am. Coll. Cardiol. 1993. Vol. 21. P. 920-925. 0735-1097(93)90348-5 [pii],
736. Gravina M., Casavecchia G., D’Alonzo N., Totaro A., Manuppelli V., Cuculo A., Vinci R., Macarini L., Di B.M., Brunetti N.D. Pheochromocytoma mimicking Takotsubo cardiomyopathy and hypertrophic cardiomyopathy: a cardiac magnetic resonance study // Am. J. Emerg. Med. 2017. Vol. 35. P. 353—355.
737. Gupta G., Pacak K. Precision medicine: an UPDATE on genotype/biochemical phenotype relationships in pheochromocytoma/paraganglioma patients // Endocr. Pract. 2017. Vol. 23. P. 690-704.
738. Hart E.A., Meijs T.A., Meijer R.C.A., Dreijerink K.M., Tesselaar M.E., de Groot C.A., Valk G.D., Chamuleau S.A.J. Carcinoid heart disease: a guide for screening and timing of surgical intervention // Neth. Heart J. 2017. Vol. 25. P. 471—478.
739. Hassan S., Tornvall P. Epidemiology, pathogenesis, and management of Takotsubo syndrome // Clin. Auton. Res. 2018. Vol. 28. P. 53—65.
740. Hilfiker-Kleiner D., Haghikia A., Berliner D., Vogel-Claussen J., Schwab J., Franke A., Schwarzkopf M., Ehlermann P., Pfister R., Michels G., Westenfeld R., Stangl V., Kindermann I., Kuhl U., Angermann C.E., Schlitt A., Fischer D., Podewski E., Bohm M., Sliwa K., Bauersachs J. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study // Eur. Heart J. 2017. Vol. 38. P. 2671-2679.
741. Hlatky M.A., Boothroyd D.B., Bravata D.M., Boersma E., Booth J., Brooks M.M., Carrie D., Clayton T.C., Danchin N., Flather M., Hamm C.W., Hueb W.A., Kahler J., Kelsey S.F., King S.B., Kosinski A.S., Lopes N., McDonald K.M., Rodriguez A., Serruys P., Sigwart U., Stables R.H., Owens D.K., Pocock SJ. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomized trials // Lancet. 2009. Vol. 373. P. 1190-1197.
742. Huxley R., Barzi E, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies // BMJ. 2006. Vol. 332. P. 73-78.
743. Ilhwan Yeo, MD, Dmitriy N. Feldman, Luke K. Kim. Spontaneous Coronary Artery Dissection: Diagnosisand Management Curr Treat Options // Cardio Med. 2018. Vol. 20. P. 27.
744. Kalla A., Krishnamoorthy P., Gopalakrishnan A., Garg J., Patel N.C., Figueredo V.M. Primary hyperparathyroidism predicts hypertension: results from the national inpatient sample // Int. J. Cardiol. 2017. Vol. 227. P. 335-337.
745. Karch S.B., Billingham M.E. Myocardial contraction bands revisited // Hum. Pathol. 1986. Vol. 17. P. 9-13. S0046-8177(86)80150-2 [pii],
746. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B., Castella M., Diener H.C., Heidbuchel H., Hendriks J., Hindricks G., Manolis A.S., Oldgren J., Popescu B.A., Schotten U., Van P.B., Vardas P., Agewall S., Camm J., Baron E.G., Budts W., Carerj S., Casselman E, Coca A., De C.R., Deftereos S., Dobrev D., Ferro J.M., Filippatos G., Fitzsimons D., Gorenek B., Guenoun M., Hohnloser S.H., Kolh P., Lip G.Y., Manolis A., McMurray J., Ponikowski P., Rosenhek R., Ruschitzka E, Savelieva I., Sharma S., Suwalski P., Tamargo J.L., Taylor C.J., Van Gelder I.C., Voors A.A., Windecker S., Zamorano J.L., Zeppenfeld K. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS // Europace. 2016. Vol. 18. P. 1609—1678.
747. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system // N. Engl. J. Med. 2001. Vol. 344. P. 501-509.
748. Korse C.M., Taal B.G., van Velthuysen M.L., Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry // Eur. J. Cancer. 2013. Vol. 49. P. 1975—1983.
749. Modlin 1.М., Oberg K., Chung D.C., Jensen R.T., de Herder W.W., Thakker R.V., Caplin M., Delle F.G., Kaltsas G.A., Krenning E.P., Moss S.F., Nilsson O., Rindi G., Salazar R., Ruszniewski P., Sundin A. Gastroenteropancreatic neuroendocrine tumours // Lancet Oncol. 2008. Vol. 9. P. 61-72.
750. Mokhles P., van Herwerden L.A., de Jong P.L., de Herder W.W., Siregar S., Constantinescu A.A., van Dornburg R.T., Roos-Hesselink J.W. Carcinoid heart disease: outcomes after surgical valve replacement // Eur. J. Cardiothorac. Surg. 2012. Vol. 41. P. 1278—1283.
751. Moller J.E., Connolly H.M., Rubin J., Seward J.B., Modesto K., Pellikka P.A. Factors associated with progression of carcinoid heart disease // N. Engl. J. Med. 2003. Vol. 348. P. 1005-1015.
752. Niederle B., Pape U.F., Costa E, Gross D., Kelestimur E, Knigge U., Oberg K., Pavel M., Perren A., Toumpanakis C., O’Connor J., O’Toole D., Krenning E., Reed N., Kianmanesh R. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum // Neuroendocrinology. 2016. Vol. 103. P. 125—138.
753. Pape U.F., Perren A., Niederle B., Gross D., Gress T., Costa E, Arnold R., Denecke T., Plockinger U., Salazar R., Grossman A. ENETS consensus guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas // Neuroendocrinology. 2012. Vol. 95. P. 135—156.
754. Pepe J., Cipriani C., Sonato C., Raimo O., Biamonte E, Minisola S. Cardiovascular manifestations of primary hyperparathyroidism: a narrative review // Eur. J. Endocrinol. 2017. Vol. 177. P. R297-R308.
755. Pillai S., Gopalan V, Smith R.A., Lam A.K. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era // Crit. Rev. Oncol. Hematol. 2016. Vol. 100. P. 190—208.
756. Plockinger U., Gustafsson B., IvanD., SzpakW., DavarJ. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: echocardiography // Neuroendocrinology. 2009. Vol. 90. P. 190-193.
757. Prakash R., Starovoytov A., Heydari M., Mancini G.B., Saw J. Catheter-induced iatrogenic coronary artery dissection in patients with spontaneous coronary artery dissection // JACC Cardiovasc. Interv. 2016. Vol. 9. P. 1851 — 1853.
758. Pugh P.J., Jones R.D., West J.N., Jones Т.Н., Channer K.S. Testosterone treatment for men with chronic heart failure // Heart. 2004. Vol. 90. P. 446—447.
759. Reuwer A.Q., van E.M., Houttuijn-Bloemendaal F.M., van der Loos C.M., Claessen N., Teeling P., Kastelein J J., Hamann J., Goffin V., von der Thusen J.H., Twickler M.T., Aten J. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? // J. Endocrinol. 2011. Vol. 208. P. 107-117.
760. Reuwer A.Q., Nowak-Sliwinska P., Mans L.A., van der Loos C.M., von der Thusen J.H., Twickler M.T., Spek C.A., Goffin V., Griffioen A.W., Borensztajn K.S. Functional consequences of prolactin signalling in endothelial cells: a potential link with angiogenesis in pathophysiology? // J. Cell. Mol. Med. 2012a. Vol. 16. P. 2035—2048.
761. Reuwer A.Q., Sondermeijer B.M., Battjes S., van Z.R., Stuijver D.J., Bisschop P.H., Twickler M.T., Meijers J.C., Schlingemann R.O., Stroes E.S. Microcirculation and athero-thrombotic parameters in prolactinoma patients: a pilot study // Pituitary. 2012b. Vol. 15. P. 472-481.
762. Rogers J.H., Lasala J.M. Coronary artery dissection and perforation complicating percutaneous coronary intervention // J. Invasive Cardiol. 2004. Vol. 16. P. 493—499.
763. Rubier S., Dlugash J., Yuceoglu Y.Z., Kumral T., Branwood A.W., Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis // Am. J. Cardiol. 1972. Vol. 30. P. 595-602. 0002-9149(72)90595-4 [pii],
764. Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N.,Wiviott S.D., Murphy S.A., Kuder J.E,Wang H., Liu T., Wasserman S.M., Sever P.S., Pedersen T.R. Evolocumab and clinical outcomes in patients with cardiovascular disease // N. Engl. J. Med. 2017. Vol. 376. P. 1713—1722.
765. Sato H., Taiteishi H. Takotsubo-type cardiomyopathy due to multivessel spasm // From ischemia to heart failure, Kodama K., Haze K., Hon M., editors. Clinical aspect of myocardial injury. Tokyo: Kagakuhyouronsha. Vol. 1990. P. 56—64.
766. Saw J., Aymong E., Mancini G.B., Sedlak T., Starovoytov A., Ricci D. Nonatherosclerotic coronary artery disease in young women // Can. J. Cardiol. 2014. Vol. 30. P. 814—819.
767. Saw J., Mancini G.B.J, Humphries K.H. Contemporary review on spontaneous coronary artery dissection //J. Am. Coll. Cardiol. 2016. Vol. 68. P. 297—312.
768. Snyder P.J., Bhasin S., Cunningham G.R., Matsumoto A.M., Stephens-Shields A.J., Cauley J.A., Gill T.M., Barrett-Connor E., Swerdloff R.S., Wang C., Ensrud K.E., Lewis C.E., Farrar J.T., Celia D., Rosen R.C., Pahor M., Crandall J.P., Molitch M.E., Cifelli D., Dougar D., Fluharty L., Resnick S.M., Storer T.W., Anton S., Basaria S., Diem S.J., Hou X., Mohler E.R. Ill, Parsons J.K., Wenger N.K., Zeldow B., Landis J.R., Ellenberg S.S. Effects of testosterone treatment in older men // N. Engl. J. Med. 2016. Vol. 374. P. 611-624.
769. Soto-Pedre E., Newey P.J., Bevan J.S., Leese G.P. Morbidity and mortality in patients with hyperprolactinaemia: the PROLEARS study // Endocr. Connect. 2017. Vol. 6. P. 580—588.
770. Stiermaier T., Eitel C., Denef S., Desch S., Schuler G., Thiele H., Eitel I. Prevalence and clinical significance of life-threatening arrhythmias in Takotsubo cardiomyopathy // J. Am. Coll. Cardiol. 2015. Vol. 65. P. 2148—2150.
771. Templin C., Ghadri J.R., Diekmann J., Napp L.C., Bataiosu D.R., Jaguszewski M., Cammann V.L., Sarcon A., Geyer V, Neumann C.A., Seifert B., Hellermann J., Schwyzer M., Eisenhardt K., Jenewein J., Franke J., Katus H.A., Burgdorf C., Schunkert H., Moeller C., Thiele H., Bauersachs J., Tschope C., Schultheiss H.P., Laney C.A., Rajan L., Michels G., Pfister R., Ukena C., Bohm M., Erbel R, Cuneo A., Kuck K.H., Jacobshagen C., Hasenfuss G., Karakas M., Koenig W., Rottbauer W., Said S.M., Braun-Dullaeus R.C., Cuculi E, Banning A., Fischer T.A., Vasankari T., Airaksinen K.E., Fijalkowski M., Rynkiewicz A., Pawlak M., Opolski G., Dworakowski R., MacCarthy P„ Kaiser C., Osswald S., Galiuto L., Crea E, Dichtl W., Franz W.M., Empen K., Felix S.B., Delmas C., Lairez O., Erne P, Bax J.J., Ford I., Ruschitzka E, Prasad A., Luscher T.F. Clinical features and outcomes of Takotsubo (stress) cardiomyopathy // N. Engl. J. Med. 2015. Vol. 373. P. 929-938.
772. Tweet M.S., Hayes S.N., Pitta S.R., Simari R.D., Lerman A., Lennon R.J., Gersh B.J., Khambatta S., Best P.J., Rihal C.S., Gulati R. Clinical features, management, and prognosis of spontaneous coronary artery dissection // Circulation. 2012. Vol. 126. P. 579—588.
773. Tweet M.S., Gulati R., Williamson E.E., Vrtiska T.J., Hayes S.N. Multimodality imaging for spontaneous coronary artery dissection in women // JACC Cardiovasc. Imaging. 2016. Vol. 9. P. 436-450.
774. Valensi P., Lorgis L., Cottin Y. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature // Arch. Cardiovasc. Dis. 2011. Vol. 104. P. 178-188.
775. van den Akker E.L., Koper J.W., van Rossum E.F., Dekker M.J., Russcher H., de Jong F.H., Uitterlinden A.G., Hofman A., Pols H.A., Witteman J.C., Lamberts S.W. Glucocorticoid receptor gene and risk of cardiovascular disease // Arch. Intern. Med. 2008. Vol. 168. P. 33—39.
776. van der Sluis R.J., van den Aardweg T., Reuwer A.Q., Twickler M.T., Boutillon E, Van E.M., Goffin V, Hoekstra M. Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility//J. Endocrinol. 2014. Vol. 222. P. 341—350.
777. Vanzetto G., Berger-Coz E., Barone-Rochette G., Chavanon O., Bouvaist H., Hacini R., Blin D., Machecourt J. Prevalence, therapeutic management and medium-term prognosis of spontaneous coronary artery dissection: results from a database of 11,605 patients // Eur. J. Cardiothorac. Surg. 2009. Vol. 35. P. 250—254.
778. Whiting D.R., Guariguata L.,Weil C., Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 // Diabetes Res. Clin. Pract. 2011. Vol. 94. P. 311—321.
779. Wittstein I.S., Thiemann D.R., Lima J.A., Baughman K.L., Schulman S.P., Gerstenblith G., Wu K.C., Rade J.J., Bivalacqua T.J., Champion H.C. Neurohumoral features of myocardial stunning due to sudden emotional stress // N. Engl. J. Med. 2005. Vol. 352. P. 539— 548.
780. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.N., Rashid A., Evans D.B. One hundred years after «carcinoid»: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States // J. Clin. Oncol. 2008. Vol. 26. P. 3063-3072.
781. Zhang R., Gupta D., Albert S.G. Pheochromocytoma as a reversible cause of cardiomyopathy: analysis and review of the literature // Int. J. Cardiol. 2017. Vol. 249. P. 319—323.
782. Zuetenhorst J.M., Bonfrer J.M., Korse C.M., Bakker R., van Т.Н., Taal B.G. Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor// Cancer. 2003. Vol. 97. P. 1609-1615.
783. Adler A.I., Stratton I.M., Neil Н.А., Yudkin J.S., Matthews D.R., Cull C.A. et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study // BMJ. 2000. Vol. 321. P. 412—419.
784. American Diabetes Association. 9. Cardiovascular disease and risk management // Diabetes. Care. 2017. Vol. 40. P. S75-S87.
785. Balakumar P., Maung U.K., Jagadeesh G. Prevalence and prevention of cardiovascular disease and diabetes mellitus // Pharmacol. Res. 2016. Vol. 113. P. 600—609.
786. Bleicken B., Hahner S., Ventz M., Quinkier M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients // Am. J. Med. Sci. 2010. Vol. 339. P. 525-531.
787. Bornstein S.R. Predisposing factors for adrenal insufficiency // N. Engl. J. Med. 2009. Vol. 360. P. 2328-2339.
788. Buleishvili M., Lobjanidze N., Ormotsadze G., Enukidze M., Machavariani M., Sanikidze T. Estrogen related mechanisms of hypertension in menopausal women // Georgian Med. News. 2016. P. 45-51.
789. Carbone E, Mach E, Vuilleumier N., Montecucco F. Potential pathophysiological role for the vitamin D deficiency in essential hypertension // World. J. Cardiol. 2014. Vol. 6. P. 260-276.
790. Corona G., Giagulli VA., Maseroli E., Vignozzi L., Aversa A., Zitzmann M. et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies //J. Endocrinol. Investig. 2016. Vol. 39. P. 967—981.
791. Curb J.D., Pressel S.L., Cutler J.A., Savage P.J., Applegate W.B., Black H. et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group//JAMA. 1996. Vol. 276. P. 1886—1892.
792. Estacio R.O., Jeffers B.W., Hiatt W.R., Biggerstaff S.L., Gifford N., Schrier R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension // N. Engl. J. Med. 1998. Vol. 338. P. 645-652.
793. Fedrizzi D., Rodrigues T.C., Costenaro F., Scalco R., Czepielewski M.A. Hypertension-related factors in patients with active and inactive acromegaly // Arq. Bras. Endocrinol. Metabol. 2011. Vol. 55. P. 468-474.
794. Ferrannini E., Cushman W.C. Diabetes and hypertension: the bad companions // Lancet. 2012. Vol. 380. P. 601-610.
795. Funder J.W. Minireview: aldosterone and the cardiovascular system: genomic and nongenomic effects // Endocrinology. 2006. Vol. 147. P. 5564—5567.
796. Geller D.S., Farhi A., Pinkerton N., Fradley M., Moritz M., Spitzer A. et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy // Science. 2000. Vol. 289. P. 119-123.
797. Hansson L., Zanchetti A., Carruthers S.G., Dahlof B., Elmfeldt D., Julius S. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group// Lancet. 1998. Vol. 351. P. 1755-1762.
798. International Diabetes Federation (IDF). Global guideline for type 2 diabetes. 2012.
799. Acosta A., Camilleri М., Shin A., Vazquez-Roque M.L, Iturrino J., Burton D. ... Zinsmeister A.R. Quantitative gastrointestinal and psychological traits associated with obesity and response to weight-loss therapy // Gastroenterology. 2015. Vol. 148. N. 3. P. 537— 546,e534.
800. Arneth В.М. Gut-brain axis biochemical signalling from the gastrointestinal tract to the central nervous system: gut dysbiosis and altered brain function // Postgrad. Med. J. 2018. Vol. 94. N. 1114. P. 446—452.
801. Aune D., Vatten L.J. Diabetes mellitus and the risk of gallbladder disease: a systematic review and meta-analysis of prospective studies // J. Diabetes Complications. 2015.
802. Aune D., Greenwood D.C., Chan D.S., Vieira R., Vieira A.R., Navarro Rosenblatt D.A. ... Norat T. Body mass ind e.x., abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies // Ann. Oncol. 2012. Vol. 23. N. 4. P. 843-852.
803. Aydin O., Nieuwdorp M., Gerdes V. The gut microbiome as a target for the treatment of type 2 diabetes//Curr. Diab. Rep. 2018. Vol. 18. N. 8. P. 55.
804. Backhed Е, Ding Н., Wang Т., Hooper L.V., Koh G.Y., Nagy A. ... Gordon J.I. The gut microbiota as an environmental factor that regulates fat storage // Proc. Natl. Acad. Sci USA. 2004. Vol. 101. N. 44. P. 15718-15723.
805. Bellentani S., Saccoccio G., Masutti E, Croce L.S., Brandi G., Sasso F. ... Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy // Ann. Intern. Med. 2000. Vol. 132. N. 2. P. 112-117.
806. Betterle C., Lazzarotto E, Spadaccino A.C., Basso D., Plebani M., Pedini B. ... Albergoni M. Celiac disease in North Italian patients with autoimmune Addison’s disease // Eur. J. Endocrinol. 2006. Vol. 154. N. 2. P. 275—259.
807. Beymer C., Kowdley K.V., Larson A., Edmonson P., Dellinger E.P., Flum D.R. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery//Arch. Surg. 2003. Vol. 138. N. 11. P. 1240-1244.
808. Bharucha A.E., Daley S.L., Low P.A., Gibbons S.J., Choi K.M., Camilleri M. ... Zinsmeister A.R. Effects of hemin on heme oxygenase-1, gastric emptyi n.g., and symptoms in diabetic gastroparesis // Neurogastroenterol. Motil. 2016. Vol. 28. N. 11. P. 1731— 1740.
809. Bhaskaran K., Douglas L, Forbes H., dos-Santos-Silva L, Leon D.A., Smeeth L. Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults // Lancet. 2014. Vol. 384. N. 9945. P. 755—765.
810. Bird C.L., Frankl H.D., Lee E.R., Haile RW. Obesity, weight gain, large weight changes., and adenomatous polyps of the left colon and rectum // Am. J. Epidemiol. 1998. Vol. 147. N. 7. P. 670-680.
811. Bjomsdottir S., Sundstrom A., Ludvigsson J.F., Blomqvist P., Kampe O., Bensing S. Drug prescription patterns in patients with Addison’s disease: a Swedish population-based cohort study // J. Clin. Endocrinol. Metab. 2013. Vol. 98. N. 5. P. 2009—2018.
812. Bleicken B., Hahner S., Ventz M., Quinkier M. Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients // Am. J. Med. Sci. 2010. Vol. 339. N. 6. P. 525-531.
813. Bliss E.S., Whiteside E. The gut-brain axis., the human gut microbiota and their integration in the development of obesity // Front. Physiol. 2018. Vol. 9. P. 900.
814. Bogazzi E, Ultimieri E, Raggi E, Russo D., Viacava P., Cecchetti D. ... Martino E. Changes in the expression of the peroxisome proliferator-activated receptor gamma gene in the colonic polyps and colonic mucosa of acromegalic patients // J. Clin. Endocrinol. Metab. 2003. Vol. 88. N. 8. P. 3938-3942.
815. Bogazzi E, Cosci C., Sardella C., Costa A., Manetti L., Gasperi M.... Martino E. Identification of acromegalic patients at risk of developing colonic adenomas // J. Clin. Endocrinol. Metab. 2006. Vol. 91. N. 4. P. 1351-1356.
816. Chen Y, Liu L., Wang X., Wang J., Yan Z., Cheng J.... Li G. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies // Cancer Epidemiol. Biomarkers Prev. 2013. Vol. 22. N. 8. P. 1395—1408.
817. Choung R.S., Locke G.R. 3rd., Schleck C.D., Zinsmeister A.R., Melton L.J. 3rd., Talley NJ. Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population // Am. J. Gastroenterol. 2012. Vol. 107. N. 1. P. 82—88.
818. Clouse R.E., Lustman P.J. Gastrointestinal symptoms in diabetic patients: lack of association with neuropathy // Am. J. Gastroenterol. 1989. Vol. 84. N. 8. P. 868—872.
819. Cote-Daigneault J., Leclerc Р., Joubert J., Bouin M. High prevalence of esophageal dysmotility in asymptomatic obese patients // Can. J. Gastroenterol. Hepatol. 2014. Vol. 28. N. 6. P. 311—314.
820. Delgado-Aros S., Locke G.R. 3rd., Camilleri M., Talley NJ., Fett S., Zinsmeister A.R., Melton L.J. 3rd. Obesity is associated with increased risk of gastrointestinal symptoms: a populationbased study//Am. J. Gastroenterol. 2004. Vol. 99. N. 9. P. 1801 — 1806.
821. Di Ciaula A., Portincasa P. Fat, epigenome and pancreatic diseases. Interplay and common pathways from a toxic and obesogenic environment // Eur. J. Intern. Med. 2014. Vol. 25. N. 10. P. 865-873.
822. Di Ciaula A., Portincasa P. Diet and contaminants: driving the rise to obesity epidemics? // Curr. Med. Chem. 2017.
823. Di Ciaula A., Wang D.Q., Portincasa P. Gallbladder and gastric motility in obese newbor n.s., preadolescents and adults // J Gastroenterol. Hepatol. 2012. Vol. 27. N. 8. P. 1298—1305.
824. Di Ciaula A., Garruti G., Baccetto R.L., Molina-Molina E., Bonfrate L., Wang D.Q., Portincasa P. Bile acid physiology//Ann. Hepatol. 2017a. Vol. 16. N. 0. P. 4—14.
825. Di Ciaula A., Garruti G., Wang D.Q., Portincasa P. Role of insulin resistance in the formation of cholesterol gallstones // Wang DQ-H, Portincasa P., editors. Gallstones: recent advances in epidemiolo g.y., pathogenes i.s., diagnosis and management. New York: Nova Science Publishers. Vol. 2017b. P. 357-372.
826. Di Ciaula A., Garruti G., Wang D Q.H., Portincasa P. Diabetes and gallstones // Wang D Q.H., Portincasa P., editors. Gallstones. Recent advances in epidemiology, pathogenesis., diagnosis and management. New York: Nova Science Publisher, 2017c. P. 373—387.
827. Di Ciaula A., Wang D.Q., Molina-Molina E., Baccetto R.L., Calamita G., Palmieri V.O., Portincasa P. Bile acids and cancer: direct and environmental-dependent effects // Ann. Hepatol. 2017d. Vol. 16. N. 0. P. 81-99.
828. Duggan C., Onstad L., Hardikar S., Blount P.L., Reid B.J., Vaughan T.L. Association between markers of obesity and progression from Barrett’s esophagus to esophageal adenocarcinoma 11 Clin. Gastroenterol. Hepatol. 2013. Vol. 11. N. 8. P. 934-943.
829. Elfstrom P., Montgomery S.M., Kampe O., Ekbom A., Ludvigsson J.F. Risk of thyroid disease in individuals with celiac disease // J. Clin. Endocrinol. Metab. 2008. Vol. 93. N. 10. P. 3915-3921.
830. Garruti G., Di Ciaula A., Wang H.H., Wang D.Q., Portincasa P. Cross-talk between bile acids and gastro-intestinal and thermogenic: clues from bariatric surgery // Ann. Hepatol. 2017. Vol. 16. N. 0. P. 62-76.
831. Hallan A., Bomme M., Hveem K., Moller-Hansen J., Ness-Jensen E. Risk factors on the development of new-onset gastroesophageal reflux symptoms. A population-based prospective cohort study: the HUNT study //Am. J. Gastroenterol. 2015. Vol. 110. N. 3. P. 393— 400. Quiz 401.
832. Hampel H., Abraham N.S., El-Serag H.B. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications // Ann. Intern. Med. 2005. Vol. 143. N. 3. P. 199—211.
833. Hassan M.M., Kaseb A., Li D., Patt Y.Z., Vauthey J.N., Thomas M.B. ... Abbruzzese J.L. Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States // Hepatology. 2009. Vol. 49. N. 5. P. 1563—1570.
834. Iida M., Ikeda M., Kishimoto M., Tsujino T., Kaneto H., Matsuhisa M.... Hori M. Evaluation of gut motility in type II diabetes by the radiopaque marker method // J. Gastroenterol. Hepatol. 2000. Vol. 15. N. 4. P. 381-385.
835. Ilhan М., Arabaci Е., Turgut S., Karaman О., Danalioglu A., Tasan E. Esophagus motility in overt hypothyroidism //J. Endocrinol. Invest. 2014. Vol. 37. N. 7. P. 639-644.
836. Insenser M., Murri M., Del Campo R., Martinez-Garcia M.A., Fernandez-Duran E., Escobar-Morreale H.E Gut microbiota and the polycystic ovary syndrome: influence of sex., sex hormones., and obesity // J. Clin. Endocrinol. Metab. 2018. Vol. 103. N. 7. P. 2552-2562.
837. Ioannou G.N.,Weiss N.S., Kowdley K.V., Dominitz J.A. Is obesity a risk factor for cirrhosis-related death or hospitalization? A population-based cohort study // Gastroenterology. 2003. Vol. 125. N. 4. P. 1053-1059.
838. Iyer P.G., Borah В J., Heien H.C., Das A., Cooper G.S., Chak A. Association of Barrett’s esophagus with type II diabetes mellitus: results from a large population-based case-control study//Clin. Gastroenterol. Hepatol. 2013. Vol. 11. N. 9. P. 1108-1114.ell05.
839. Jenkins P.J., Frajese V., Jones A.M., Camacho-Hubner C., Lowe D.G., Fairclough P.D. ... Besser G.M. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly // J Clin Endocrinol Metab. 2000. Vol. 85. N. 9. P. 3218—3221.
840. Jung H.K., Kim D.Y., Moon 1.Н., Hong Y.S. Colonic transit time in diabetic patients — comparison with healthy subjects and the effect of autonomic neuropathy // Yonsei Med. J. 2003. Vol. 44. N. 2. P. 265-272.
841. Kawagishi T., Nishizawa Y, Okuno Y, Sekiya K., Morii H. Segmental gut transit in diabetes mellitus: effect of cisapride // Diabetes Res. Clin. Pract. 1992. Vol. 17. N. 2. P. 137—144.
842. Ko G.T., Chan W.B., Chan J.C., Tsang L.W., Cockram C.S. Gastrointestinal symptoms in Chinese patients with type 2 diabetes mellitus // Diabet Med. 1999. Vol. 16. N. 8. P. 670—674.
843. Kong M-F, Horowitz M., Jones K.L., Wishart J.M., Harding P.E. Natural history of diabetic gastroparesis // Diabetes Care. 1999. Vol. 22. N. 3. P. 503—507.
844. Koppman J.S., Poggi L., Szomstein S., Ukleja A., Botoman A., Rosenthal R. Esophageal motility disorders in the morbidly obese population // Surg. Endosc. 2007, Vol. 21. N. 5. P. 761-764.
845. Kopylov U., Ben-Horin S., Lahat A., Segev S., Avidan B., Carter D. Obesity, metabolic syndrome and the risk of development of colonic diverticulosis // Digestion. 2012. Vol. 86. N. 3. P. 201-205.
846. Kubo A., Corley D.A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis // Cancer. Epidemiol. Biomarkers Prev. 2006. Vol. 15. N. 5. P. 872-878
847. Larsson S.C.,Wolk A. Overweig h.t., obesity and risk of liver cancer: a meta-analysis of cohort studies // Br. J. Cancer. 2007. Vol. 97. N. 7. P. 1005—1008.
848. Lee S.D., Keum B., Chun H.J., Bak Y.T. Gastroesophageal reflux disease in type ii diabetes mellitus with or without peripheral neuropathy // J. Neurogastroenterol. Motil. 2011. Vol. 17. N. 3. P. 274-278.
849. Ley R.E., Backhed E, Tumbaugh P., Lozupone C.A., Knight R.D., Gordon J.I. Obesity alters gut microbial ecology // Proc. Natl. Acad. Sci USA. 2005. Vol. 102. N. 31. P. 11070—11075.
850. Ley R.E., Turnbaugh P.J., Klein S., Gordon J.I. Microbial ecology: human gut microbes associated with obesity // Nature. 2006. Vol. 444. N. 7122. P. 1022—1023.
851. Liangpunsakul S., Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepa-titis? //J. Clin. Gastroenterol. 2003. Vol. 37. N. 4. P. 340—343.
852. Lluch I., Ascaso J.F., Mora Е, Minguez М., Pena A., Hernandez A., Benages А. Gastroesophageal reflux in diabetes mellitus // Am. J. Gastroenterol. 1999. Vol. 94. N. 4. P. 919-924.
853. Martin C.R., Osadchiy V., Kalani A., Mayer E.A. The brain-gut-microbiome axis // Cell. Mol. Gastroenterol. Hepatol. 2018. Vol. 6. N. 2. P. 133—148.
854. Melmed S., Colao A., Barkan A., Molitch M., Grossman A.B., Weinberg D. ... Acromegaly Consensus Group. Guidelines for acromegaly management: an update // J. Clin. Endocrinol. Metab. 2009. Vol. 94. N. 5. P. 1509-1517.
855. Myhre A.G., Aarsetoy H., Undlien D.E., Hovdenak N., Aksnes L., Husebye E.S. High frequency of coeliac disease among patients with autoimmune adrenocortical failure // Scand. J. Gastroenterol. 2003. Vol. 38. N. 5. P. 511—515.
856. Ning Y, Wang L., Giovannucci E.L. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies // Obes. Rev. 2010. Vol. 11. N. I. P. 19—30.
857. Pearson J.A., Agriantonis A., Wong F.S., Wen L. Modulation of the immune system by the gut microbiota in the development of type 1 diabetes // Hum. Vaccin. Immunother. 2018.
858. Pirola C.J., Gianotti T.F., Castano G.O., Mallardi P., San Martino J., Ledesma M.M.G.L. ... Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis // Gut. 2014.
859. Portincasa P., Wang D.Q.H. Gallstones // Podolsky K.D., Camilleri M., Fitz J.G., Kalloo A.N., Shanahan E, Wang T.C., editors. Yamada's atlas of gastroenterology. 5th ed. Wiley-Blackwe 1.1., Hoboke.n. New Jersey, 2016. P. 335—353.
860. Ricci J.A., Siddique R., Stewart W.F., Sandler R.S., Sloan S., Farup C.E. Upper gastrointestinal symptoms in a U.S. national sample of adults with diabetes // Scand. J. Gastroenterol. 2000. Vol. 35. N. 2. P. 152-159.
861. Rokkas T., Portincasa P. Colon neoplasia in patients with type 2 diabetes on metformin: a meta-analysis // Eur. J. Intern. Med. 2016. Vol. 33. P. 60—66.
862. Rokkas T., Pistiolas D., Sechopoulos P., Margantinis G., Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis // World. J. Gastroenterol. 2008. Vol. 14. N. 22. P. 3484-3489.
863. Roman S., Marjoux S., Thivolet C., Mion E Oesophageal function assessed by high-resolution manometry in patients with diabetes and inadequate glycaemic control // Diabet. Med. 2014. Vol. 31. N. 11. P. 1452-1459.
864. Ron E., Gridley G., Hrubec Z., Page W., Arora S., Fraumeni J.F.Jr. Acromegaly and gastrointestinal cancer // Cancer. 1991. Vol. 68. N. 8. P. 1673—1677.
865. Ronchi C.L., Coletti E, Fesce E., Montefusco L., Ogliari C., Verrua E.... Arosio M. Detection of small bowel tumors by videocapsule endoscopy in patients with acromegaly // J. Endocrinol. Invest. 2009. Vol. 32. N. 6. P. 495-500.
866. Sanchez-Alcoholado L., Castellano-Castillo D., Jordan-Martinez L., Moreno-Indias I., Cardila-Cruz P., Elena D. ... Jimenez-Navarro M. Role of gut microbiota on cardio-metabolic parameters and immunity in coronary artery disease patients with and without type-2 diabetes mellitus // Front. Microbiol. 2017. Vol. 8. P. 1936.
867. Shabanzadeh D.M., Skaaby T., Sorensen L.T., Eugen-Olsen J., Jorgensen T. Metabolic biomarkers and gallstone disease — a population-based study// Scand. J. Gastroenterol. 2017. Vol. 52. N. 11. P. 1270-1277.
868. Singh S., Sharma A.N., Murad M.H., Buttar N.S., El-Serag H.B., Katzka D.A., Iyer PG. Central adiposity is associated with increased risk of esophageal inflammati o.n., metaplas i.a., and adenocarcinoma: a systematic review and meta-analysis // Clin. Gastroenterol. Hepatol. 2013. Vol. 11. N. 11. P. 1399—1412. el397.
869. Tanaka Y, Sakata Y, Hara M., Kawakubo H., Tsuruoka N., Yamamoto K. ... Fujimoto K. Risk factors for Helicobacter pylori infection and endoscopic reflux esophagitis in healthy young Japanese volunteers// InternMed. 2017. Vol. 56. N. 22. P. 2979—2983.
870. Terzolo M., Reimondo G., Gasperi M., Cozzi R., Pivonello R., Vitale G. ... Colao A. Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy//J. Clin. Endocrinol. Metab. 2005. Vol. 90. N. 1. P. 84-90.
871. Thomas C., Auwerx J., Schoonjans K. Bile acids and the membrane bile acid receptor TGR5 — connecting nutrition and metabolism//Thyroid. 2008. Vol. 18. N. 2. P. 167—174.
872. Tottey W., Feria-Gervasio D., Gaci N., Laillet B., Pujos E., Martin J.F. ... Brugere J.F. Colonic transit time is a driven force of the gut microbiota composition and metabolism: in vitro evidence //J. Neurogastroenteroi. Motil. 2017. Vol. 23. N. 1. P. 124-134.
873. Wang D.Q.H., Portincasa P., editors. Gallstones. Recent advances in epidemiology, pathogenesis, diagnosis and management. 1st ed. New York: Nova Science Publisher, 2017. P. 1-676.
874. Wang D.Q., Portincasa P., Tso P. Transintestinal cholesterol excretion: a seconda r.y., non-biliary pathway contributing to reverse cholesterol transport // Hepatology. 2017. Vol. 66. N. 4. P. 1337-1340.
875. Wolinski K., Stangierski A., Dyrda K., Nowicka K., Pelka M., Iqbal A. ... Ruchala M. Risk of malignant neoplasms in acromegaly: a case-control study // J. Endocrinol. Invest. 2017. Vol. 40. N. 3. P. 319-322.
876. Wong VW, Chitturi S., Wong G.L., Yu J., Chan H.L., Farrell G.C. Pathogenesis and novel treatment options for non-alcoholic steatohepatitis // Lancet Gastroenterol. Hepatol. 2016. Vol. 1. N. I. P. 56-67.
877. Wu H., Esteve E., Tremaroli V, Khan M.T., Caesar R., Manneras-Holm L. ... Backhed F. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes., contributing to the therapeutic effects of the drug // Nat. Med. 2017. Vol. 23. N. 7. P. 850—858.
878. Yokota A., Fukiya S., Islam K.B., Ooka T., Ogura Y, Hayashi T. ... Ishizuka S. Is bile acid a determinant of the gut microbiota on a high-fat diet? // Gut. Microbes. 2012. Vol. 3. N. 5. P. 455—459.
879. Ze E.Y., Kim B.J., Kang H., Kim JG. Abdominal visceral to subcutaneous adipose tissue ratio is associated with increased risk of erosive esophagitis // Dig. Dis. Sci. 2017. Vol. 62. N. 5. P. 1265-1271.
880. Zhang Z.J., Zheng Z.J., Shi R., Su Q., Jiang Q., Kip K.E. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis // J. Clin. Endocrinol. Metab. 2012. Vol. 97. N. 7. P. 2347-2353.
881. Zhao E, Feng J., Li J., Zhao L., Liu Y, Chen H. ... Wei Y. Alterations of the gut microbiota in Hashimoto’s thyroiditis patients // Thyroid. 2018. Vol. 28. N. 2. P. 175—186.
882. James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J. et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) //JAMA. 2014. Vol. 311. P. 507-520.
883. Leung A.A., Nerenberg K., Daskalopoulou S.S., McBrien K., Zarnke K.B., Dasgupta K. et al. Hypertension Canada’s 2016 Canadian hypertension education program guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension // Can. J. Cardiol. 2016. Vol. 32. P. 569—588.
884. Mancia G., Grassi G. Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the argument // Hypertension. 2014. Vol. 63. P. 29—36.
885. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M. et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) // J. Hypertens. 2013. Vol. 31. P. 1281-1357.
886. Mazza A., Beltramello G., Armigliato M., Montemurro D., Zorzan S., Zuin M. et al. Arterial hypertension and thyroid disorders: what is important to know in clinical practice? // Ann. Endocrinol. 2011. Vol. 72. P. 296-303.
887. Melcescu E., Phillips J., Moll G., Subauste J.S., Koch C.A. 11 Beta-hydroxylase deficiency and other syndromes of mineralocorticoid excess as a rare cause of endocrine hypertension // Horm. Metab. Res. 2012. Vol. 44. P. 867—878.
888. Mihailidou A.S., Loan Le T.Y., Mardini M., Funder J.W. Glucocorticoids activate cardiac mineralocorticoid receptors during experimental myocardial infarction // Hypertension. 2009. Vol. 54. P. 1306-1312.
889. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. 2011. Last updated Nov 2016.
890. Patel A., Group А.С., MacMahon S., Chalmers J., Neal B., Woodward M. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial // Lancet. 2007. Vol. 370. P. 829—840.
891. Pilz S., Kienreich K., Drechsler C., Ritz E., Fahrleitner-Pammer A., Gaksch M. et al. Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study // J. Clin. Endocrinol. Metab. 2012. Vol. 97. P. E75-E79.
892. Prisant L.M., Gujral J.S., MulloyA.L. Hyperthyroidism: a secondary cause of isolated systolic hypertension //J. Clin. Hypertens. (Greenwich). 2006. Vol. 8. P. 596—599.
893. Sahakitrungruang T. Clinical and molecular review of atypical congenital adrenal hyperplasia //Ann. Pediatr. Endocrinol. Metab. 2015. Vol. 20. P. 1—7.
894. Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes // Kidney Int. 2002. Vol. 61. P. 1086-1097.
895. Tuomilehto J., Rastenyte D., Birkenhager W.H., Thijs L., Antikainen R., Bulpitt C.J. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators // N. Engl. J. Med. 1999. Vol. 340. P. 677-684.
896. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 // BMJ. 1998. Vol. 317. P. 703-713.
897. Vecchione C., Colella S., Fratta L., Gentile M.T., Selvetella G., Frati G. et al. Impaired insulin-like growth factor I vasorelaxant effects in hypertension // Hypertension. 2001. Vol. 37. P. 1480-1485.
898. Verheist J., Abs R. Cardiovascular risk factors in hypopituitary GH-deficient adults // Eur. J. Endocrinol. 2009. Vol. 161. SuppL 1. P. S41—S49.
899. Weber M.A., Schiffrin E.L., White W.B., Mann S., Lindholm L.H., Kenerson J.G. et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension //J. Clin. Hypertens. (Greenwich). 2014. Vol. 16. P. 14—26.
900. Wilczynski C., Shah L., Emanuele M.A., Emanuele N., Mazhari A. Selective hypoaldosteronism: a review // Endocr. Pract. 2015. Vol. 21. P. 957—965.
901. Xiang G.D., Pu J.H., Sun H.L., Zhao L.S. Alpha-lipoic acid improves endothelial dysfunction in patients with subclinical hypothyroidism // Exp. Clin. Endocrinol. Diabetes. 2010. Vol. 118. N. 9. P. 625-629.
902. Yoon H.E., Ghee J.Y., Piao S., Song J.H., Han D.H., Kim S. et al. Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy// Nephrol. Dial. Transplant. 2011. Vol. 26. P. 800—813.
903. Zennaro M.C., Lombes M. Mineralocorticoid resistance //Trends. Endocrinol. Metab. 2004. Vol. 15. P. 264-270.
904. Zennaro M.C., Boulkroun S., Fernandes-Rosa F. An update on novel mechanisms of primary aldosteronism //J. Endocrinol. 2015. Vol. 224. P. R63—R77.
905. Zimmet P., Alberti K.G., Magliano D.J., Bennett P.H. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies // Nat. Rev. Endocrinol. 2016. Vol. 12. P. 616—622.
906. Biondi В., Cooper D.S. The clinical significance of subclinical thyroid dysfunction // Endocr. Rev. 2008. Vol. 29. P. 76-131.
907. Blouin K., Despres J.P., Couillard C. et al. Contribution of age and declining androgen levels to features of the metabolic syndrome in men // Metabolism. 2005. Vol. 54. P. 1034—1040.
908. Boehm U., Bouloux P.M., Dattani M.T. et al. Expert consensus statement on congenital hypogonadotropic hypogonadism — pathogenesis, diagnosis and treatment // Nat. Rev. Endocrinol. 2015. Vol. 11. N. 9. P. 547-564.
909. Cani P.D., Delzenne N.M. Gut microflora as a target for energy and metabolic homeostasis // Curr. Opin. Clin. Nutr. Metab. Care. 2007. Vol. 10. P. 729-734.
910. Adams L.A., Feldstein A., Lindor K.D., Angulo Р. Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction // Hepatology. 2004. Vol. 39. N. 4. P. 909-914.
911. Als-Nielsen B., Koretz R.L., Kjaergard L.L., Gluud C. Branched-chain amino acids for hepatic encephalopathy // Cochrane Database Syst. Rev. 2003. N. 2. P. CD001939.
912. Balakrishnan C.H., Rajeev H. Correlation of serum prolactin level to Child Pugh scoring system in cirrhosis of liver // J. Clin. Diagn. Res. 2017. Vol. 11. N. 7. P. ОСЗО— OC33.
913. Ballestri S., Nascimbeni E, Baldelli E., Marrazzo A., Romagnoli D., Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk // Adv. Ther. 2017. Vol. 34. N. 6. P. 1291-1326.
914. Bano A., Chaker L., Plompen E.P., Hofman A., Dehghan A., Franco O.H., ... Peeters R.P. Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam study // J. Clin. Endocrinol. Metab. 2016. Vol. 101. N. 8. P. 3204—3211.
915. Baranova A., Tran T.P., Birerdinc A., Younossi Z.M. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease // Aliment. Pharmacol. Ther. 2011. Vol. 33. N. 7. P. 801—814.
916. Bataller R., Sancho-Bru P., Gines P., Brenner D.A. Liver fibrogenesis: a new role for the reninangiotensin system //Antioxid. Redox. Signal. 2005. Vol. 7. N. 9—10. P. 1346—1355.
917. Bellentani S., Scaglioni E, Marino M., Bedogni G. Epidemiology of non-alcoholic fatty liver disease // Dig. Dis. 2010. Vol. 28. N. 1. P. 155—161.
918. Bianco A.C., Salvatore D., Gereben B., Berry M.J., Larsen P.R. Biochemistry., cellular and molecular biolo g.y., and physiological roles of the iodothyronine selenodeiodinases // Endocr. Rev. 2002. Vol. 23. N. I. P. 38—89.
919. Bothou C., Beuschlein E, Spyroglou A. Links between aldosterone excess and metabolic complications: a comprehensive review // Diabetes Metab. 2019. Vol. 46. P. 1.
920. Brady C.W. Liver disease in menopause // World J. Gastroenterol. 2015. Vol. 21. N. 25. P. 7613-7620.
921. Cai Z., Jiang X., Pan Y., Chen L., Zhang L., Zhu K. ... Chen M. Transcriptomic analysis of hepatic responses to testosterone deficiency in miniature pigs fed a high-cholesterol diet // BMC Genomics. 2015. Vol. 16. P. 59.
922. Cerda C., Perez-Ayuso R.M., Riquelme A., Soza A., Villaseca P., Sir-Petermann T. ... Arrese M. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome // J. Hepatol. 2007. Vol. 47. N. 3. P. 412-417.
923. Chanson P., Salenave S. Metabolic syndrome in Cushing’s syndrome // Neuroendocrinology. 2010. Vol. 92. Suppl. 1. P. 96-101.
924. Chung G.E., Kim D., Kim W., Yim J.Y., Park M.J., Kim Y.J. ... Lee H.-S. Non-alcoholic fatty liver disease across the spectrum of hypothyroidism // J. Hepatol. 2012. Vol. 57. N. 1. P. 150-156.
925. Cicatiello A.G., Di Girolamo D., Dentice M. Metabolic effects of the intracellular regulation of thyroid hormone: old players., new concepts // Front. Endocrinol. (Lausanne). 2018. Vol. 9. P. 474.
926. D’Eon T.M., Souza S.C., Aronovitz M., Obin M.S., Fried S.K., Greenberg A.S. Estrogen regulation of adiposity and fuel partitioning. Evidence of genomic and non-genomic regulation of lipogenic and oxidative pathways //J. Biol. Chem. 2005. Vol. 280. N. 43. P. 35983— 35991.
927. Eshraghian A., Hamidian Jahrdmi A. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review // World J. Gastroenterol. 2014. Vol. 20. N. 25. P. 8102—8109.
928. Eslam M., Sanyal A.J., George J. et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease // Gastroenterol. 2020. Vol. 158. P. 1999— 2014 el.
929. Eun C.R., Ahn J.H., Seo J.A., Kim N.H. Pheochromocytoma with markedly abnormal liver function tests and severe leukocytosis // Endocrinol. Metab. (Seoul). 2014. Vol. 29. N. 1. P. 83-90.
930. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASDEASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease //J. Hepatol. 2016. Vol. 64. N. 6. P. 1388—1402.
931. Fallo E, Dalia Pozza A., Tecchio M., Топа E, Sonino N., Ermani M. ... Sechi L.A. Nonalcoholic fatty liver disease in primary aldosteronism: a pilot study // Am. J. Hypertens. 2010. Vol. 23. N. I. P. 2-5.
932. Fede G., Spadaro L., Tomaselli T., Privitera G., Germani G., Tsochatzis E. ... Purrello F. Adrenocortical dysfunction in liver disease: a systematic review // Hepatology. 2012. Vol. 55. N. 4. P. 1282-1291.
933. Ferrau E, Korbonits M. Metabolic syndrome in Cushing’s syndrome patients// Front. Horm. Res. 2018. Vol. 49. P. 85-103.
934. Gariani K., Toso C., Philippe J., Orci L.A. Effects of liver transplantation on endocrine function: a systematic review // Liver. Int. 2016. Vol. 36. N. 10. P. 1401 — 1411.
935. Geach T. Poor thyroid function linked to NAFLD // Nat. Rev. Endocrinol. 2016. Vol. 12. N. 8. P. 434-435.
936. Gild P., Cole A.P., Krasnova A., Dickerman B.A., von Landenberg N., Sun M.... Trinh Q.D. Liver disease in men undergoing androgen deprivation therapy for prostate cancer // J. Urol. 2018. Vol. 200. N. 3. P. 573-581.
937. Grattagliano I., Montezinho L.P., Oliveira P.J., Fruhbeck G., Gomez-Ambrosi J., Montecucco F.... Portincasa P. Targeting mitochondria to oppose the progression of nonalcoholic fatty liver disease // Biochem. Pharmacol. 2019. Vol. 160. P. 34—45.
938. Greenway C.V., Lautt W.W. Distensibility of hepatic venous resistance sites and consequences on portal pressure //Am. J. Phys. 1988. Vol. 254. N. 3. Pt 2. P. H452— H458.
939. Grossmann M., Wierman M.E., Angus P., Handelsman D.J. Reproductive endocrinology of nonalcoholic fatty liver disease // Endocr. Rev. 2019. Vol. 40. N. 2. P. 417—446.
940. Hennemann G., Docter R., Friesema E.C., de Jong M., Krenning E.P., Visser T.J. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability// Endocr. Rev. 2001. Vol. 22. N. 4. P. 451—476.
941. Hong J.W., Kim J.Y., Kim Y.E., Lee E.J. Metabolic parameters and nonalcoholic fatty liver disease in hypopituitary men // Horm. Metab. Res. 2011. Vol. 43. N. 1. P. 48—54.
942. Hossain N., Stepanova M., Afendy A., Nader E, Younossi Y, Rafiq N. ... Younossi Z.M. Nonalcoholic steatohepatitis (NASH) in patients with polycystic ovarian syndrome (PCOS) // Scand. J. Gastroenterol. 2011. Vol. 46. N. 4. P. 479—484.
943. Huang L., Smit J.W., Meijer D.K., Vore M. Mrp2 is essential for estradiol- 17beta(beta-D-glu-curonide)- induced cholestasis in rats// Hepatology. 2000. Vol. 32. N. I. P. 66-72.
944. Jakobsson T., Vedin L.L., Parini P. Potential role of thyroid receptor beta agonists in the treatment of hyperlipidemia // Drugs. 2017. Vol. 77. N. 15. P. 1613-1621.
945. Jaruvongvanich V, Sanguankeo A., Riangwiwat T., Upala S. Testosterone., sex hormone-binding globulin and nonalcoholic fatty liver disease: a systematic review and meta-analysis // Ann. Hepatol. 2017. Vol. 16. N. 3. P. 382-394.
946. Jia Y., Yee J.K.,Wang C., Nikolaenko L., Diaz-Arjonilla M., Cohen J.N. ... Swerdloff R.S. Testosterone protects high-fat/low-carbohydrate diet-induced nonalcoholic fatty liver disease in castrated male rats mainly via modulating endoplasmic reticulum stress // Am. J. Physiol. Endocrinol. Metab. 2018. Vol. 314. N. 4. P. E366-376.
947. Jonas M.M., Krawczuk L.E., Kim H.B., Lillehei C., Perez-Atayde A. Rapid recurrence of nonalcoholic fatty liver disease after transplantation in a child with hypopituitarism and hepatopulmonary syndrome // Liver. Transpl. 2005. Vol. 11. N. 1. P. 108-110.
948. Jones FL, Sprung V.S., Pugh C.J., Daousi C., Irwin A., Aziz N.... Cuthbertson D.J. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls., independent of obesity and insulin resistance // J. Clin. Endocrinol. Metab. 2012. Vol. 97. N. 10. P. 3709-3716.
949. Kalambokis G., Milionis H.J. Addison’s disease and hypertransaminasemia // Expert. Rev. Endocrinol. Metab. 2009. Vol. 4. N. 3. P. 251—261.
950. Karagiannis A., Harsoulis F. Gonadal dysfunction in systemic diseases // Eur. J. Endocrinol. 2005. Vol. 152. N. 4. P. 501-513.
951. Kaur P., Rizk N.M., Ibrahim S., Younes N., Uppal A., Dennis K. ... Cheema A.K. iTRAQ-based quantitative protein expression profiling and MRM verification of markers in type 2 diabetes//J. Proteome Res. 2012. Vol. 11. N. 11. P. 5527—5539.
952. Kim S., Kwon H., Park J.H., Cho B., Kim D., Oh S.W. ... Choi H.C. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease //BMC Gastroenterol. 2012. Vol. 12. P. 69.
953. Kim G., Huh J.H., Lee K.J., Kim M.Y., Shim K.Y., Baik SK. Relative adrenal insufficiency in patients with cirrhosis: a systematic review and meta-analysis // Dig. Dis. Sci. 2017. Vol. 62. N. 4. P. 1067-1079.
954. Kumar A., Blackshear C., Subauste J.S., Esfandiari N.H., Oral E.A., Subauste A.R. Fatty liver disea s.e., worn e.n., and aldosterone: finding a link in the Jackson Heart Study // J. Endocr. Soc. 2017. Vol. 1. N. 5. P. 460—469.
955. Kumar M., Gupta G.K., Wanjari S.J., Так V, Ameta M., Nijhawan S. Relative adrenal insufficiency in patients with alcoholic hepatitis // J. Clin. Exp. Hepatol. 2019. Vol. 9. N. 2. P. 215-220.
956. Kus A., Arlukowicz-Grabowska M., Szymanski K., Wunsch E., Milkiewicz M., Ploski R. ... Krawczyk M. Genetic risk factors for autoimmune thyroid disease might affect the susceptibility to and modulate the progression of primary biliary cholangitis // J. Gastrointestin. Liver. Dis. 2017. Vol. 26. N. 3. P. 245—252.
957. Liu G., Grifman M., Keily B.. Chatterton J.E., Staal F.W., Li Q.X. Mineralocorticoid receptor is involved in the regulation of genes responsible for hepatic glucose production // Biochem. Biophys. Res. Commun. 2006. Vol. 342. N. 4. P. 1291 — 1296.
958. Liu S.H., Lazo M., Koteish A., Kao W.H., Shih M.H., Bonekamp S. ... Clark J.M. Oral contraceptive pill use is associated with reduced odds of nonalcoholic fatty liver disease in menstruating women: results from NHANES III // J. Gastroenterol. 2013. Vol. 48. N. 10. P. 1151-1159.
959. Ludwig J., Viggiano T.R., McGill D.B., Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease // Mayo Clin. Proc. 1980. Vol. 55. N. 7. P. 434—438.
960. Ludwig U., Holzner D., Denzer C., Greinert A., Haenle M.M., Oeztuerk S. ... Study E. Subclinical and clinical hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study of a random population sample aged 18 to 65 years // BMC Endocr. Disord. 2015. Vol. 15. P. 41.
961. Malik R.,Hodgson H. The relationship between the thyroid gland and the liver// QJM. 2002. Vol. 95. N. 9. P. 559—569.
962. Matsumoto R., Fukuoka H., Iguchi G., Nishizawa H., Bando H., Suda K. ... Takahashi Y. Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency // Growth. Hormon. IGF Res. 2014. Vol. 24. N. 5. P. 174-179.
963. Meex R.C.R., Watt M J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance // Nat. Rev. Endocrinol. 2017. Vol. 13. N. 9. P. 509. Retrieved from .
964. Meloni A., Willcox N., Meager A., Atzeni M., Wolff A.S., Husebye E.S. ... Congia M. Autoimmune polyendocrine syndrome type 1: an extensive longitudinal study in Sardinian patients // J. Clin. Endocrinol. Metab. 2012. Vol. 97. N. 4. P. 1114—1124.
965. Mintziori G., Poulakos P., Tsametis C., Goulis D.G. Hypogonadism and non-alcoholic fatty liver disease // Minerva Endocrinol. 2017. Vol. 42. N. 2. P. 145—150.
966. Molina-Molina Е., Lunardi Baccetto R.,Wang D.Q., de Bari О., Krawczyk M., Portincasa P. Exercising the hepatobiliary-gut axis. The impact of physical activity performance // Eur. J. Clin. Investig. 2018. Vol. 48. N. 8. P. el2958.
967. Molina-Molina E., Krawczyk M., Stachowska E., Lammert F, Portincasa P. Non-alcoholic fatty liver disease in non-obese individuals: prevalen c.e., pathogenesis and treatment // Clin. Res. Hepatol. Gastroenterol. 2019. Vol. 43. N. 6. P. 638—645.
968. Nakajima K., Hashimoto E., Kaneda H., Tokushige K., Shiratori K., Hizuka N., Takano K. Pediatric nonalcoholic steatohepatitis associated with hypopituitarism // J. Gastroenterol. 2005. Vol. 40. N. 3. P. 312-315.
969. Nikolaenko L., Jia Y., Wang C., Diaz-Arjonilla M., Yee J.K., French S.W. ... Swerdloff R.S. Testosterone replacement ameliorates nonalcoholic fatty liver disease in castrated male rats // Endocrinology. 2014. Vol. 155. N. 2. P. 417—428.
970. Nishizawa H., Iguchi G., Murawaki A., Fukuoka H., Hayashi Y, Kaji H. ... Takahashi Y. Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy // Eur. J. Endocrinol. 2012. Vol. 167. N. 1. P. 67— 74.
971. Noguchi R., Yoshiji H., Ikenaka Y, Kaji K., Shirai Y, Aihara Y. ... Fukui H. Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats // Int. J. Mol. Med. 2010. Vol. 26. N. 3. P. 407—413.
972. Palmisano B.T., Zhu L., Stafford J.M. Role of estrogens in the regulation of liver lipid metabolism//Adv. Exp. Med. Biol. 2017. Vol. 1043. P. 227-256.
973. Pan J.J., Fallon M.B. Gender and racial differences in nonalcoholic fatty liver disease //World J. Hepatol. 2014. Vol. 6. N. 5. P. 274—283.
974. Panidis D., Tziomalos K., Papadakis E., Vosnakis C., Chatzis P., Katsikis I. Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility // Endocrine. 2013. Vol. 44. N. 3. P. 583—590.
975. Papanastasiou L., Fountoulakis S., Vatalas LA. Adrenal disorders and non-alcoholic fatty liver disease // Minerva Endocrinol. 2017. Vol. 42. N. 2. P. 151 — 163.
976. Perarnau J.M., Bacq Y. Hepatic vascular involvement related to pregnan c.y., oral contracep-tiv e.s., and estrogen replacement therapy // Semin. Liver. Dis. 2008. Vol. 28. N. 3. P. 315— 327.
977. Piercy M., Shin S.H. Comparative studies of prolactin secretion in estradiol-primed and normal male rats induced by ether stre s.s., pimozide and TRH // Neuroendocrinology. 1980. Vol. 31. N. 4. P. 270-275.
978. Polyzos S.A., Goulis D.G., Kountouras J., Mintziori G., Chatzis P., Papadakis E. ... Panidis D. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of noninvasive indices predicting hepatic steatosis and fibrosis // Hormones (Athens). 2014. Vol. 13. N. 4. P. 519-531.
979. Rizvi A.A., Kerrick J.G. Liver involvement and abnormal iron variables in undiagnosed Addison’s disease // Endocr. Pract. 2001. Vol. 7. N. 3. P. 184—188.
980. Rotterdam EASPCWG. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) // Hum. Reprod. 2004. Vol. 19. N. 1. P. 41-47.
981. Sancho-Bru Р., Bataller R., Colmenero J., Gasull X., Moreno M., Arroyo V. ... Gines P. Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells //Am. J. Physiol. Gastrointest. Liver. Physiol. 2006. Vol. 291. N. 5. P. G877— G884.
982. Sarkar M., Wellons M., Cedars M.I., VanWagner L., Gunderson E.P., Ajmera V.... Terrault N. Testosterone levels in pre-menopausal women are associated with nonalcoholic fatty liver disease in midlife // Am. J. Gastroenterol. 2017. Vol. 112. N. 5. P. 755—762.
983. Sattar N.. Forrest E., Preiss D. Non-alcoholic fatty liver disease // Br. Med. J. 2014. Vol. 349. P. g4596.
984. Schwimmer J.B., Pardee P.E., LavineJ.E., Blumkin A.K., CookS. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease // Circulation. 2008. Vol. 118. N. 3. P. 277-283.
985. Schwinge D., Carambia A., Quaas A., Krech T., Wegscheid C., Tiegs G. ... Schramm C. Testosterone suppresses hepatic inflammation by the downregulation of IL-17, CXCL-9, and CXCL-10 in a mouse model of experimental acute cholangitis // J. Immunol. 2015. Vol. 194. N. 6. P. 2522—2530.
986. Senmaru T., Fukui M., Okada H., Mineoka Y., Yamazaki M., Tsujikawa M. ... Nakamura N. Testosterone deficiency induces markedly decreased serum triglycerides, increased small dense L D.L., and hepatic steatosis mediated by dysregulation of lipid assembly and secretion in mice fed a high-fat diet // Metabolism. 2013. Vol. 62. N. 6. P. 851—860.
987. Sigala B., McKee C., Soeda J., Pazienza V, Morgan M., Lin C.I. ... Oben J.A. Sympathetic nervous system catecholamines and neuropeptide Y neurotransmitters are upregulated in human NAFLD and modulate the fibrogenic function of hepatic stellate cells // PLoS One. 2013. Vol. 8. N. 9. P. e72928.
988. Sinclair M., Grossmann M., Gow P.J., Angus P.W. Testosterone in men with advanced liver disease: abnormalities and implications // J. Gastroenterol. Hepatol. 2015. Vol. 30. N. 2. P. 244-251.
989. Sinha R.A., Singh B.K., Yen P.M. Direct effects of thyroid hormones on hepatic lipid metabolism // Nat. Rev. Endocrinol. 2018. Vol. 14. N. 5. P. 259—269.
990. Stieger B. Role of the bile salt export pu m.p., BS E.P., in acquired forms of cholestasis // Drug. Metab. Rev. 2010. Vol. 42. N. 3. P. 437-445.
991. Torun E., Ozgen I.T., Gokee S., Aydin S., Cesur Y. Thyroid hormone levels in obese children and adolescents with non-alcoholic fatty liver disease // J. Clin. Res Pediatr. Endocrinol. 2014. Vol. 6. N. I. P. 34-39.
992. Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome // World. J. Gastroenterol. 2014. Vol. 20. N. 26. P. 8351-8363.
993. Vatner D.F.,Weismann D., Beddow S.A., Kumashiro N., Erion D.M., Liao X.H. ... Samuel V.T. Thyroid hormone receptor-beta agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways // Am. J. Physiol. Endocrinol. Metab. 2013. Vol. 305. N. 1. P. E89-E100.
994. Volzke H., Aumann N., Krebs A., Nauck M., Steveling A., Lerch M.M. ... Wallaschofski H. Hepatic steatosis is associated with low serum testosterone and high serum DHEAS levels in men // Int. J. Androl. 2010. Vol. 33. N. 1. P. 45—53.
995. Wada T., Ohshima S., Fujisawa E., Koya D., Tsuneki H., Sasaoka T. Aldosterone inhibits insulininduced glucose uptake by degradation of insulin receptor substrate (IRS) 1 and IRS2 via a reactive oxygen species-mediated pathway in 3T3-L1 adipocytes // Endocrinology. 2009. Vol. 150. N. 4. P. 1662-1669.
996. Wada T., Miyashita Y, Sasaki M., Aruga Y., Nakamura Y., Ishii Y. ... Sasaoka T. Eplerenone ameliorates the phenotypes of metabolic syndrome with NASH in liver-specific SREBP- 1c Tg mice fed high-fat and high-fructose diet // Am. J. Physiol. Endocrinol. Metab. 2013. Vol. 305. N. 11. P. E1415- E1425.
997. Wang P., Tait S.M., Chaudry I.H. Sustained elevation of norepinephrine depresses hepatocellular function // Biochim. Biophys. Acta. 2000. Vol. 1535. N. 1. P. 36—44.
998. Wang H.H., Liu M., Clegg D.J., Portincasa P., Wang D.Q. New insights into the molecular mechanisms underlying effects of estrogen on cholesterol gallstone formation // Biochim. Biophys. Acta. 2009. Vol. 1791. N. II. P. 1037-1047.
999. Wang X., Lu Y, Wang E., Zhang Z., Xiong X., Zhang H. ... Li X. Hepatic estrogen receptor alpha improves hepatosteatosis through upregulation of small heterodimer partner // J. Hepatol. 2015. Vol. 63. N. 1. P. 183-190.
1000. Wang N., Zhai H., Zhu C., Li Q., Han B., Chen Y. ... Lu Y. Combined association of vitamin D and sex hormone binding globulin with nonalcoholic fatty liver disease in men and postmenopausal women: a cross-sectional study // Medicine (Baltimore). 2016. Vol. 95. N. 4. P. e2621.
1001. Watanabe M., Houten S.M., Mataki C., Christoffolete M.A., Kim B.W., Sato H. ... Auwerx J. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation// Nature. 2006. Vol. 439. N. 7075. P. 484-489.
1002. Woods C.P., Hazlehurst J.M., Tomlinson J.W. Glucocorticoids and non-alcoholic fatty liver disease // J. Steroid. Biochem. Mol. Biol. 2015. Vol. 154. P. 94—103.
1003. Xia E, Xu X., Zhai H., Meng Y, Zhang H., Du S. ... Lu Y. Castration-induced testosterone deficiency increases fasting glucose associated with hepatic and extra-hepatic insulin resistance in adult male rats// Reprod. Biol. Endocrinol. 2013. Vol. 11. P. 106.
1004. Xu C., Xu L., Yu C., Miao M., Li Y. Association between thyroid function and nonalcoholic fatty liver disease in euthyroid elderly Chinese // Clin. Endocrinol. 2011. Vol. 75. N. 2. P. 240-246.
1005. Xu L., Xu C., Yu C., Miao M., Zhang X., Zhu Z. ... Li Y. Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study // PLoS One. 2012. Vol. 7. N. 8. P. e44136.
1006. Yamashita R., Kikuchi T., Mori Y, Aoki K., Kaburagi Y, Yasuda K., Sekihara H. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase В cascade // Endocr. J. 2004. Vol. 51. N. 2. P. 243—251.
1007. Yang Y, Qi Z.R., Zhang T.T., Kang Y.J.,Wang X. Rapidly progressive non-alcoholic fatty liver disease due to hypopituitarism. Report of 5 cases // Neuro Endocrinol. Lett. 2018. Vol. 39. N. 2. P. 99—104.
1008. Yim J.Y., Kim J., Kim D., Ahmed A. Serum testosterone and non-alcoholic fatty liver disease in men and women in the US // Liver. Int. 2018. Vol. 38. N. 11. P. 2051—2059.
1009. Yuan X.X., Zhu H.J., Pan H., Chen S., Liu Z.Y., Li Y. ... Gong F.Y. Clinical characteristics of nonalcoholic fatty liver disease in Chinese adult hypopituitary patients // World. J. Gastroenterol. 2019. Vol. 25. N. 14. P. 1741-1752.
1010. Zhu L., Brown W.C., Cai Q., Krust A., Chambon P., McGuinness O.P., Stafford J.M. Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance // Diabetes. 2013. Vol. 62. N. 2. P. 424—434.
1011. Zietz B., Lock G., Plach B., Drobnik W., Grossmann J., Scholmerich J., Straub R.H. Dysfunction of the hypothalamic-pituitary-glandular axes and relation to Child-Pugh classification in male patients with alcoholic and virus-related cirrhosis // Eur. J. Gastroenterol. Hepatol. 2003. Vol. 15. N. 5. P. 495—501.
1012. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management // Endocr. Rev. 2004. Vol. 25. P. 102—152.
1013. Cooper D.S., Biondi B. Subclinical thyroid disease // Lancet. 2012. Vol. 379. P. 1142—1154.
1014. Danzi S., Klein I. Thyroid hormone and blood pressure regulation // Curr. Hypertens. Rep. 2003. Vol. 5. P. 513-520.
1015. Dawber T.R., Meadors G.F., Moore F.E. Jr. Epidemiological approaches to heart disease: the Framingham study//Am. J. Public. Health. 1951. Vol. 41. P. 279—286.
1016. Demerath E.W., Sun S.S., Rogers N. et al. Anatomical patterning of visceral adipose tissue: race, sex, and age variation // Obesity. 2007. Vol. 15. P. 2984—2993.
1017. Ding E.L., Song Y., Malik V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis // JAMA. 2006. Vol. 295. P. 1288—1299.
1018. Duntas L.H. Thyroid disease and lipids // Thyroid. 2002. Vol. 12. P. 287—293.
1019. Fallo F., Veglio F., Bertello C. et al. Prevalence and characteristics of the metabolic syndrome in primary hyperaldosteronism //J. Clin. Endocrinol. Metab. 2006. Vol. 91. P. 454—459.
1020. Feldman T., Borow K., Sarne D.H., Neumann A., Lang R.M. Myocardial mechanics in hyperthyroidism: importance of left ventricular loading conditions, heart rate and contractile state //J. Am. Coll. Cardiol. 1986. Vol. 7. P. 967—974.
1021. Fu J., Bonder M.J., Cenit M.C. et al. The gut microbiome contributes to a substantial proportion of the variation of blood lipids//Circ. Res. 2015. Vol. 117. P. 817—824.
1022. Grais I.M., Sowers J.R. Thyroid and the heart //Am. J. Med. 2014. Vol. 127. P. 691—698.
1023. Haffner S.M., Lehto S., Ronnemaa T. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction // N. Engl. J. Med. 1998. Vol. 339. P. 229-234.
1024. Hazlehurst J.M., Tomlinson J.W. Non-alcoholic fatty liver disease in common endocrine disorders// Eur. J. Endocrinol. 2013. Vol. 169. P. R27-R37.
1025. Jabbar A., Pingitore A., Pearce S.H.S., Zaman A., lervasi G., Razvi S. Thyroid hormones and cardiovascular disease // Nat. Rev. Cardiol. 2017. Vol. 14. P. 39—55.
1026. Kahaly G.J. Cardiovascular and atherogenic aspects of subclinical hypothyroidism // Thyroid. 2000. Vol. 10. P. 665-679.
1027. Kelly D.M., Jones Т.Н. Testosterone and obesity // Obes. Rev. 2015. Vol. 16. P. 581-606.
1028. Kirchengast S., Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome // Hum. Reprod. 2001. Vol. 16. P. 1255—1260.
1029. Koren O., Spor A., Felin J. et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis// Proc. Natl. Acad. Sci USA. 2011. Vol. 108. P. 4592-4598.
1030. Kvit K.B., Kharchenko N.V. Gut microbiota changes as a risk factor for obesity // Wiad. Lek. 2017. Vol. 70. P. 231-235.
1031. Larsen N., Vogensen F.K., van den Berg F.W. et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults // PLoS One. 2010. Vol. 5. P. e9085.
1032. Lenders J.W., Eisenhofer G., Mannelli M., Pacak K. Phaeochromocytoma // Lancet. 2005. Vol. 366. P. 665-675.
1033. Maratou E., Hadjidakis D.J., Kollias A. et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism // Eur. J. Endocrinol. 2009. Vol. 160. P. 785—790.
1034. Newell-Price J., Bertagna X., Grossman A.B., Nieman L.K. Cushing’s syndrome // Lancet. 2006. Vol. 367. P. 1605-1617.
1035. O’Reilly M.W., Taylor A.E., Crabtree N.J. et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione // J. Clin. Endocrinol. Metab. 2014. Vol. 99. P. 1027-1036.
1036. Procopio M., Barale M., Bertaina S. et al. Cardiovascular risk and metabolic syndrome in primary hyperparathyroidism and their correlation to different clinical forms // Endocrine. 2014. Vol. 47. P. 581-589.
1037. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism // Nature. 2001. Vol. 414. P. 799-806.
1038. Schwingel P.A., Cotrim H.P., Salles B.R. et al. Anabolic-androgenic steroids: a possible new risk factor of toxicant-associated fatty liver disease// Liver. Int. 2011. Vol. 31. P. 348—353.
1039. Semple R.K., Savage D.B., Cochran E.K., Gorden P., O’Rahilly S. Genetic syndromes of severe insulin resistance // Endocr. Rev. 2011. Vol. 32. P. 498—514.
1040. Sowers J.R., Whaley-Connell A., Epstein M. The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension // Ann. Intern. Med. 2009. Vol. 150. P. 776-783.
1041. Speiser P.W., White P.C. Congenital adrenal hyperplasia // N. Engl. J. Med. 2003. Vol. 349. P. 776-788.
1042. Taddei S. et al. Impaired endohelium-dependent vasodilation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy // J. Clin. Endocrinol. Metab. 2003. Vol. 7. P. 411-414.
1043. Valassi E., Klibanski A., Biller B.M. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia // J. Clin. Endocrinol. Metab. 2010. Vol. 95. P. 1025—1033.
1044. Whaley-Connell A., Johnson M.S., Sowers J.R. Aldosterone: role in the cardiometabolic syndrome and resistant hypertension // Progr. Cardiovasc. Dis. 2010. Vol. 52. P. 401—409.
1045. Wu F.C., von Eckardstein A. Androgens and coronary artery disease // Endocr. Rev. 2003. Vol. 24. P. 183-217.
1046. Zarotsky V., Huang M.Y., Carman W. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men // Andrology. 2014. Vol. 2. P. 819-834.
1047. Франческо Джорджино (Francesco Giorgino) Section of Internal Medicine, Endocrinology and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari Medical School, Bari, Italy
1048. Ремко Гроббен (Remco Grobben) University Medical Center Utrecht, Utrecht, The Netherlands
1049. Гала Гутьеррес (Gala Gutierrez) Department of Endocrinology and Nutrition, University Clinic of Navarra, Pamplona, Spain
1050. Эйнар А. Харт (Einar A. Hart) University Medical Center Utrecht, Utrecht, The Netherlands
1051. Пабло Иримиа Сиэйра (Pablo Irimia Sieira) Departamento de Neurologia, Ch'nica Universidad de Navarra, Pamplona, Spain
1052. Марцин Кравчик (Marcin Krawczyk) Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany, Laboratory of Metabolic Liver Diseases, Center for Preclinical Research, Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland
1053. Фрэнк Ламмерт (Frank Lammert) Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany
1054. M. Ф. Ландечо (M. F. Landecho) General Health Check-up Unit, Internal Medicine Department, Ch'nica Universidad de Navarra, Pamplona, Spain
1055. Энтони Лембо (Antony Lembo) Division of Gastroenterology, Beth Israel and Deaconess Center, Harvard Medical School, Boston, MA, USA
1056. Лука Либерале (Luca Liberale) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy
1057. Center for Molecular Cardiology, University of Ziirich, Schlieren, Switzerland
1058. Мария Ллаверо (Maria Llavero) Department of Endocrinology and Nutrition, University Clinic of Navarra, Pamplona, Spain
1059. Ashikaga Е., Honda Н., Suzuki Н., Hosaka N., Hirai Y., Sanada D. et al. Impact of fibroblast growth factor 23 on lipids and atherosclerosis in hemodialysis patients // Ther. Apher. Dial. 2010. Vol. 14. P. 315-322.
1060. Bargnoux A.S., Vetromile E, Kuster N., Barberet J., Dupuy A.M., Ribstein J. et al. Markers of bone remodeling are associated with arterial stiffness in renal transplanted subjects // J. Nephrol. 2015. Vol. 28. P. 765-772.
1061. Biscetti E, Straface G., Porreca C.F., Bertoletti G., Vincenzoni C., Snider E et al. Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis// Cardiovasc. Diabetol. 2015. Vol. 14. P. 139.
1062. Born-Frontsberg E., Reincke M., Rump L.C., Hahner S., Diederich S., Lorenz R. et al. Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s registry // J. Clin. Endocrinol. Metab. 2009. Vol. 94. P. 1125-1130.
1063. Brandenburg V.M., Kleber M.E., Vervloet M.G., Tomaschitz A., Pilz S., Stojakovic T. et al. Fibroblast growth factor 23 (FGF23) and mortality: the Ludwigshafen risk and cardiovascular health study //Atherosclerosis. 2014. Vol. 237. P. 53-59.
1064. Cappola A.R., Fried L.P., Arnold A.M., Danese M.D., Kuller L.H., Burke G.L. et al. Thyroid status, cardiovascular risk, and mortality in older adults // JAMA. 2006. Vol. 295. P. 1033-1041.
1065. Caprio M., Newfell B.G., la Sala A., Baur W., Fabbri A., Rosano G. et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion // Circ. Res. 2008. Vol. 102. P. 1359-1367.
1066. Carbone E, Montecucco F. The role of the intraplaque vitamin d system in atherogenesis // Scientiflca (Cairo). 2013. Vol. 2013. P. 620504.
1067. Catena C., Colussi G., Nadalini E., Chiuch A., Baroselli S., Lapenna R. et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment // Arch. Intern. Med. 2008. Vol. 168. P. 80-85.
1068. Chou Т.М., Sudhir К., Hutchison S.J., Ko E., Amidon T.M., Collins P. et al. Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo // Circulation. 1996. Vol. 94. P. 2614-2619.
1069. Colao A., Di Somma C., Filippella M., Rota E, Pivonello R., Orio F. et al. Insulin-like growth factor-1 deficiency determines increased intima-media thickness at common carotid arteries in adult patients with growth hormone deficiency // Clin. Endocrinol. 2004. Vol. 61. P. 360—366.
1070. Colao A., Di Somma C., Rota E, Pivonello R., Savanelli M.C., Spiezia S. et al. Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intimamedia thickness at carotid arteries in patients with severe GH deficiency // J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 2056-2062.
1071. Dardano A., Ghiadoni L., Plantinga Y, Caraccio N., Berni A., Duranti E. et al. Recombinant human thyrotropin reduces endothelium-dependent vasodilation in patients monitored for differentiated thyroid carcinoma //J. Clin. Endocrinol. Metab. 2006. Vol. 91. P. 4175—4178.
1072. Desjardins L., Liabeuf S., Renard C., Lenglet A., Lemke H.D., Choukroun G. et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages // Osteoporos Int. 2012. Vol. 23. P. 2017—2025.
1073. Donate-Correa J., Mora-Fernandez C., Martinez-Sanz R., Muros-de-Fuentes M., Perez H., Meneses-Perez B. et al. Expression of FGF23/KLOTHO system in human vascular tissue// Int. J. Cardiol. 2013. Vol. 165. P. 179-183.
1074. Higashi Y., Quevedo H.C., Tiwari S., Sukhanov S., Shai S.Y., Anwar A. et al. Interaction between insulin-like growth factor-1 and atherosclerosis and vascular aging // Front. Horm. Res. 2014. Vol. 43. P. 107-124.
1075. Houston J., Smith K., Isakova T., Sowden N., Wolf M., Gutierrez O.M. Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease // J. Ren. Nutr. 2013. Vol. 23. P. 12—20.
1076. Hu X., Ma X., Pan X., Hao Y, Luo Y, Lu Z. et al. Fibroblast growth factor 23 is associated with the presence of coronary artery disease and the number of stenotic vessels // Clin. Exp. Pharmacol. Physiol. 2015. Vol. 42. P. 1152—1157.
1077. Hu X., Ma X., Luo Y, Xu Y, Xiong Q., Pan X. et al. Elevation in fibroblast growth factor 23 and its value for identifying subclinical atherosclerosis in first-degree relatives of patients with diabetes // Sci Rep. 2016. Vol. 6. P. 34696.
1078. Inci A., Sari E, Olmaz R., Coban M., Dolu S., Sarikaya M. et al. Soluble Klotho levels in diabetic nephropathy: relationship with arterial stiffness // Eur. Rev. Med. Pharmacol. Sci. 2016. Vol. 20. P. 3230-3237.
1079. Jaffe I.Z., Newfell B.G., Aronovitz M., Mohammad N.N., McGraw A.P., Perreault R.E. et al. Placental growth factor mediates aldosterone-dependent vascular injury in miceЦ J. Clin. Invest. 2010. Vol. 120. P. 3891-3900.
1080. Johnsen S.P., Hundborg H.H., Sorensen H.T., Orskov H., Tjonneland A., Overvad K. et al. Insulin-like growth factor (IGF) I, -II, and IGF binding protein-3 and risk of ischemic stroke//J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 5937—5941.
1081. Juul A., Scheike T., Davidsen M., Gyllenborg J., Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study // Circulation. 2002. Vol. 106. P. 939—944.
1082. Karamouzis L, Berardelli R., D’Angelo V., Fussotto B., Zichi C, Giordano R et al. Enhanced oxidative stress and platelet activation in patients with Cushing’s syndrome // Clin. Endocrinol. 2015. Vol. 82. P. 517-524.
1083. Kelly D.M., Jones Т.Н. Testosterone: a vascular hormone in health and disease // J. Endocrinol. 2013. Vol. 217. P. R47-R71.
1084. King G.L, Johnson S.M. Receptor-mediated transport of insulin across endothelial cells // Science. 1985. Vol. 227. P. 1583-1586.
1085. Lutsey P.L., Parrinello С.М, Misialek J.R., Hoofnagle A.N., Henderson C.M., Laha T.J. et al. Short-term variability of vitamin D-related biomarkers // Clin. Chem. 2016. Vol. 62. P. 1647-1653.
1086. Maiolino G., Flego A., Rossi G.P. Os 35-09 long-term outcome of surgically- and medically-treated patients of the primary aldosteronism prevalence in hypertensives (Papy) study // J. Hypertens. 2016. Vol. 34. Suppl. 1. ISH 2016 Abstract Book. P. e40l.
1087. Markussis V., Beshyah S.A., Fisher C., Sharp P., Nicolaides A.N., Johnston D.G. Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults // Lancet. 1992. Vol. 340. P. 1188—1192.
1088. McVeigh G.E., Brennan G.M., Johnston G.D., McDermott B.J., McGrath L.T., Henry W.R. et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulindependent) diabetes mellitus // Diabetologia. 1992. Vol. 35. P. 771—776.
1089. Milliez P., Girerd X., Plouin P.F., Blacher J., Safar M.E., Mourad J.J. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism //J. Am. Coll. Cardiol. 2005. Vol. 45. P. 1243-1248.
1090. Mirza M.A., Hansen T., Johansson L., Ahlstrom H., Larsson A., Lind L. et al. Relationship between circulating FGF23 and total body atherosclerosis in the community // Nephrol. Dial. Transplant. 2009a. Vol. 24. P. 3125-3131.
1091. Mirza M.A., Larsson A., Lind L., Larsson T.E. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community // Atherosclerosis. 2009b. Vol. 205. P. 385-390.
1092. Nishimura M., Uzu T., Fujii T., Kuroda S., Nakamura S., Inenaga T. et al. Cardiovascular complications in patients with primary aldosteronism // Am. J. Kidney Dis. 1999. Vol. 33. P. 261 —266.
1093. Nofer J.R. Estrogens and atherosclerosis: insights from animal models and cell systems // J. Mol. Endocrinol. 2012. Vol. 48. P. R13-R29.
1094. Pitt B., Zannad E, Remme W.J., Cody R., Castaigne A., Perez A. et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators // N. Engl. J. Med. 1999. Vol. 341. P. 709—717.
1095. Pitt B., Remme W., Zannad E, Neaton J., Martinez E, Roniker B. et al. Eplerenone, a selective aldosterone block e.r., in patients with left ventricular dysfunction after myocardial infarction // N. Engl. J. Med. 2003. Vol. 348. P. 1309-1321.
1096. Qin Z., Liu X., Song M., Zhou Q., Yu J., Zhou B. et al. Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies // Atherosclerosis. 2017. Vol. 261. P. 1-11.
1097. Rossi G.P., Cesari M., Cuspidi C., Maiolino G., Cicala M.V., Bisogni V. et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism // Hypertension. 2013. Vol. 62. P. 62—69.
1098. Savard S., Amar L., Plouin P.F., Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study // Hypertension. 2013. Vol. 62. P. 331-336.
1099. Shah N.H., Dong C., Elkind M.S., Sacco R.L., Mendez A.J., Hudson B.I. et al. Fibroblast growth factor 23 is associated with carotid plaque presence and area: the northern Manhattan study //Arterioscler. Thromb. Vase. Biol. 2015. Vol. 35. P. 2048—2053.
1100. Sukhanov S., Higashi Y., Shai S.Y, Blackstock C., Galvez S., Vaughn C. et al. Differential requirement for nitric oxide in IGF-l-induced anti-apoptot i.c., anti-oxidant and anti-atherosclerotic effects // FEBS Lett. 2011. Vol. 585. P. 3065—3072.
1101. Takeda R., Matsubara T., Miyamori L, Hatakeyama H., Morise T. Vascular complications in patients with aldosterone producing adenoma in Japan: comparative study with essential hypertension. The Research Committee of Disorders of Adrenal Hormones in Japan // J. Endocrinol. Investig. 1995. Vol. 18. P. 370—373.
1102. Tan К.С., Chow W.S., Ai V.H., Metz C., Bucala R., Lam K.S. Advanced glycation end products and endothelial dysfunction in type 2 diabetes // Diabetes Care. 2002. Vol. 25. P. 1055-1059.
1103. Turemen E.E., Cetinarslan B., Sahin T., Canturk Z., Tarkun I. Endothelial dysfunction and low grade chronic inflammation in subclinical hypothyroidism due to autoimmune thyroiditis // Endocr. J. 2011. Vol. 58. P. 349—354.
1104. Yamada H., Kuro O.M., Hara K., Ueda Y, Kusaka I., Kakei M. et al. The urinary phosphate to serum fibroblast growth factor 23 ratio is a useful marker of atherosclerosis in early-stage chronic kidney disease // PLoS One. 2016. Vol. 11. P. e0160782.
1105. Yue P., Chatterjee K., Beale C., Poole-Wilson P.A., Collins P. Testosterone relaxes rabbit coronary arteries and aorta // Circulation. 1995. Vol. 91. P. 1154—1160.
1106. Юдит Лопес (Judith Lopez) Department of Endocrinology and Nutrition, University Hospital of Canarias and University of La Laguna, Tenerife, Spain
1107. Ане Мингес Олаондо (Ane Minguez Olaondo) Departamento de Neurologia, CUnica Universidad de Navarra, Pamplona, Spain
1108. M. Паула Македо (M. Paula Machedo) Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciencias Medicas, Universidade Nova de Lisboa, Lisbon, Portugal
1109. Эдуардо Мартинес-Вила (Eduardo Martinez-Vila) Departamento de Neurologia, Clinica Universidad de Navarra, Pamplona, Spain
1110. Алессандро Масколо (Alessandro Mascolo) Department of Emergency and Organ Transplantation (DETO), Nephrology, Dialysis and Kidney Transplantation Unit, University of Bari «Aldo Moro», Bari, Italy
1111. Сильвия Матино (Silvia Matino) Department of Emergency and Organ Transplantation (DETO), Nephrology, Dialysis and Kidney Transplantation Unit, University of Bari «Aldo Moro», Bari, Italy
1112. Рональд С. А. Мейер (Ronald C. A. Meijer) Department of Cardiothoracic Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands
1113. Фабрицио Монтекукко (Fabrizio Montecucco) Ospedale Policlinico San Martino, Genoa, Italy, First Clinic of Internal Medicine and Centre of Excellence for Biomedical Research (CEBR), Department of Internal Medicine, University of Genoa, Genoa, Italy, IRCCS Ospedale Policlinico San Martino Genoa — Italian Cardiovascular Nework, Genoa, Italy
1114. Хендрик M. Натхо (Hendrik M. Nathoe) Department of Cardiology, University Medical Center, Utrecht, The Netherlands
1115. Хагит Пелег (Hagit Peleg) Rheumatology Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
1116. M. Пертиконе (M. Perticone) Department of Experimental and Clinical Medicine, University Magna Graecia of Catanzaro, Catanzaro, Italy
1117. Ф. Пертикони (F. Perticone) Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
1118. Франческо Пеше (Francesco Pesce) Department of Emergency and Organ Transplantation (DETO), Nephrology, Dialysis and Kidney Transplantation Unit, University of Bari «Aldo Moro», Bari, Italy
1119. Ана Ф. Пина (Ana F. Pina) Chronic Diseases Research Center, NOVA Medical School/Faculdade de Ciencias Medicas, Universidade Nova de Lisboa, Lisbon, Portugal
1120. Пьеро Портинкаса (Piero Portincasa) Department of Biomedical Sciences and Human Oncology, University of Bari «Aldo Moro», Clinica Medica «Augusto Murri», Bari, Italy
1121. Якуб Ригели (Jakub Regieli) Private cardiology clinic, Amsterdam, The Netherlands
1122. Микеле Россини (Michele Rossini) Department of Emergency and Organ Transplantation (DETO), Nephrology, Dialysis and Kidney Transplantation Unit, University of Bari «Aldo Moro», Bari, Italy
1123. Мартин Раттледж (Martin Ruttledge) Neurology Department, Beaumont Hospital, Dublin 9, Ireland
1124. Хавьер Сальвадор (Javier Salvador) Department of Endocrinology and Nutrition, University Clinic of Navarra, Pamplona, Spain, CIBERObn, Institute Carlos III, Madrid, Spain
1125. Марсель Т. Б. Твиклер (Marcel Th. В. Twickler) Department of Endocrinology, Diabetology and Metabolic Diseases, Antwerp University Hospital, Edegem, Belgium, AZ Monica, Antwerp/Deurne, Belgium
1126. Алессандра Веккье (Alessandra Vecchie) First Clinic of Internal Medicine,
1127. Department of Internal Medicine, University of Genoa, Genoa, Italy
1128. Дэвид К. X. Ванг (David Q. H. Wang) Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY, USA
1129. В. Сантестебан-Морионес (V. Santesteban-Moriones) General Health Check-up Unit, Internal Medicine Department, Clinica Universidad de Navarra, Pamplona, Spain, Department of Endocrinology and Nutrition, Clinica Universidad de Navarra, Pamplona, Spain, Department of Nutrition, Food Sciences and Physiology, University of Navarra, Pamplona, Spain, Centre for nutrition research, University of Navarra, Pamplona, Spain, CIBER fisiopatologia de la obesidad у nutricion (CIBERObn), Instituto de Salud Carlos 111, Madrid, Spain
1130. Томас Соммерс (Thomas Sommers) Division of Gastroenterology, Beth Israel and Deaconess Center, Harvard Medical School, Boston, MA, USA
1131. П. Сунсундэги (P. Sunsundegui) General Health Check-up Unit, Internal Medicine Department, Clinica Universidad de Navarra, Pamplona, Spain
1132. Марго Э. Тесселаар (Margot E. Tesselaar) Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
1133. Амелия Кьяра Тромбетта (Amelia Chiara Trombetta) Research Laboratory and Clinical Division of Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
1134. Эльдад Бен-Шитрит (Eldad Ben-Chetrit) Rheumatology Unit, Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
1135. Доменико Бонамонте (Domenico Bonamonte) Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy
1136. Альдо Бонавентура (Aldo Bonaventura) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy
1137. Федерико Карбоне (Federico Carbone) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy
1138. Маттео Казула (Matteo Casula) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy
1139. Стивен А. Дж. Шамуло (Steven A. J. Chamuleau) University Medical Center Utrecht, Utrecht, The Netherlands
1140. Григориос Кристидис (Grigorios Christidis) Department of Medicine II, Saarland University Medical Center, Saarland University, Homburg, Germany
1141. Маурицио Кутоло (Maurizio Cutolo) Research Laboratory and Clinical Division of Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
1142. Джузеппина Д'Этторре (Giuseppina D’Ettorre) Department of Emergency and Organ Transplantation (DETO), Nephrology, Dialysis and Kidney Transplantation Unit, University of Bari «Aldo Moro», Bari, Italy
1143. Франко Даллегри (Franco Dallegri) First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy, IRCCS Ospedale Policlinico San Martino — Italian Cardiovascular Network, Genoa, Italy
1144. Агостино Ди Чиаула (Agostino Di Ciaula) Clinica Medica «А. Murri», Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy, Division of Internal Medicine, Hospital of Bisceglie (BAT), ASL BAT, Bisceglie, Italy, International Society of Doctors for Environment — ISDE, Basel, Switzerland
1145. Хавьер Эскалада (Javier Escalada) Department of Endocrinology and Nutrition, University Clinic of Navarra, Pamplona, Spain, CIBERObn, Institute Carlos 111, Madrid, Spain
1146. Анджела Филони (Angela Filoni) Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy
1147. Хавьер Гаргалло (Javier Gargalio) Department of Endocrinology and Nutrition, University Clinic of Navarra, Pamplona, Spain
1148. Габриэлла Гаррути (Gabriella Garruti) Section of Internal Medicine, Endocrinology and Metabolic Diseases, Department of Emergency and Organ Transplantation, University of Bari Medical School, Bari, Italy
1149. Лорето Джезуальдо (Loreto Gesualdo) Department of Emergency and Organ Transplantation (DETO), Nephrology, Dialysis and Kidney Transplantation Unit, University of Bari «Aldo Moro», Bari, Italy

- Вернуться в оглавление раздела "Нейрофизиология"

Редактор: Искандер Милевски. Дата обновления публикации: 20.12.2023